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The aim of this project was to determine if a difference could be discerned 
in the metabolism of the essential amino acid, tryptophan in cataract patients 
compared with normal controls. To investigate this aspect an oral tryptophan 
loading protocol was used. In order to assess the response of tryptophan 
metabolites to the load an HPLC technique with dual electrochemical and 
fluorescence detection was developed which could simultaneously measure 
tryptophan and seven of its metabolites. Serum samples were analysed at 0, 
1, 2, 4 and 6 hours for total and free tryptophan, 5-hydroxyanthranilic acid, 
3-hydroxyanthranilic acid, kynurenine, kynurenic acid, xanthurenic acid, 
anthranilic acid and 5-hydroxytryptophan.
Statistically significant differences were found. An increased response to the 
tryptophan load was found in cataract patients for two metabolites, 
kynurenine and 5-hydroxyanthranilic acid. A diminished response was found 
for kynurenic acid and total tryptophan. From the data it appeared that 
there may be two or more sub-groups of cataract patients who metabolise 
tryptophan differently from controls.
Since it has been shown recently that certain aminophenolic metabolites of 
tryptophan can modify lens proteins and thereby mimic cataract formation, 
the finding of a difference in tryptophan metabolism in cataract patients may 
represent a significant step in the quest for a biochemical basis for this 
disease.
Abstract
The most common cause for human blindness is cataract. Surgery is the
only available treatment and the cause of cataract is unknown.
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1.1 Cataract
Of the many causes of human blindness in the world today, the most common is opacity 
of the lens. In 1982, the World Health Organisation estimated that more than 42 million 
people were blind, and 17 million of these (40%) were blind because of cataract [1]. In 
developed countries, the incidence of cataract in the older population (>50 yr) is 15%, 
while in the developing countries the incidence is much higher (40%) [2].
Although, its presence is not life-threatening, a cataract, especially in the advanced stages, 
considerably lowers the quality of life of the sufferer. Of additional importance to public 
health officials and governments is the cost of this disease to the community. It has been 
calculated that 12% of the total Medicare budget in the USA is spent on the treatment of 
cataract [3]. An assessment of The National Eye Institute has estimated that if the rate of 
cataract progression could be slowed enough to delay the need for surgery by even 10 
years, the number of cataract operations in the USA could be reduced by 45% annually 
[4].
Cataract can be defined as partial or complete opacity of the lens, sufficient to impair 
normal vision.
1.1.1 Anatom y and Physiology of the Lens
The lens is supported by the suspensory ligaments (or zonules) and forms the division 
between the anterior and posterior cavities of the eye (Figure 1.1) The posterior cavity 
contains the retina and is filled with a transparent, connective tissue gel, the vitreous 
humor. Nutrients are supplied to the retina by a vascular tunic, the choroid which 
continues anteriorly as the ciliary body. This body is responsible for the formation of the 
aqueous humor, the distal attachment of the suspensory ligaments, and contains the
Figure 1.2
Diagram of Section through Lens
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smooth muscle controlling the accommodation of the lens. The anterior cavity is filled 
with the aqueous humor and is further divided into the anterior and posterior chambers by 
a round contractile diaphragm, the iris. The opening in the iris forms the pupil. The iris, 
together with the ciliary body and the choroid collectively make up the pigmented vascular 
layer known as the uvea. Covering the choroid is the white opaque external protective 
coat, the sclera. The sclera gradually transforms at the limbus into the uniquely 
transparent, convex, fibrous tissue structure, the cornea. Light entering the eye must 
pass through the cornea, the aqueous humor, the pupil, the lens, and the vitreous before 
reaching the retina [5].
The lens (Figure 1.2) is an encapsulated tissue which is supplied neither with blood 
vessels nor nerves. It relies entirely on the aqueous humor, at its anterior surface for its 
nutrients, its oxygen supply and its waste-product management. The vitreous humor, at 
its posterior surface, maintains the shape of the eyeball. The capsule is composed of 
complex polysaccharides and collagen produced by the single layer epithelial cells on the 
anterior surface of the lens (beneath the capsule). The capsule allows the passage of small 
molecules from the aqueous humor to the lens epithelium. Cells within this single layer 
of cuboidal epithelium divide and migrate towards the equatorial region of the lens where 
they differentiate and elongate to form the cortical fibre cells. The highest mitotic rate 
occurs in a ring, the germinative region, near the periphery of the lens [6]. During this 
process the cellular organelles (mitochondria, ribosomes and cell nucleus) are degraded 
and the new fibre moves toward the centre as it is covered with newer differentiating 
cells. This forms a cellular "how" at equatorial region of the lens. The arrows in Figure
1.2 indicate the direction of cell migration. Eventually a cell fibre extends from the front 
of the lens to the rear, meeting at regions called the lens sutures. With this unique growth 
pattern, the lens increases in size and weight throughout life, never losing its original 
cells. The oldest cells (nuclear fibres) are therefore at the nucleus of the lens. No new
Table 1.1 The Classification of Cataract *
According to Cataract Maturity 
Immature - scattered opacities separated by clear zones 
Mature - cortex is totally opaque
Hypermature - cataract has become smaller and has a wrinkled capsule due to leakage of water. 
Intumescent - lens has become swollen by imbibed water 
Morgagnian.- hypermature cataract with total liquefaction of the cortex
According to Age o f Onset
Congenital - at birth 
Infantile - less than 10 years 
Juvenile - less than 20 years 
Presenile - less than 40 years 
Senile - over 40 years
M orphological
Capsular - congenital or acquired 
Subcapsular - can be posterior or anterior 
Nuclear - congenital or senile 
Cortical - congenital or senile
Lamellar - congenital involving one lamella of the nuclear (foetal) zone 
Sutural - congenital, common, Y-shaped opacities in the nucleus
A etio log ica l
Senile (age-related) - can be cortical, nuclear, or subcapsular.
Traumatic - as a result of injury to the lens 
Metabolic - associated with a metabolic disorder 
Toxic - associated with prolonged drug therapy
Secondary - as a result of some other primary ocular disease *
Maternal - associated with maternal infections (eg rubella) or drug ingestion (eg. thalidomide) 
Hereditary - associated with congenital syndrome (eg Down's) or unassociated (ie dominant inheritance)
*Kanski, J., The Lens : classification o f cataract, in Clinical Ophthalmology, 2nd., Edition. Butterworths & Co. 
234-240.
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protein synthesis occurs in these fibres and damaged proteins are not replaced. The cell 
fibres of the cortex, although deficient in organelles are thought to retain the ability to 
synthesise crystallins [7].
The energy requirements of the lens are supplied by adenosine triphosphate (ATP) 
generated within the lens primarily by anaerobic glycolysis, but also by aerobic 
metabolism within the epithelial layer [8].
Unlike other species (except some primates) the human lens is a very pale yellow colour 
which intensifies during the sixth decade. The colour is partly due to metabolites of Trp, 
principally the glucoside of 30HKyn which absorbs UV radiation and prevents damaging 
wavelengths of less than 400 nm from reaching the retina [9].
1.1.2 The C lassification  o f C ataracts
The partial nature of the opacities in most cataracts and their variability in colour and 
extent has led to several classification systems [10]. Some of these are outlined in Table
1.1 The location of the opacity within the lens and its stage of development has led to a 
system of classification based on morphology and on cataract maturity, respectively. 
When the cause of cataract is known, for example, trauma or ionising irradiation, a 
classification based on aetiology is often used. Cataract due to indeterminate factors were 
classified according to the age of onset of the cataract. The use of a particular 
classification system will depend on the type of investigation in which the system will be 
used. The classification may be morphological if the investigation is associated with a 
diagnostic screening clinic, or it may aetiological if the investigation is an epidemiological 
survey. Two or more systems of classification can be employed to categorise a cataract.
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Although often grouped as an aetiological class (see Table 1.1), the cause of senile (age- 
related) cataract is unknown and for epidemiological and for biochemical purposes more 
specific classifications systems have been proposed. In the search for a cause for cataract 
many of these studies have been performed and this has led to a need for a more robust 
(ease of use, reproducibility between observers, etc) and quantifiable classification of the 
severity of cataract. Several systems have been proposed [11-13], but those of Chylack 
[13] known as the LOCS and LOCSII and that of Taylor [12] are the most popular. Both 
systems use a standard set of photographs of different types and stages in cataract 
development for comparison with the lens under examination. A comparison of both 
systems has been published [14].
Cataract formation includes many physical and chemical changes which are associated 
with the appearance of the lens in vitro and this led to a system of cataract classification 
based on the nuclear colour of the lens [15] and an additional modification taking into 
account the effect of sodium ions [16].
1.1.3 Physical and Chemical Changes of Cataract
In the normal lens there is an abrupt change in refractive index (RI) as light passes from 
the aqueous humor to the capsule, and a further change from the capsule to the 
epithelium. Minimum scattering also occurs at the concentric layers and from the sutures. 
In the bovine lens, the RI increases as a function of increasing protein concentration from 
the anterior surface (periphery) to the nucleus (centre) of the lens [9, 17]. In man, 
however, water content is highest (protein content low) at the periphery and uniformly 
low (protein content high) throughout the lens [18], Any localised change to the protein 
concentration or cellular structure will change the uniform dispersion of the lens fibres, 
resulting in a opacity due to discontinuities in the RI.
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The mechanism of formation of these opacities appears from the physical and chemical 
evidence, to differ between cortical and nuclear cataracts. Cortical cataract lenses have a 
low wet weight and a low total protein content compared to normal lenses [19], whereas 
pure nuclear cataract lenses are normal in weight and protein content. The protein 
concentration changes occurring in the lens cortex often appear to result from osmotic 
alterations. These changes involve the more recently formed fibres and result from 
disturbance in membrane permeability and defects in ion transport, leading, for example, 
to the accumulation of sodium and chloride [20]. Opacities in the nuclear region, on the 
other hand, are associated with protein aggregation, a process involving both covalent 
and non-covalent reactions and not necessarily accompanied by electrolyte or hydration 
changes. Greater amounts of these protein aggregates have been isolated from nuclear 
cataracts than cortical cataracts [15] and the darker nuclear cataracts have compounds 
bound by non-disulphide covalent bonds which appear to be associated with the nuclear 
colour [21, 22].
Protein aggregation probably results from a conformational change in protein structure, 
and may cause increased light scattering and a nuclear sclerosis associated with an 
increase in nuclear colour [9]. The conformational change is non-specific and can occur 
in any of the major and minor proteins (including enzymes) found in the lens and several 
causes for the initiation of the change have been suggested. However, a lack of 
convincing evidence has cast doubt on a number of proposals such as the popular 
sunlight (or UV-light) hypothesis [23]. The free-radical hypothesis is difficult to test 
[24]. Racémisation of aspartyl residues and the oxidation of methionine may follow the 
conformational changes rather than initiate them [25].
Glycosylation [26], carbamylation [27], and binding of glutathione [21] have been 
demonstrated to initiate a general protein conformational change by -
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1) increasing the reactivity of protein thiol groups
2) rendering the protein more susceptible to proteolysis
3) releasing bound-water (syneresis)
4) altering the environment of protein Trp
It has been established [9], that as the protein conformation changes and the molecule 
unfolds, the sulphydryl groups are exposed and oxidised to form disulphide links 
between and within molecules resulting in very high molecular weight (HMW) protein 
aggregates of greater than 50 million Daltons [9, 25]. Other changes associated with the 
formation of the HMW aggregates are a decrease in the 8-crystallin (a water-soluble 
protein) and an increase in the water insoluble proteins [21]. Greater amounts of the 
insoluble proteins have been isolated from nuclear cataract and of particular importance is 
the increase in amount of urea-insoluble coloured protein which can be solubilised in urea 
containing mercaptoethanol [21]. Further evidence in the support of these changes is the 
loss of glutathione, the decrease in the concentration of protein thiols and an increase in 
the amount of methionine sulphoxide [21], all pointing to an oxidising environment 
within the nucleus of the nuclear cataract lens.
The coloured insoluble proteins from the nucleus of cataractous lenses have also been 
associated with traces of products from the oxidation of Trp, namely Kyn and derivatives 
[22], AA [28] and possibly P-carbolines [29].
1.2 Tryptophan Metabolism
Tryptophan (Trp), as an amino acid is unique is a number of ways. It contains an indole 
nucleus; it is the only essential amino acid bound to plasma albumin [30]; and it can be
F igure 1.3
The Principal M etabolic Fate of T ryptophan
----- n— CHvCHCOOH
ZT 6h
w 3-Indolelactic Acid 
H
5-Hydroxytryptophan
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metabolised by several different pathways to a number of specific and physiologically 
important products [31].
A minimum daily requirement for this amino acid is 0.25 g [32] with a recommended 
daily intake of 0.5 g [33].
Once ingested there are four metabolic outcomes for dietary Trp. As an essential amino 
acid, it may be incorporated into de novo synthesis of protein, or it may be metabolised 
by one of three metabolic pathways. Figure 1.3 outlines the major metabolic fate of 
dietary Trp. Only 1% of ingested Trp is metabolised via 50H T to serotonin [34]. 
Serotonin itself can be acetylated in the pineal gland, and then methylated to form 
melatonin. A small proportion (<1%) of ingested Trp is transaminated to indolepyruvic 
acid, then decarboxylated to indoleacetic acid and excreted in the urine [35]. Trp itself can 
also be decarboxylated to tryptamine, deaminated to indoleacetaldehyde, and converted by 
aldehyde dehydrogenase to indoleacetic acid and excreted [36].
A very small amount (<1%) of the ingested Trp may be converted to 3-indolepyruvic acid 
and 3-indoleacetic acid by tissue enzymes, but may also appear in the plasma after 
absorption from the intestine. Intestinal bacteria convert Trp to these two compounds and 
also indoleacetamide [34] which may subsequently appear in the plasma.
The major portion of the ingested Trp, however, is metabolised via the kynurenine 
oxidative pathway to nicotinamide adenine dinucleotide or completely oxidised through 
acetyl CoA to carbon dioxide and water. The initial steps in this oxidative pathway are 
outlined in Figure 1.4.
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The metabolic pathway of Trp oxidative degradation will be briefly outlined here but will 
be reviewed in more detail later in the individual metabolite chapters.
Trp is oxidised in the liver by the highly specific (for L-Trp) rate-limiting enzyme 
tryptophan 2,3 dioxygenase (a) (Figure 1.4). The enzyme has a short-half life of 2 hrs, 
but is further regulated by induction by some hormones, activation of its apoenzyme by 
haem, stabilisation by its substrate (Trp), and inhibition by some of the subsequent 
metabolites of the pathway [31]. Trp may also be oxidised by the less specific, but 
widely distributed enzyme, indoleamine 2,3-dioxygenase present in kidney, heart, lung, 
brain, intestinal mucosa and adrenal gland. This enzyme, which also cleaves D-Trp and 
other indoleamines, utilises the superoxide anion as its oxygen source instead of 
molecular oxygen [31].
The oxidative cleavage (molecular oxygen) of the indole ring of Trp by tryptophan 2,3 
dioxygenase produces formyl kynurenine which is rapidly hydrolysed by the very active 
formylkynurenine formamidase (b) to kynurenine (Kyn). The principal metabolic 
outcome for Kyn is hydroxylation to 3-hydroxykynurenine (30HKyn) by kynurenine 
hydroxylase.is) [31]. With an excess flux through the pathway, however, or a metabolic 
block, Kyn may be transaminated by kynurenine aminotransferase (e) to kynurenic acid 
(KA), or cleavage by the vitamin B6-dependent enzyme, kynureninase (d) to anthranilic 
acid (AA). AA may be further catabolised by a microsomal hydroxylases to 5- 
hydroxyanthranilic acid (50HA) or 3-hydroxyanthranilic acid (30HA) [37]. Like its 
precursor, 30HKyn can also be transaminated and by the same enzyme, kynurenine 
amino transfer as e(e) to xanthurenic acid (XA), but the preferred metabolism is via 
kynureninase (d) to 3 OH A in the presence of pyridoxal [38].
COOH
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Of equal importance, but not examined as part of this thesis, is the fate of Trp metabolism 
after 30HA. Under the catalytic activity of 3-hydroxyanthranilic acid oxidase(f), 30HA 
is rapidly oxidised to acroleyl aminofumarate, which can either undergo enzymic 
decarboxylation to aminomuconic semialdehyde and eventually complete oxidation, or 
can be non-enzymically cyclised(h) to quinolinic acid for eventual NAD synthesis 
(Figure 1.5). It appears that the direction of metabolic flux is determined by the amount of 
substrate available for the enzyme, picolinic carboxylase(g). Once the carboxylase is 
saturated with its substrate, acroleyl aminofumarate, any excess aminofumarate is then 
available for non-enzymic cyclisation to quinolinic acid. As a result there is increased flux 
along this branch of the pathway and therefore increased synthesis of nicotinamide 
nucleotides [38].
Under normal liver concentrations of nicotinamide, the enzyme nicotinam ide  
deamidase{\) and nicotinamide phosphoribosyl transferase(m) are saturated with their 
substrate and therefore contribute little to nucleotide synthesis suggesting that this 
mechanism becomes significant only when nucleotide production by other pathways is 
dangerously low. On the other hand, nicotinate phosphoribosyltransf erase (k) normally 
operates below its Vmax which implies that an increased intake of nicotinic acid (niacin)
would result in an increase in the rate of incorporation into NAD. Also quinolinate 
phosphoribosyltransferase (i) normally operates below its Km and therefore is capable of 
utilising any increase in available substrate [31].
In summary, any increase in the rate Trp metabolism such as occurs after an oral loading 
dose, should initially induce and stabilise tryptophan 2,3 dioxygenase (a) and 
subsequently increase the concentration of the metabolites shown in Figure 1.4. At the 
metabolic branch point shown in Figure 1.5, picolinic carboxylase (g) is likely to become 
saturated with acroleyl aminofumarate and thus a finite amount of the original Trp is
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completely oxidised to acetyl CoA. The excess substrate (aminofumarate) will be non- 
enzymically cyclised to quinolinic acid leading to the production of NAD. Any excess 
NAD can be hydrolysed to nicotinamide by NADase(n). Nicotinamide in excess can be 
methylated to N^-methyl nicotinamide and excreted or it may be oxidised to methyl 
pyridone carboxamide prior to excretion.
1.2.1 The Tryptophan Load Test & Vitamin B6
It has been known since the 1940s that xanthurenic acid is excreted in large quantities in 
the urine of individuals with vitamin B6 deficiency, and XA was known to be a 
metabolite of Trp [39]. The development of methods to assess both XA and KA led to a 
procedure for the assessment of vitamin B6 deficiency by measuring these two 
metabolites after a loading dose of L-Tip. Early investigations used relatively large doses 
compared to the normal daily intake of Trp. This led to recommendations for a 
standardised dose of 2 g L-Trp given in milk or orange juice [40, 41]. Others however 
have suggested that rather than a constant dose of 2 g, a weight-related dose of 50 mg Trp 
be given for every kg body-weight [42].
The rationale behind the loading test derives from the presence of the vitamin B6 
dependent enzyme, kynureninase, in the Trp metabolic pathway (Figure 1.4). Under 
ideal conditions, the activity of the pathway enzymes is sufficient to prevent any 
accumulation of metabolites. The Km of kynurenine aminotransferase for its substrates is 
relatively high and the Km of kynurenine hydroxylase and kynureninase is low for their 
substrate and metabolic flux therefore proceeds in the direction of 30HA [38]. In vitamin 
B6 deficiency the activity of kynureninase (vitamin B6 dependent) is lowered. The 
activity of tryptophan 2,3 dioxygenase remains high (particularly after a Trp load), Kyn 
and 3 OH Kyn accumulate, exceeding the Km of the aminotransferase resulting in an 
increase of KA and XA (Figure 1.6). The aminotransferase is also a vitamin B6
3 0009 03132042  2
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dependent enzyme but it appears to be less affected by a deficiency because it either (1) 
binds its coenzyme more tightly than does kynureninase, (2) has a slower rate of turnover 
or (3) it is a mitochondrial enzyme and is relatively protected compared to cytosolic 
enzymes [43]. Assessment of the response to the Trp load has been gauged by the 
measurement of the excretion of XA and KA excretion in the urine [44].
It has been observed [45] that several and varied pathological conditions result in the 
abnormal excretion of Tip metabolites and the authors noted that it was unlikely that they 
all resulted from a vitamin B6 deficiency. Also because of the inducible nature of 
tryptophan 2,3 dioxygenase and other influences on the Trp metabolic pathway, the 
reliability of the Tip load test has been questioned as a reliable indicator of vitamin B6 
deficiency [43]. This does not mean, however, that the test is not useful as a procedure 
for determining the ability of an individual to cope with a metabolic stress imposed with 
such a load.
1.2.2 E osinophilia-M yalgia  Syndrom e and T ryptophan
In January, 1990 the Australian Health Department recalled all products which contained 
Trp as the major or sole ingredient, and Trp was subsequently restricted only for use as 
treatment of patients under medical supervision [46]. A hiatus in the use of Trp in 
patients on this research program therefore occurred.
Prior to the recall, in October, 1989, an association between the use of oral preparations 
of Trp and the appearance of symptoms of eosinophilia and severe myalgia was notified 
to the New Mexico Department of Health in the USA. The symptoms were not consistent 
with any then known diagnostic entity [47]. A retrospective case-control report [48] 
prepared by the New Mexico Health Department and the Centre for Disease Control 
(CDC) led to the New Mexico state ban and a subsequent nationwide ban. The CDC
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recommended that for a case to be diagnosed as Eosinophilia-Myalgia Syndrome (EMS) it 
should be characterised by (1) an eosinophilia count of > 1000 cells per mm3, (2) a 
generalised myalgia of severity sufficient to affect a patient's ability to pursue usual daily 
activities, and (3) an absence of infection, infestation (esp. trichinosis) or neoplasm 
which would could account for one the above symptoms [47],
The Food and Drug Administration (FDA) in the following month, November, 1989, 
sought a nationwide recall of Trp-containing products and announced a public alert, while 
they evaluated the production procedures of companies in Japan, where Trp was 
produced [49]. By December, 1989, 730 cases of EMS had been reported from all states 
to the CDC. Four deaths had been reported in patients who met the EMS criteria of the 
CDC. From those cases reported to have ingested Trp prior to the onset of symptoms the 
median dose of Trp was 1.5 g per day (range 0.5 to 5 g per day) [50].
Although a recommendation [51] of the potential neurotoxicity of Trp had been published 
in 1988, the sudden appearance of so many cases in 1989 led to the expectation of a toxic 
contaminant in batches of Trp [52]. Several papers [53-56] then appeared further 
describing the clinical features of EMS, and its similarities with other diseases such as 
eosinophilia fasciitis, scleroderma, and eosinophilia myositis and toxic oil syndrome. It 
was also suggested that abnormal Trp metabolism rather than a contaminant was the cause 
[53, 55]. No effective therapy was available for the disease [56].
It wasn't until July 1990, that a report [57] linking EMS and the brand of Trp used, 
implicated the one manufacturer. Virtually all the Tip sold in the world as part of health 
food supplements, is manufactured in bulk in Japan by six companies [58]. Although 
different production methods are used, bacterial fermentation is the common process, 
using Bacillus amyloliquefaciens with anthranilic acid as the starting material [57]. One
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company (Showa Denko, K.K., Tokyo), however, had introduced a genetically 
engineered variety of the bacterium, B.amyloliquefaciens, (Strain V) to increase the yield 
of Trp. They also reduced the amount of activated charcoal filtering in the process. Both 
these factors were significantly associated with the occurrence of EMS and Trp from this 
source. This study [57] also identified an additional peak ("Peak E") in the HPLC 
analysis of batches of Trp produced by this company.
Two reports appearing in November, one from the manufacturer’s laboratory, [59] and 
one jointly from the FDA and CDC [60], identified Peak E as the di-tryptophan aminal of 
acetaldehyde (Figure 1.7a) which rapidly decomposes in acid solution to 1-methyl- 
1,2,3,4-tetrahydro P-carboline-3-carboxylic acid (Figure 1.7b). Toxicity of the 
compounds was estimated to be very high with a dosage of only 6-7 mg (based on 2 g 
trp/day for 30 days) required to trigger EMS [58].
By June 1990, at least 1,500 cases including 26 deaths had been reported in the United 
States [61], but only two cases were reported in Australia. The first reported case [62] 
involved a woman who had acquired the Trp while in the United States and the second 
[63] was a 23 year old male who could not recall the source or the quantity of Trp used. 
Animal models have been used in an attempt to elucidate the pathogenesis of the disease 
[61].
In February, 1990, all patients and controls in this study who had been loaded with Trp 
up until that time, were contacted by mail and requested to attend the hospital where the 
loading test had been carried out. In all 22 patients and 5 controls were contacted, but 
only 15 returned for a follow up examination consisting of a full blood count and 
consultation with a medical officer. None of the patients or controls examined had
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developed myalgia or unusual skin rash since the Trp load nor exhibited eosinophilia at 
the time of examination. The research program continued in September, 1990.
1.3 Role of Tryptophan in Cataract
As far back as 1957, a metabolite of Trp was implicated in cataract formation. Ogino and 
Ichihara [64] were able to extract AA and 50HA from the urine of patients suffering from 
senile cataract, but could not isolate either substance from the urine of control subjects. 
The urinary extracts containing the 50HA, when injected into scorbutic guinea pigs, 
produced cataracts in those animals. They maintained that the quinonimine carboxylic acid 
produced from 50HA was the cataractogenic substance. This quinoid, like other quinoid 
substances was able to induce experimental cataracts. This was achieved when the 
purported quinonimine was injected into the scorbutic guinea pigs. Due to the pronounced 
reactivity of such o-quinonimines, it seems unlikely that this would in fact be the 
compound which was injected.
Anthranilic 5-HydroxyanthraniIic Quinonimine Carboxylic
Acid Acid Acid
Musajo [65], however, was unable to find 50HA in the urine of cataract patients. No 
other investigations were recorded for Trp metabolism and cataract, until the 1980s when 
Costa and co-workers [66] found an increase in some Trp metabolites in the urine, 
generally in conjunction with increasing severity of cataract. Especially increased were 
Kyn, KA, the glycine conjugate of AA (o- aminohippuric acid) and 30HA, though the 
latter was not increased in the severely affected group. They did not, however, observe 
any A A or 50HA in the urine of their patients.
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Trp was also implicated in cataract formation when Cotlier and Sharma in 1980 [67] 
reported that both free and protein-bound Tip were increased approximately two-fold in 
the plasma of cataract and aphakic patients above that of age-matched controls. They also 
reported finding increased indole acids and binding of Trp to lens protein and the 
presence of Trp dioxygenase activity in the ciliary body.
This finding was challenged in 1981 by Allegri and Angi who found no differences in 
both total and free Trp concentrations in fasting cataract and control subjects [68], The 
elevated Tip levels, they suggested, resulted from an altered metabolism of Trp in cataract 
patients and that fasting levels were the same in both groups. The issue was further 
complicated by the report of an English group, who found fasting levels of free and total 
Trp were approximately two-fold higher in cataract patients [69]. An Australian study 
subsequently found no significant difference in fasting serum Trp levels [70].
It is interesting that all these investigations used an indirect fluorescence method based on 
the detection of Tip as the norhannan derivative [71] and this method is notoriously prone 
to interference [72]. To what extent this may explain the differences between these 
studies is not known. The situation regarding Tip involvement in cataract formation was 
at best unclear.
Trp loading has been used by several workers for various pathological conditions (see 
Chapter 4). Much of the work done, however, reported on the urinary excretion of Trp 
metabolites, or on the response of Trp itself. No authors have studied the response of 
serum Trp metabolites to Tip loading especially in age-related cataract.
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The Italian group mentioned earlier [66] found that the serum levels of free and total Trp 
showed no significant difference between cataract patients and controls, both before and 2 
hrs after a 50 mg/kg load of L-Trp.
Another group in Italy [73, 74] measured free and total Trp levels only in the serum of 
cataract patients and controls. In their first report Libondi, et al [73] determined fasting 
levels in 53 cataractous adult patients and 27 controls. They concluded as have others 
[66,68,70] that there was no significant difference between cataract and control patients.
Trp is the only amino acid which is bound to albumin to any appreciable extent [30], and 
it had been reported [75], that acetylsalicylic acid can alter the binding of Tip to albumin, 
thereby lowering serum total Trp and releasing free Trp for uptake into tissues and 
metabolism. Patients suffering from rheumatoid arthritis and using acetylsalicylic acid as 
medication were found to have a lower incidence of cataract [76]. Sporadic use of aspirin 
in low-dosage was reported as not offering protection against cataract development [77]. 
Harding, [7] however, reported that it did offer protection. Also, it has been shown [78], 
that in vitro aspirin does protect lens protein against chemical modification (viz. 
carbamylation). Further work on the role of aspirin in cataract has been suggested [79]. 
Nevertheless, the suggestion that high-dose aspirin therapy may retard the development 
of cataract [80] added support to the notion that there maybe a link between Trp 
metabolism and cataract formation. The possible link between cataract and aspirin use is 
discussed fully in a review by Harding [7].
It has been known for some time that Trp and some of its oxidation metabolites are 
present in the human lens [9, 22, 28, 29]. Allegri lound that the concentration of free Tip 
decreases with the evolution of cataract, and suggested that since there was no evidence 
for the leakage from the lens, that the Trp is metabolised into pigments via Kyn,
Introduction Page 18
contributing to the yellow-brown colour of cataractous lenses [81]. Bessems and 
Hoenders [82] however, found no such decrease in Trp.
One of the o-aminophenol metabolites of Trp, 30HA has been shown to readily oxidise at 
neutral pH [83] and has been proposed as a chemical model for the development of 
nuclear cataract [84]. This metabolite has not been demonstrated in the human lens, but 
30HKyn, also a o-aminophenol metabolite of Trp has recently been shown [85] to 
modify proteins in a similar manner to 30HA. 30HKyn has been identified as a 
significant UV-filter compound in the human lens [86]. Both 30HA and 30HKyn have 
demonstrated an ability to act as effective antioxidants in biological systems [87]. The 
consequence of the oxidised aminophenols was not established in that study, but the 
reaction of oxidised aminophenols with lens proteins had been proposed previously [88] 
as a possible mechanism for nuclear cataract formation.
It is evident that Trp has been linked with cataract, but the data are not extensive and a 
controversy has emerged even over the levels of plasma Trp in cataract patients. It was 
necessary therefore to examine whether differences are evident in the manner in which the 
amino acid is metabolised between persons suffering from cataract and those without the
disease.
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2.1 Introduction
The metabolites of Trp have been assayed by various means and techniques since 1901-03 
when F. Hopkins and S. Cole first determined the structure of Trp [89].
These techniques have included colorimetry, fluorimetry, thin-layer chromatography, gas 
chromatography, and high-performance liquid chromatography.
2 .1 .1 . C olorim etry
Analytical assays employing this technique are mainly of historical interest and usually 
require a separate method for each metabolite [90-92]. These techniques are notoriously 
plagued by interferences from metabolites of similar structure and therefore were not specific 
enough for the purposes of this study.
2 .1 .2 . F lu orim etry
The most popular method using this principle was that of Denckla and Dewey [71] which 
used the formation of the fluorophore, norharman from Trp by condensation with 
formaldehyde. This method, like its predecessors was troubled with many interferences 
[72] and was not as specific as originally reported.
2.1 .3 . T hin-layer chrom atography
Although very selective when used two-dimensionally, this technique could not be easily or 
accurately quantified [93, 94], and was not considered suitable for the measurement of the 
small quantities of metabolites investigated in this study. The related technique of two­
dimensional paper chromatography has been used by previous investigators [64,95,96]
2.1 .4 . G as-liquid  chrom atography
Gas liquid chromatography (GLC) in the late sixties and early seventies was used as a
Methodology Page 21
method of high sensitivity, but these methods usually assayed only one metabolite. 
Derivatisation and the development of the electron capture detector increased the sensitivity 
of the technique, but still only allowed the measurement of one or two metabolites [97]. This 
limitation made the technique of GLC less suitable for use as a method for the assay of 
several Trp metabolites simultaneously.
2.1.5. H igh perform ance liquid chrom atography
Of the five techniques, the most popular method is the relatively recent development of 
HPLC. The large variety of solid phases available to the technique contrasts with the relative 
deficiency of solid phases accessible in TLC and GLC. Alterations to the mobile phase is 
usually the only means of optimising a method on these forms of chromatography.
The introduction of reversed-phase chromatography had allowed the separation of very 
similar structures (eg. 50HT and Trp) and completely different structures (eg. KA and Trp) 
in the same assay run. Reversed phase chromatography contrasts to normal phase 
chromatography by having a relatively inert stationary phase (usually a hydrocarbon) and a 
slightly more polar mobile phase (usually water, methanol, acetonitrile, ethanol, or 
propanol). The selectivity of reversed-phase HPLC is dominated by solvent effects. These 
effects in an aqueous mobile phase allow for easier optimisation of a method by varying the 
organic solvent, the addition of a buffer salt, and by adjusting the pH of the mobile phase 
[98].
The versatility of this technique made it the obvious method of choice for investigation of 
Trp metabolites in the biological samples intended for this study.
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2 .2  Materials & Methods
2.2.1 C hem icals
All chemicals used in buffers were of analytical grade. The water used was double-glass 
distilled and passed through a Milli-Q system prior to use.
The nine reference metabolites investigated were :
i) Tryptophan (Trp), 3-hydroxykynurenine (30HKyn), 3-hydroxyanthranilic 
acid(30HA), and kynurenine(Kyn) - (representing the Kvnurenine pathway).
ii) Xanthurenic acid(XA), 5-hydroxyanthranilic acid(50HA), kynurenic acid(KA), 
anthranilic acid(AA) (representing the Kvnurenine-Branched pathway).
in) 5-hydroxytryptophan (50HT) (representing the Serotonin pathway!.
These chemicals were obtained from either Sigma Chemical Company (St.Louis, MO, USA) 
or from Fluka AG, Switzerland.
2.2.2 A pparatus.
The liquid chromatograph used consisted of a ICI-Instruments Model 1100 Solvent Delivery 
pump, an ICI-Instruments Automated Sample Injector Model LC1600, a Shimadzu 
Electrochemical Detector Model L-ECD-6, and a Hewlett-Packard Programmable 
Fluorescence Detector 1046A. Chromatograms were recorded using the ICI Instruments 
DP800 Software package. Analytical separations were performed on a Beckman 
Instruments stainless steel column, 10 cm x 4.6 i.d. packed with 5um Ultrasphere-octyl 
(C8). A 3 cm long Brownlee RP8 column was fitted as a guard column. The system 
configuration is shown in Figure 2.1.
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Figure 2.1 HPLC System  C onfiguration
Figure 2.2 Photograph of HPLC System
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2 .2 .3  C hrom atographic C onditions.
The optimum mobile phase was found to be 20 mM sodium acetate buffer at pH 4.50, with 
no organic modifier present. The buffer was prepared from a mixture of stock solutions of 
200 mM sodium acetate and 200 mM acetic acid to obtain a pH of 4.50. This 200 mM 
buffer was then diluted 1 to 10 to produce the final mobile phase, which was then readjusted 
to pH 4.50 with 5M NaOH, filtered and degassed by sonication under vacuum prior to use. 
The solvent flow rate was 0.6 mL/min and separations were performed at ambient 
temperature. Detection was achieved amperometrically at 990 mV and also fluorimetrically at 
excitation and emission wavelength optimised for each metabolite.
2.2.4 O ptim isation M ethod
The stock solution of the nine reference metabolites was prepared by dissolving each in 20 
mM acetate-citrate buffer, pH 4.5 at a concentration of 100 mg/L [99]. Aliquots were stored 
frozen at -20° C. A standard curve was prepared from the frozen stock solutions diluted 
with 20 mM acetate buffer. A four point standard curve was run prior to each batch of 
samples.
The parameters listed below were investigated in sequence to optimise the chromatographic 
separation of the metabolites. Individual dilutions of each metabolite were used to measure 
operating potentials and fluorescence spectra.
2.2.4.1 pH
Volumes of 200 mM acetic acid and 200 mM sodium acetate were varied to produce the 
desired pH. This solution was then diluted 1 to 20 to obtain an operating acetate 
concentration of 20 mM.
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2.2.4.2 Acetate Concentration
After establishing the optimal pH, the buffer was prepared with 200 mM acetic acid and 
sodium acetate and this solution was then diluted to achieve the desired concentrations. If 
necessary, the pH was adjusted with concentrated hydrochloric acid or 5M sodium 
hydroxide.
2.2.4.3 Ionic Strength
In order to test the effect of salt concentration, sodium chloride was added to the 20 mM 
acetate buffer, pH 4.50, to produce a final concentration of chloride ion equivalent to 0.1 M 
and 0.2 M.
2.2.4.4 Applied Potential
To determine the optimum operating potential, each metabolite was injected (20 mL) on 
column and the operating potential changed incrementally in a stepwise manner from 300 mV 
to 1000 mV. Potentials were confirmed or compared against cyclic voltammetry.
2.2.4.5 Fluorescence Spectra
Excitation and emission maxima were determined by stop-flow and manual scanning of each 
metabolite. Photomultiplier response was optimised for each metabolite at 10 ng on column. 
The detector was then programmed to set each optimised wavelength at a time prior to elution 
of the appropriate peak. Fluorescence peak maxima were confirmed or compared against a 
recording spectrofluorimeter.
2.2.4.6 Linearity and Sensitivity
To determine the linearity and sensitivity of the detectors, increasing amounts of each 
metabolite were injected onto the column and the detector responses were measured as peak
area.
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2.3 Results & Discussion
Initially, attempts were made to separate Trp metabolites using established methods [99, 
100] employing 10 mM acetate buffer at pH 4.84 with no organic modifier. In the procedure 
of Krstulovic et al. [99] Trp metabolites were separated on a C-18 column in 40 mM acetate­
citrate buffer with 7% acetonitrile. In another method [100] a 10 mM sodium acetate buffer at 
pH 4.84 containing no organic modifier was employed.
Using the 40 mM acetate-citrate buffer [99], 50HA, a metabolite of major concern in this 
study, was found to partially co-elute with 30HKyn. In an attempt to rectify this, the 
organic modifier was reduced but it was found that concentrations of acetonitrile below 0.5% 
did not allow elution of the compounds from the column. As shown in Figure 2.3, 
resolution of metabolites eluting prior to Trp, was not altered significantly by concentrations 
of acetonitrile below 7%.
Figure 2.3 . The effect of an organic m odifier
C8 column, 10 cm x 4.6 mm;.
20 mM acetate buffer, pH 4.5; 0.6 mL/min
The 10 mM acetate buffer at pH 4.84 produced a longer analysis time, but afforded better
Figure 2.4
The effect o f pH on the retention tim es of tryptophan m etabolites
C8 column, 10 cm x 4.6 mm;.
20 mM acetate buffer; 0.6 mL/min
Figure 2.5
The effect o f Acetate Ion C oncentration
C8 column, 10 cm x 4.6 mm;.
Acetate buffer, pH 4.5; 0.6 mL/min
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resolution.
The 40 mM buffer was chosen as the starting mobile phase for the optimisation of the C8 
column. Changing the pH of the mobile phase in the range pH 3.0 - pH 5.0 was found to 
affect the retention times of some metabolites, most notably that of AA. In general, a mobile 
phase of low pH produced good separation of the slower eluting compounds, but yielded 
poor separation of the earlier compounds. The highest pH tested (pH 5.0) gave the poorest 
separation. As shown in Figure 2.4, the separation between Trp and XA decreased as the 
pH was raised from 4.5 to 5.0. Since the Trp peak in serum samples following a Trp load 
was large it obscured the XA peak if buffers of pH 4.85 or 5.0 were used. Varying the 
concentration of acetate did not have a major affect on metabolite retention time. Because of 
the large peak expected in a sample obtained after a loading dose, it was necessary to have 
the Trp peak resolving at the maximum distance away from other metabolites. The best 
separation was obtained using 20 mM acetate, where 30HA, XA, and Trp show the best 
resolution (Figure 2.5).
The effect of the increase in the ionic strength on the retention times of the metabolites was 
not significant.
The oxidation potentials of each compound were measured by plotting peak area at each 
potential. Figure 2.6 shows the polargraphic plot of each metabolite. Of the compounds 
tested only KA did not elicit any response from the electrochemical detector up to 1000 mV. 
This finding agrees with that of others [99].
(20 mM acetate buffer, pH 4.5 and flow-rate 0.6 mL/min.)
Figure 2.7
C hrom atogram  illustrating the separation o f reference
com pounds with ECD at 990 mV
LEGEND
1 = 50HA 2 = 30HKyn 3 = 50HT 4 = Kyn 5 = 30HA
6 =  XA 7 = KA 8 = Trp 9 = A A
i i  i i i i
10 20 30 40 50 60
Time (minutes)
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Figure 2.6 Polargraphic Curves o f Tryptophan
M etabolites
The limiting current and the half-wave potentials for each of the compounds are listed in 
Table 2.1.
TABLE 2.1
METABOLITES LIM ITING CURRENT !/2WAVE p o t e n t i a l
(m illivolts) (m illivolts)
5-Hydroxyanthranilic acid 500 370
3-H ydroxykynurenine 500 430
5-H ydroxytryptophan 600 455
Kynurenine >1000 >1000
3-Hydroxyanthranilic acid 700 635
Xanthurenic acid not tested not tested
Kynurenic acid not electroactive not electroactive
Tryptophan 1000 810
Anthranilic acid not tested not tested
The chromatogram displayed in Figure 2.7 shows the electrochemically detected separation
(20 mM acetate buffer, pH 4.5 and flow-rate 0.6 mL/min.)
Figure 2.8
C hrom atogram  illustrating the separation o f reference
com pounds w ith program m able fluorescence detection
LEGEND
1 = 50HA 2 = 30HKyn 3 = 50HT 4 = Kyn 5 = 30HA
6 = XA 7 = KA 8 = Trp 9 = A A
10 20 30 40 50 60
Time (minutes)
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of metabolites in 20 mM acetate buffer, pH 4.50, each at a concentration of 1 mg/mL or 10 
ng on-column per injection, and at an operating potential of 990 mV. At this potential all 
compounds except Kyn are above or at their limiting current. Kyn requires an operating 
potential of at least 900 mV to elicit a response from the detector.
Of all the Trp metabolites investigated only three compounds (30HKyn, Kyn, and XA) did 
not show any native fluorescence at the operating pH of 4.50. However, KA (which did not 
exhibit any electrochemical activity) was detectable by fluorescence. Fluorescence data 
reported elsewhere [101] indicate that these three compounds do fluoresce, and also that KA 
had a higher maximum than that found in the current study. The data in the literature, 
however, were obtained in alkaline conditions at pH 11 (ie. the medium at which their 
fluorescence intensity is considered the highest) while the spectral characteristics listed here 
were acquired in acidic conditions. Furthermore, as indicated in the instrument's operating 
manual [102] the design of fluorescence detectors makes difficult the exact comparisons of 
spectral data, obtained on other equipment. The fluorescence spectra of the metabolites at 
pH 4.50 are listed in Table 2.2 and the fluorescence chromatogram of the metabolites in 20 
mM acetate buffer is shown in Figure 2.8
TABLE 2.2 FLUORESCENCE CHARACTERISTICS
METABOLITES Excitation Wavelength
________ (nanometres)________
Emission Wavelength
________(nanometres)_______
5-Hydroxyanthranilic acid 
3 - Hydroxykynurenine
237
Non-fluorescent at pH 4.5
453
Non-fluorescent at pH 4.5
5-Hydroxytryptophan 230 340
Kynurenine Non-fluorescent at pH 4.5 Non-fluorescent at pH 4.5
3-Hvdroxvanthranilic acid 235 450
Xanthurenic acid Non-fluorescent at pH 4.5
Kynurenic acid 238 375
Tryptophan 227 356
Anthranilic acid 244 403
Figure 2.9 L inearity o f Tryptophan Response
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Table 2.3 lists the sensitivity and linearity of each of the metabolites expressed in picomoles 
injected on-column. The limit of detection was taken as a signal to noise ratio of 2:1. The 
detector response was found to be linear for the concentration range likely to be observed in 
our samples, but for some metabolites larger amounts were injected and the response was 
still found to be linear. The upper levels which were tested are listed in the Table but the 
upper linear limit may be significantly higher.
TABLE 2.3 : DETECTOR PERFORM ANCE
M etabolite D etector Sensitiv ity
(picom ol)
L inearity
(picom ol)
Recovery
%
Signal:N oise
50H A Fluorés. 6 1300 99 14
3 0 H K y n 480 mV 9 890 30 20
50H T 990 mV 4 910 76 45
K yn 990 mV 96 192 106 20
30H A 990 mV 6 1300 ! 98 20
XA 990 mV 7 970 ! 35 ! 10
KA Fluorés. 5 105 ! 76 1 7
Trp Fluorés 2 6000 ! 105 40
Trp 990 mV 2 2000 ! 98 I 10
AA 990 mV 7 290 | 92 ! 10
Tryptophan was unique amongst the compounds investigated. Since the procedure was to 
have a loading dose of Trp, it was expected that the serum Trp level would be of a higher 
magnitude than that of its metabolites. For this reason higher concentrations of Trp were 
used to determine the linearity of the detectors. Other reports have shown Trp levels as high 
as 300 pmol/L, therefore samples up to this concentration (6000 pmol on column) were 
injected onto the HPLC column. Both detection systems were used to check the linearity of 
Trp. Although UV detection was not considered an option, because of its lower sensitivity 
for other metabolites, it was included in the linearity experiment as a comparison. There are
C E G E N D
1 = 50HA 2 = 30HKyn 3 = 50HT 4 = Kyn 5 = 30HA
6 = XA 7 = KA 8 = Tip 9 = A A
Figure 2.10
Chrom atogram  illustrating the separation o f a spiked serum
sam ple with ECD at 990 mV
I I I I • •
10 20 30 40 . 50 60
Time (minutes)
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several methods in the literature [100, 103-107] which use UV as the detection for 
measuring Trp following HPLC. Figure 2.9 illustrates the linearity graph for each detection 
system. It can be seen from the graphs that fluorescence and UV at 280 nm are both linear 
for trp concentrations up to 282 pmol/L, whereas ECD was linear only to a concentration of 
94 nmol/L. Clearly, if Trp were to be measured by ECD, less material would have to be 
injected or the sample diluted prior to injection.
Figure 2.10 shows the chromatogram obtained from the electrochemical detector. The 
sample was 1 mL of serum* spiked with 0.5 |ig of each metabolite. Some large peaks were 
found to be present in serum samples which interfered with the quantification of 50HA 
(peak 1) and 30HKyn (peak 2) at 990 mV. Although 50HA was completely masked at this 
potential, 30HKyn was sometimes seen but was not adequately resolved from the serum 
peak to be quantified. However, 50HA was able to be measured by fluorescence without 
any interfering peaks, as shown in Figure 2.11. This chromatogram was the same sample 
shown in Figure 2.10, but recorded by the programmable fluoresence detector. This 
detector also makes possible the measurement of the non-electroactive KA (peak 7) which 
elutes immediately prior to Trp (peak 8).
It was desirable for an HPLC assay intended for routine use to be the shortest possible. 
However, this requirement needs to be balanced against the need for adequate resolution of 
most if not all of the compounds of interest
The 20 mM acetate buffer described in this chapter provides resolution of the earlier eluting 
compounds and also allows for maximum separation of Trp. Since the HPLC system was to 
be used to monitor samples from a Trp load test, it was essential that the chromatography
* Serum samples were prepared as outlined in Chapter 3.
L E G E N D
1 = 50HA 2 = 30HKyn 3 = 50HT 4 = Kyn 5 = 30HA  
6 = XA 7 =  Trp 8 =  AA
Figure 2.11
Chrom atogram  illustrating the separation o f a spiked serum
sam ple with program m able fluorescence detection.
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system provide maximal separation of Trp from the closest eluting metabolites. The amount 
of Trp present in either a serum or a urine sample following the load produces a very broad 
chromatographic peak which does not interfere with any of the metabolites present. For this 
reason we have found that even though the analysis time was longer than that obtained with 
acetate-citrate buffer [99], the increased separation obtained with the 20 mM acetate buffer at 
pH 4.50 allows better resolution with physiological samples.
Non-protein constituents in serum and urine were also found to interfere with 
electrochemical detection. One of these compounds was found to be uric acid, the 
electrochemical nature of which has been described in earlier reports [108, 109]. This 
excretion product elutes as a large broad peak between 50HA and 30HKyn and can be seen 
contributing to the broad peak in Figure 2.10. Uric acid does not oxidise below 500 mV, 
and 30HKyn can be detected using dual electrochemical cells connected in series; the first 
with an operating potential of 480 mV and the second, with an operating potential of 990 
mV. However, as can be seen from Table 2.3 the percentage recovery of 30HKyn at this 
potential was only 30%. This method, therefore proved unsuitable for the measurement of 
30HKyn in serum.
The programmable fluorescence detector was introduced to facilitate the measurement of 
50HA since it could not be measured at 990 mV because of interference from other serum 
constituents. The programmable capability of this detector increased the selectivity of the 
system and also allowed the measurement of the previously undetectable KA.
The method described in this chapter provides a sensitive and selective assay for the major 
metabolites of the Trp-Kyn degradation pathway and for Trp metabolites arising from branch 
pathways. No other method in the available literature at the time of development achieved 
this objective.
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3.1 Introduction
The development of high performance liquid chromatography, and more particularly the use 
of reversed phase techniques has allowed the measurement of a large variety of small 
molecules in biological fluids As shown in the previous chapter, it is possible to optimise 
buffers, columns, and detectors such that molecules of similar structures can be separated 
and measured with sensitivity, precision and accuracy.
One of the greatest challenges in quantifying small molecules in biological fluids is to 
remove the effects of the larger molecules, such the larger peptides, lipids and proteins. This 
must be achieved with minimal change to the molecules to be measured.
Crude biological samples when directly injected onto an HPLC column can cause major 
problems, and blood serum (or plasma) is no exception. Serum has relatively high 
concentrations of proteins (40-60 g/L) and unless they are removed from the sample by 
chemical or physical means, they can block the flow of mobile phase through the column. 
Over the years, many techniques of protein removal from biological specimens have been 
introduced and many of these remain suitable for modem techniques such as HPLC. These 
will be discussed later in this chapter. Plasma is often chosen as a specimen because it is not 
necessary to wait for blood to clot before separating the plasma from the cells. However, 
other problems can arise from the presence of the anti-coagulant itself. Furthermore, 
because the coagulation process has been interrupted, clot formation may occur 
spontaneously during subsequent processing. Urine, on the other hand, because of its 
lower protein concentration (usually less than 0.1 g/L), does not require protein removal. 
However because of its chemical complexity, analysis of urine involves other preparation 
techniques.
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This chapter describes the experiments used to establish a specimen handling protocol prior 
to analysis by the HPLC method described in Chapter 2.
3.2. Materials and Methods
All metabolites used in these experiments are the same as stated in the Materials & Methods 
section (section 2.2) in Chapter 2. Pooled sera described in this chapter was obtained from 
samples taken from patients having routine biochemical examinations in the Biochemistry 
Department of the Illawarra Regional Hospital, Wollongong.
All blood samples were collected using the B-D Vacutainer system of evacuated blood 
collection tubes, with a tube holder, and a special 21 gauge hypodermic needle (obtained 
from Becton-Dickinson & Co., Lane Cove NSW). Blood was collected into tubes 
containing no anticoagulant (unless otherwise stated).
The HPLC method of analysis of Trp metabolites is the technique described in Chapter 2.
Trichloroacetic acid, perchloric acid, phosphoric acid, and sulphosalicylic acid were obtained 
from Ajax Chemicals (Ajax Chemicals, Auburn, NSW) and were of analytical grade. All 
reagents were prepared using distilled, deionised water.
Serum was precipitated in plastic 10 mL plastic centrifuge tubes (Hardie Health Care 
Products, Gladesville, NSW), mixed on a vortex mixer and transferred to 2 mL plastic 
micro-centrifuge tubes with snap-on caps. 10
10 mL blood specimens were centrifuged in a Heraeus Labofuge at 1,780 x g for 10 minutes 
(unless otherwise stated). Precipitated serum specimens were centrifuged in Centra-IEC 
Microcentrifuge at 15,600 x g for 3 minutes (unless otherwise stated).
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Centricon-30 centrifugal ultrafilters were obtained from Amicon (Supplied by Australian 
Medical & Scientific, Chatswood, NSW) Centricon-30 ultrafilters were centrifuged in a 
Heka fixed-angle rotor centrifuge for 30 minutes at 3200 g (5500 rpm).
A special gas mixture (5% CO2 ; 95% N2) was supplied from CIG Gases Ltd. Cringila, 
NSW.
ABL-30 Blood Acid-Base Analyser (Radiometer, Copenhagen supplied by Foss Electric 
Pty. Ltd. Lane Cove, NSW) was used to measure serum pH and pCC>2 levels.
Any additional materials used in the methods described below are listed separately under that 
method.
3.2.1 Choice o f Specim en
Three different types of blood collection tubes were available: (i) an evacuated tube 
containing di-potassium ethylene diamine tetra-acetic acid (EDTA) as an anti-coagulant to 
obtain a WHOLE BLOOD specimen; (ii) an evacuated tube containing lithium heparin as an 
anti-coagulant in a second tube so that after centrifugation PLASMA could be obtained; (iii) a 
third evacuated tube containing no additives, so that after separation from the blood cells, 
SERUM could be obtained.
3.2.2 Sam ple clean-up
Four well known protein-precipitating acids were tested for their effect on the 
electrochemical and fluorescence detection systems.
F igu re 3.1
C en tricon -30  A pparatus
L E G E N D
1. Centricon apparatus before assembly. Both sections are filled with 5% C02; 95% 
N2 gas mixture after serum is placed in top section.
2. Both sections are sealed with Parafilm after gasing and then centrifuged.
3. After centrifugation, Parafilm is removed and the ultra-filtrate is contained in the 
bottom section.
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1. A "pooled" serum sample, spiked with Trp and eight of its metabolites (50HA, 
30HKyn, 50HT, Kyn, 30HA, XA, KA, AA), was divided into 1 mL aliquots. 
Mobile phase (20 mM acetate buffer, pH 4.5), also spiked with the same metabolites, 
was divided into the same volumes and number of aliquots.
2. Each precipitant was added to one aliquot of spiked serum and to one aliquot of 
spiked mobile phase. The solutions were mixed immediately on a vortex mixer and 
then centrifuged at 15,600 x g for 3 minutes.
3. The supernatants were injected onto the HPLC and the effects on the ECD and 
fluorescence detectors were recorded.
3.2.3 Free and Bound Tryptophan
3.2.3.1 Separation of Free from Protein-Bound Tryptophan.
The increase in pH during ultrafiltration and the alteration of Trp binding has been described 
by earlier workers [68]. This experiment was performed to confirm this and to evaluate the 
efficacy of a modified ultrafiltration device.
1. A serum sample was divided into 6 x 1  mL aliquots and each added to the top part of a 
Centricon-30 apparatus.
2. Three samples were assembled as shown in Figure 3.1. The Centricon-30 assemblies 
were charged with an atmosphere of 5% CO2 ; 95% N2 as follows (refer to Figure 3.1):
a) A tube was fitted to the gas cylinder and the regulator adjusted to allow a flow of 30 
mL/min. The tube (capped with a hypodermic needle) was inserted into the bottom half
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of the assembly and gas was allowed to fill the assembly for 30 seconds. The top half 
of the assembly was immediately inserted into the lower half and the connection point 
covered with several layers of Parafilm (Figure 3.1; No.l).
b) 1 mL of serum was added to the top half of the assembly containing the membrane 
filter. Two layers of Parafilm were used to seal the top of the assembly.(Figure 3.1; 
No.2)
c) The Parafilm seal was punctured with the needle and gas tube; the tip of the needle 
positioned above the surface of the serum. Gas (5% CO2 ; 95% N2) was allowed to 
displace the air above the serum for 30 seconds and the top was sealed with another 
two layers of Parafilm.
d) The sealed apparatus was centrifuged for 30 minutes at 3200 g.
e) The protein-free filtrate was removed from the bottom half of the assembly. (Figure 
3.1; No.3)
3. The remaining three sera were assembled similarly, but were not charged with an 
atmosphere of 5% CO2 ; 95% 4
4. The pH and the total CO2 of the serum were measured prior to ultrafiltration in all 
samples. The filtrates were measured after centrifuging. These analyses were determined 
using a ABL-30 Blood Acid-Base Analyser
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3.2.3.2 Recovery of Free Tryptophan
In order to test the recovery of Trp from the plasma and ensure that Trp was not being lost 
through the membrane during the centrifugal filtration the following experiment was 
performed:
1. Trp was added to 0.9% saline to produce a concentration of about 400 umol/L. Serum 
was assayed with the endogenous concentration of Trp.
2. Spiked saline was added to three Centricon-30 assemblies and sera was added to another 
three.
3. Serum and saline were then filtered through the Centricon-30 assemblies. Each pair of 
assemblies (serum and saline) was treated with 5% CO2 and the other pair contained air (ie, 
received no treatment). The sera were treated with 10% TCA to remove protein. The 
supernatants and the filtrates were injected and the amount of Trp present was determined by 
HPLC.
3.2.3.3 Storage of Samples Prior to Analysis for Free Tryptophan
Reports in the literature [68] have indicated that the freezing of serum samples will alter the 
binding of Trp to albumin and increase the free Trp levels. Since it was anticipated that 
specimens collected during this study would not be able to be processed immediately, it was 
necessary to confirm the storage effects on free Trp. The following experiment was 
performed.
1. 20 mL of blood was withdrawn from a fasting subject and allowed to clot for 30 
minutes at room temperature.
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2. The clotted blood was centrifuged in the collection tube (1780 x g for 10 min), the 
serum was removed and divided into 9 aliquots of 1 mL each -
Treatment :
Aliquots 1-3 : centrifuged in Centricon-30 (5% CO2 ; 95% N2) for 20 min and the 
filtrate frozen in dry-ice. ("Fresh" specimens)
Aliquots 4-6 : stored in portable polystyrene foam box containing the dry-ice 
container, but not in contact with the dry-ice. This kept the specimens cold but not 
frozen. ("cold"-specimens)
Aliquots 7-9: frozen immediately in dry-ice ("frozen" specimens)
3. The Centricon-30 apparatus was charged with the atmosphere of 5% CO2; 95% N2 
as outlined above in 3.2.3.1
4. The "frozen specimens" were thawed 24 hours after collection and centrifuged 
(filtered) through Centricon-30 in an atmosphere of 5% CO2; 95% N2.
5. The "cold specimens" were filtered through Centricon-30 (5% CO2; 95% N2) 24 
hours after collection.
6. All protein-free filtrates were then analysed by HPLC.
3.2.4 Stability o f M etabolites
The following experiment was designed to determine if the protein precipitating solution was 
suitable as a storage medium for each of the metabolites being investigated. It had been 
reported that some of the Trp metabolites were unstable in strong acid solutions [99].
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1. Solutions (100 mg/L) of Trp and eight of its metabolites (50HA, 30HKyn, 50HT, 
Kyn, 30HA, XA, KA, AA) were prepared, and 100 |iL of each solution was added 
to 20 mL of pooled sera. A blank was prepared by adding 50 pL of each metabolite to 
10 mL of acetate buffer, pH 4.5.
2. Half of the spiked pooled serum (10 mL) was precipitated with cold 10% 
trichloroacetic acid (6.67 mL). The mixture was centrifuged (3000 rpm for 10 min) 
and the supernatant removed.
3. Each preparation (spiked pooled serum, TCA supernatant, and spiked buffer) was 
divided into two 1.0 mL aliquots and frozen at -20° C. Two of each were kept for 
immediate analysis (Day 1).
4. Frozen aliquots were thawed and analysed after 1 day, 4 days, 12 days, 18 days, 
25 days, 51 days and 90 days. Protein was removed from spiked pooled sera samples 
by precipitating with 10% cold TCA. The supernatants were injected onto HPLC. A 
freshly prepared standard of each metabolite was run on each day of assay.
5. Results of each day were compared to the fresh standard and the results calculated 
in pmol of metabolite/litre of serum or buffer.
3.3 RESULTS
3.3.1 Choice of Specim en
There are reports in the literature of the effects of anticoagulants on some of the metabolites 
of Trp, or more particularly, Trp itself. Heparin has been shown to affect the binding of 
tryptophan to albumin and consequently raise the free Trp level [68]. EDTA has been
Table 3.1
Percentage o f protein removed from  plasm a
(from Blanchard1)
Ratio o f Precipitant : Plasm a
PRECIPITA NT pH 1.0 : 1.0 0.6 : 1.0
10% TCA 1.4 - 2.0 99.5% 99.6%
6 % HCIO4 <1.5 99.1% 98.9%
5% HPO3 1.6 - 2.7 98.3% 98.1%
Acetonitrile 8.5 - 9.5 97.2% 45.8%
Acetone 9 -1 0 96.2% 33.6%
Ethanol 9 -1 0 91.4% 41.7%
Methanol 8.5 - 9.5 73.4% 32.2%
(NH4)2S04 7.0 - 7.7 53.4% 41.0%
1 Blanchard, J., E valu a tion  o f  the re la tiv e  e fficacy  o f  va r iou s tech n iqu es f o r  d ep ro te in iz in g  p la s m a  sa m p les  p r io r  
to H P L C  a n a lysis . Journal of Chromatography, 1981. 226: p. 455-460.
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reported to give low recoveries and variable effects on the assay of Trp [110]. It was not 
considered necessary to validate these claims since it was decided that serum would be the 
blood specimen-type of choice. This is discussed fully in section 3.4.1.
3.3.2 Sam ple Clean-up
Of the précipitants tested by Blanchard [111], the most efficient for protein removal were the 
acids (Table 3.1). Some of the organic solvents were efficient when used in a 1:1 ratio, but 
this would compromise the sensitivity of the detection and generate problems of retention for 
metabolites by rp-HPLC. Ammonium sulphate, although having the advantage of being a 
single reagent, did not remove sufficient protein. Sulphosalicylic acid (5%) was not tested 
by Blanchard [111], but because it is in common usage as a protein precipitant, this reagent 
was included in the four acids tested.
The three acids listed in Table 3.1 were tested for their effect on the electrochemical and 
fluorescence HPLC detection systems. In addition, sulphosalicylic acid was also tested.
10% Trichloroacetic acid.
TCA had no effect on the fluorescence chromatogram but produced an oxidation peak early 
in the electrochemical chromatogram.
6% Perchloric Acid.
Perchloric acid had no effect on the fluorescence chromatogram but produced a very large 
oxidation peak early in the electrochemical chromatogram.
5% Phosphoric Acid
Phosphoric acid also had no effect on the fluorescence chromatogram and produced a very 
large oxidation peak early in the electrochemical chromatogram.
Table 3.2
Serum pH Changes on U ltrafiltration
Filtered in 5% CO2
(n = 3)
P H _______________ Total C 0 2  (m m o l /L )
Pre-Filtr. j Post-Filtr % Change Pre-Filtr Post-Filtr % Change
Serum 7.564 I 7.511 - 0.70% 25.9 28.9 +11.6%
Filtered in Room Air
(n = 3)
pH Total CO 2  (m m o l /L )
Pre-Filtr. Post-Filtr % Change Pre-Filtr Post-Filtr % Change
Serum 7.587 8.146 +7.4% 23.5 21.8 - 7.2%
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5 % Sulphosalicylic Acid.
Sulphosalicylic acid caused considerable and prolonged interference in the fluorescence 
chromatogram and but had no effect on the electrochemical chromatogram. Furthermore, this 
precipitant has been reported to be incapable of quantitatively liberating trp from plasma 
proteins [112].
30HKyn although electroactive was masked somewhat by the "TCA" peak. It was not 
fluorescent. The fluorescence absorbance peak from sulphosalicylic acid extended into the 
region of the chromatogram containing the 50HA, 50HT and Kyn peaks, and was therefore 
unsuitable. Unfortunately, 30HKyn could not be reliably assayed in the serum samples, 
because of the large "TCA" peak, as shown in Figure 2.10.
It was considered at the time that it would be advisable to proceed with TCA as the 
precipitating agent of choice.
3.3.3 Free and Bound Tryptophan
3.3.3.1 Separation of Free and Bound Tryptophan
Three serum samples were assayed for pH and total C02 both before and after ultrafiltration 
in order to monitor changes taking place during centrifugation of the serum. The results are 
shown in Table 3.2. The serum samples centrifuged in room air resulted in a decrease 
(7.2%) in the mean carbon dioxide level from 23.5 mmol/L to 21.8 mmol/L, but there was 
an increase in the mean pH from 7.587 to pH 8.146, an increase of 7.4%. A decrease in pH 
was prevented when the samples were centrifuged in an atmosphere of 5% carbon dioxide. 
The mean level of carbon dioxide in the samples increased from 25.9 to 28.9 mmol/L 
(11.6% increase), but the mean pH of 7.511 was not significandy different from the original 
pH 7.564 (0.7% decrease).
Table 3.3
Tryptophan Present after U ltrafiltration  
(p m o l/L itr e )
5% CO2 ; Balance N2 Room A ir (no treatm ent)
Unfiltered Filtered Recovery Unfiltered Filtered : Recovery
Saline (n=3) 416 415 99.8% 412 402 ! 98%
Serum (n=3) 383 111 29% 373 252 ! 68%
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The results shown in the table were measured on a Radiometer ABL-30 Blood Gas 
Analyser. The pH measurements have a precision of +/- 0.001 and the total CO2 have a 
precision of +/- 0.1 mmol/L.
3.3.3.2 Recovery of Free Tryptophan
Table 3.3 summarises the recovery of Trp from the Centricon-30 apparatus after 
ultrafiltration. There is a mean recovery of 99.8% Trp from a saline solution when filtered 
in 5% CO2 through the 30,000 Dalton cut-off membrane (Centricon-30 apparatus). Also 
with a 98% recovery after ultrafiltration in room air, it is clear that Trp does not bind 
significantly to the membrane and passes directly through it. However, with only 29% 
recovery of the Trp from the serum specimen it is evident that since the Trp does not bind to 
the membrane then it is most likely bound to protein or similar molecule which does not pass 
through the membrane. In contrast, with no pH control (ie. in room air), Trp is released 
from protein and allowed to pass through the membrane, producing an artefactually raised 
"free" Trp recovery of 68%.
Assuming the unfiltered Trp is bound to albumin and the filtered Trp is "free" or unbound 
Trp, then this experiment produced a value of 29% in 5% CO2 for free Trp. This is close to 
values reported in the literature of 19-33% [67] and 14-19% [113] under controlled pH 
conditions.
3.3.3.3 Storage of Free Tryptophan
Table 3.4 summarises the results of processing and storing a serum sample for the 
determination of free Trp. The sample was divided into three triplicate aliquots and 
processed as outlined in section 3.2.3.3. The table shows the mean results of three methods 
of sample storage: (i) centrifuged in 5% CO2 immediately and the filtrate frozen in dry ice;
Table 3.4
Free Tryptophan Storage after 24 hrs 
Tryptophan 
(pm ol/L itre)
(n=3) FRESH COLD FROZEN
Mean 13.1 13.4 10.9
Std. E rro r 0.41 0.36 0.03
Figure 3.2
Free Tryptophan Stability
Fresh
Cold
Frozen
l
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(ii) serum stored cold (approx. 4°C) for 24 hr; (iii) serum immediately frozen. The stored 
sera were allowed to come to ambient temperature and centrifuged in 5% CO2 . The filtrates 
were assayed by HPLC.
When the t-test for equality of means was applied to the data in Table 3.4, there was a 
significant difference at the 5% level between the fresh specimen and frozen specimen; and 
also a significant difference between the cold storage and frozen storage.
There is no apparent difference if serum is stored in the cold (about 4°C) compared with 
freshly ultrafiltered specimens. There is, however, a reduction in the mean free Trp of about 
18% when the sera are frozen and thawed 24 hr later. This finding differs from that of 
Allegri, et al [68] who found an increase in free Trp when serum was stored frozen. From 
these results it was decided to keep the specimens cold and then separate the free Trp within 
24 hr of collection. It was mentioned earlier that it was not always possible to ultrafilter the 
specimens at the collection site. As was shown in the previous experiment, a CO2
atmosphere was required to prevent disruption of the Trp binding to protein and this facility 
was only available at the Wollongong site.
3.3.4 Stability  o f M etabolites
It was not always possible to analyse blood specimens from patients receiving the Trp load 
on the same day, since the loading procedure was performed in Hospitals (eg. Sydney Eye 
Hospital, Liverpool Hospital) remote from the analysing laboratory at Wollongong Hospital. 
For this reason it was necessary to determine the stability of the various metabolites, both in 
separated plasma, and in the trichloroacetic acid supernatant. Storage was at -20 °C.
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F igure 3.3 S tab ility  o f 5-H ydroxyanthranilic Acid
Figure 3.4 Stability  o f 5-H ydroxytryptophan
Specimen Preparation Page 46
On the designated day (Days 1,4,12,18,51,90), the frozen samples were thawed, mixed and
t era «"• • - '. t — F - - T  T n
analysed as outlined in section 3.2.4. The values obtained were compared to the freshly 
prepared standard mixture.
The average value obtained for each metabolite in the three storage media (buffer, serum and 
TCA supernatant) is shown in Figures 3.3 to 3.10. Error bars are shown for duplicate 
assays. Displayed on the X-axes are the days after storage at -20 °C.
Although a series of metabolite standards were used to calibrate the HPLC on each day of 
analysis, some variability (increasing and decreasing values) was observed . It was shown 
earlier (Chapter 2) that the metabolites were stable for at least 3 months, when stored at pH
4.5 in 20 mM acetate buffer at a concentration of 100 mg/L. However, in this experiment the 
metabolites added to buffer for the 90 day period were at the same concentration as those in 
the serum and 1.67 times the concentration of those in the TCA supernatant. At these lower 
concentrations (10^ - 102 times lower) the metabolites may be expected to be more labile 
than those stored at much higher concentrations. The purpose of the experiment was 
primarily to determine the preferred method of storage of samples (either left as frozen in 
serum, or precipitated immediately and the TCA supernatant frozen) and was not intended to 
verify the stability at low concentrations in buffer.
Figure 3.3 illustrates the stability of 50HA over 90 days when stored in pH 4.5 buffer, 
pooled sera and TCA supernatant. The values for 50HA in serum and TCA are similar up 
until Day 25 where the serum levels deteriorate in comparison to the metabolite stored in the 
TCA supernatant. This represents a drop from the Day 1 to Day 25 of 69% in serum and a 
drop of 38% in TCA. There is little decrease for at least 18 days. It is interesting that the 
metabolite in buffer has a higher assayed value throughout the period of the experiment. The 
slight increase at Day 18 can be explained by the higher standard error of the mean. It would
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appear that 50HA is stable when stored at -20 °C for 3 weeks in either serum or TCA, but 
with greater stability in TCA.
Figure 3.4 shows the stability of 50HT in the three media over a period of 90 days at -20 
°C. As with 50HA the metabolite in buffer shows a higher value than either metabolite in 
serum or TCA. Similarly, the stability of 50HT is reasonable over a 12 day period in 
serum, and then there is a deterioration over the remaining period. This represents a loss of 
39% metabolite in serum after 18 days, decreasing to 68% after 90 days. Loss in TCA is 
49% after 18 days and 80% at 90 days. It would seem that 50HT is reasonably stable in 
serum for the first two weeks at -20 °C, but with a greater loss in both matrices after a longer 
period.
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Figure 3.5 Stability o f K ynurenine
3.6 Stability of 3-H ydroxyanthranilic Acid
Specimen Preparation Page 48
Figure 3.5 illustrates the stability of Kyn in buffer, serum and TCA supernatant. There is 
reasonable stability in either serum or TCA for up to 51 days. The loss is 41% in serum but 
only 24% in TCA at 51 days. There is a decrease shown by Kyn in TCA (but not in serum) 
at 90 days. There is, however a greater error in the duplicates at this point. Kyn appears 
stable in either serum or TCA for a period of about 9 weeks at -20 °C.
The stability of 30HA is outlined in Figure 3.6. There is considerable difference between 
the values recovered in serum and those in TCA, with the TCA values much higher in the 
earlier samples. The serum values are closer to the buffer values than those of TCA. There is 
also a considerable decrease in the 30HA values in TCA (56%) and serum (50%) from 0 to 
18 days. However the decrease in 12 days is 23% in serum and only 2% in TCA. The serum 
values are more stable for 12 days, and then show a decrease of 22% to stabilise for the next 
30 days and then decrease again at 90 days. It should be noted that there is a higher starting 
level of 30HA in TCA although an equivalent amount of metabolite was added to each 
solution. The reason for this is unknown. Overall, TCA appears to be the best storage for 
30HA and should be analysed within 2 weeks.
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Figure 3.7 Stability  o f Xanthurenic Acid
Figure 3.8 Stability of K ynurenic Acid
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Figure 3.7 outlines the storage of XA over 90 days at -20 PC. Both serum and TCA levels 
have a higher starting level than the buffer and both remain relatively consistent for 18 days. 
XA then drops by about 25% in both TCA and serum at 25 days, but then continues to drop 
considerably to 90 days. It would seem that either TCA or serum is a suitable storage 
medium provided analysis is performed within 3 weeks.
KA stability is represented by Figure 3.8 which shows constant stability over the 90 day 
period for all three storage media which vary over the whole period by 27% for serum and 
37% for both buffer and TCA. There is no decreasing trend (ie decrease over 3 consecutive 
points) over the 90 day period, in any of the storage media. It appears that KA is stable 
when stored at -20 PC in either TCA or serum for 3 months.
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Figure 3.9 Stability o f Tryptophan
Figure 3.10 Stability o f A nthranilic Acid
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Figure 3.9 graphs the stability of Trp over 90 days. No exogenous Trp was added to the 
pooled sera, so the measured Trp was native to the sample in both the serum and TCA 
storage media. There is a small loss of Trp in the first 18 days (16% in serum and 24% in 
TCA), but this loss does not continue in TCA to any appreciable extent until the end of the 
90 day period. Continued storage in serum on the other hand results in a further loss of 19% 
from 18 days to 51 days, and a cumulative loss of 50% at 90 days.
AA does not show any appreciable loss in -20 °C storage in any of the three media over the 
90 day period as is shown in Figure 3.10. There is only a 12% loss of AA in serum over 
this period, and a 15% loss in TCA.
In summary, it would seem that most of the metabolites under investigation should be stable 
in either serum or precipitated with 10% TCA and stored frozen at -20 °C for about two 
weeks. Ideally, all samples collected should be analysed within two weeks of collection.
3.4 DISCUSSION
3.4.1 Choice of Sample
Sometimes in clinical work, it is more convenient to use whole blood taken as a capillary 
sample from a finger-prick, rather than serum. A finger-prick is often easier to obtain and 
less objectionable for the subject especially when several samples have to be taken over the 
time period of 6 hr used in this study. It is often more traumatic to have multiple venous 
samples taken by needle and syringe. Finger-prick sampling, however, requires the blood 
sample be immediately precipitated before clotting is initiated, and therefore collection and 
processing apparatus must be available at the time of collection. This presented some 
difficulties due to the location of patients in different hospitals. The total amount of 
equipment needed to be compact and portable. There is also the risk of contamination (and
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dilution) of the sample with extravascular fluid from the surrounding tissue. For these 
reasons, it was decided not to use finger-prick capillary blood.
If venous blood were to be used, the type of anticoagulant had to be considered. It was 
quicker and easier to centrifuge non-coagulated blood than to have to wait for a blood 
specimen to clot before centrifuging. The addition of an anti-coagulant, however, could 
introduce interference and therefore the choice of anti-coagulant had to be considered. 
Heparin, ethylene diamine tetra acetic acid (EDTA) and sodium citrate are commonly used 
anti-coagulants and each posed different problems for preparation and analysis of 
metabolites. Although heparinised plasma has been used in the assay of Trp metabolites (eg 
Kyn [90]), it has also been shown to increase the amount of free Trp [68]. EDTA has been 
reported to lower the recovery of Trp and to give variable results [110]. It was therefore 
considered appropriate to avoid the use of anticoagulants and collect blood for serum rather 
than plasma.
Whole blood was not considered an option as a sample, because of the possible partitioning 
of metabolites in the intracellular and extracellular compartments. Some substances are 
evenly distributed between the blood cells and the plasma, whilst others are more 
concentrated within the cytoplasm of the cell [114].
Most reports in the literature describe the assay of Trp in serum rather than plasma, although 
the reasons for the preference are not always stated. One study [115] has shown that the pH 
of whole blood is higher when heparin rather than EDTA is used as an anticoagulant. 
Therefore to prevent possible interference from the various anti-coagulants, serum rather 
than plasma was chosen as the preferred specimen type.
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3.4.1.1 Urine
The other biological material commonly used for clinical analysis is urine and most methods 
have relied on paper or thin-layer chromatography. The preparation of urine specimens used 
in this thesis was based on the work of Benassi and co-workers [91], and although this 
technique was used and the extract freeze dried, not all of the processed urine specimens had 
been completed at the time of writing.
3.4.2 Sam ple Clean-Up
It is essential to have some form of sample purification for crude biological material since 
direct injection of crude extracts onto an HPLC column can cause considerable problems. 
Lipids, proteins and soluble compounds can irreversibly bind to the stationary phase. 
Plasma proteins can also precipitate as a result of their contact with the organic solvents and 
inorganic buffer salts commonly utilised in mobile phases [111]. This results in a rapid 
increase in back-pressure and deterioration of column performance.
Plasma proteins may be removed from the compounds of interest by the use of pre-columns 
or by chemical hydrolysis, solvent extraction, ultrafiltration, dialysis, or precipitation by 
acids or heavy metal ions.
The use of a pre-column in the HPLC system [116] allows for the direct injection of a serum 
or urine sample; since the protein in the sample being removed by the pre-column inserted 
prior to the analytical column in the HPLC system. This method for analysis is expensive 
and requires an elaborate switching mechanism to divert the sample from the pre-column and 
onto the analytical column after protein-removal. Also, regular replacement of the pre­
column is necessary.
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CberoigaLhxdrply$i$ requires the use of strong mineral acids and high temperatures. Both 
conditions can destroy the structure of sensitive compounds such as Trp metabolites and this 
was considered unsuitable.
Dialysis has been tried successfully by several workers [117, 118]. This method, although 
effective, was determined to be too time consuming and cumbersome for reasons of 
simplicity and transportability of equipment, as outlined below. It has also been suggested 
that there may be error because of the disturbance of binding equilibria [117]. Although, 
equilibrium dialysis has the advantage of using small samples volumes, it is very difficult to 
maintain plasma pH during the dialysis [118].
Ultrafiltration is a quick and easy method, but by removing protein from the sample, the 
buffering capacity provided by the protein is altered and the pH of the sample is increased 
[119]. An increase in pH can allow for the oxidation of many of the Trp metabolites. 
However, ultrafiltration has proved a useful technique for separating free and bound Trp in 
human serum. This technique was evaluated and has proved satisfactory for the current 
study.
Most organic reagents used in solvent extraction methods when added to serum cause 
dénaturation of the protein present and are, in effect, protein précipitants. These were 
considered together with the other precipitating agents such as heavy metal ions and acids.
An important feature of an appropriate method for this study is its simplicity and the lack of 
reliance on sophisticated instrumentation. The method must allow rapid processing of the 
samples since many samples may be obtained in one day. The equipment must be easily 
transported since many of the subjects would be at different sites such as The Sydney Eye 
Hospital, The Lidcombe Hospital and The Liverpool Hospital. Special equipment would not
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be available at all these sites and movement of equipment to the sites was not always 
possible. Protein precipitation techniques usually only require the presence of a centrifuge, 
the precipitating agent, and a pipette. It appeared that a method employing protein 
precipitation would be the most convenient since the protein removal may have to occur as 
soon as possible after collection of the sample.
It was necessary when preparing samples for HPLC that the protein removal step did not 
dilute the specimen to any significant extent. Dilution of the specimen would lower the 
detection limit and prevent the measurement of the already small amounts of metabolites 
present, especially in fasting samples. Ideally the precipitating agent would remove greater 
than 90% of the protein from the sample when added in a ratio of less than 1:1. The 
precipitating agent should not interfere with the detection system and should not affect the 
HPLC column. Blanchard [111] evaluated 12 commonly used protein precipitating agents. 
Of these the single reagent précipitants were considered the easiest to use and the most 
convenient. The three acids (Table 3.1) were the most efficient protein-removers and 10% 
trichloroacetic acid proved to the best of the three at a ratio of 0.6:1. It also had the least 
adverse affect on the metabolite chromatogram. The carboxyl group on trp has been reported 
[112] to be responsible for the binding the active sites on albumin and TCA was 
demonstrated to render this binding labile.
3.4.3 Free and Bound Tryptophan
As mentioned in Chapter 1, Trp is the only amino acid which binds to albumin [30] and 
because of this, it is necessary to assay both the free amino acid and that which is bound to 
albumin. Several methods for separating the free Trp from the total (bound and unbound) 
Trp have been described but most involve either dialysis or ultrafiltration. Femstrom [120] 
and Rocchi [105] used dialysis and found it suitable for free Trp. Wood [118] found a good
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correlation between ultrafiltration methods and equilibrium dialysis, but found it difficult to 
control pH with dialysis techniques.
The pH of serum is held close to neutral pH in part by the buffering capacity of the 
amphoteric nature of the plasma proteins and by the retention of CO2 in the bicarbonate- 
carbonic acid buffering mechanism. It has been shown (section 3.3.3.1) that the removal of 
protein through ultrafiltration, plus the loss of CO2 from the sample, caused an increase in 
the pH. The increase in pH was associated with an artificial increase in the recovery of free 
Trp from the ultrafiltered serum (see section 3.3.3.2). Therefore, it was essential to 
ultrafilter the serum sample in an atmosphere that maintains the pH during the procedure.
Since it was considered that analysis of free Trp could not always be undertaken on the same 
day as sampling it was important to check the effect of storage conditions on the content of 
free Trp. It has been reported by others [68] that the ultrafiltration of plasma must take place 
on the same day. It has also been reported [68] that the freezing of serum can lead to 
changes in free Trp levels of up to 50%, and also that centrifuging in air (pH changes) and 
in the presence of heparin (as anticoagulant) [115] can lead to the release Trp from albumin. 
The effect of freezing has been confirmed in the present study and a significant difference 
was found between samples stored frozen for 24 hr and those stored at 4 °C or analysed 
immediately. Therefore, it was decided not to freeze, but to keep the serum specimens cold 
for free Trp analysis, until ultrafiltration could be commenced within 24 hr.
3.5 SPECIMEN PROCESSING
This section outlines the method designed as a result of the foregoing experiments and was 
the procedure used to process the specimens following collection of specimens during the 
Trp loading procedure. The procedure is outlined in Figure 3.11.
Figure 3.11 Sam ple Preparation for HPLC
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3.5 .1  B lood
1. The blood specimens were allowed to clot at 37°C (to enhance the clotting 
mechanism) for about 20 min., and then centrifuged for 10 min at 1,780 x g.
2. The serum was transferred from the clot into a 5 mL plastic screw-capped tube and 
labelled with the name and time.
3. An aliquot of 1 mL of serum was pipetted into a 2 mL plastic sample cup and 
capped. This aliquot was not frozen but kept cold and was used for the free Trp 
analysis. (For reasons of simplicity this step is not represented in the flow diagram in 
Figure 3.11)
4. Cold 10% TCA (0.67 mL) was added to a second aliquot of exactly 1.0 mL 
serum. This was immediately vortexed.
5. The mixture was transferred to a microcentrifuge tube and centrifuged for 3 min at 
15,600 x g.
6. The TCA-supematant was transferred to a HPLC vial and frozen on dry-ice as soon 
as possible. This supernatant was used for the analysis of total Trp and metabolites. 7
7. The remainder of serum in the 5 mL tube was frozen on dry-ice as soon as 
possible. This sample was used for clinical biochemical analysis. (For reasons of 
simplicity this step is not represented in the flow diagram in Figure 3.11)
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3.5 .2  U rine
1. Urine specimens were adjusted to pH 3 (Merckotest pH Indicator Strips) with 5M 
acetic acid as soon as possible after collection.
2. The pH-adjusted urine was then frozen on dry-ice.
3. The process for treatment of the preserved urine is not described in this thesis.
3.5.3 Aqueous Humor & Lens
1. The aqueous humor specimen and the lens were transferred (in their appropriate 
containers) from the freezer in the operating theatre to a dry-ice container for transport 
to the laboratory.
2. The process for treatment of aqueous humor and lens is described in Chapter 14.
larç
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4.1 Introduction
Metabolic loading tests are a common method for assessing the homeostatic mechanisms in 
healthy individuals and in various disease states. They are often used as biochemical probes 
in the clinical diagnosis of a metabolic disturbance or an inherited metabolic dysfunction. 
The most commonly used loading test is the glucose tolerance test. An oral glucose load of 
75 g is given and serum glucose levels are measured at timed intervals to assess the response 
to this metabolic stress. An abnormal and sustained increase in the blood glucose level is 
diagnostic of diabetes mellitus. An oral glucose tolerance test is not always necessary for the 
diagnosis of diabetes mellitus, such as in cases where the fasting glucose is abnormally high. 
In subjects without diabetic symptoms and normal fasting levels, the extra stress from an 
oral load can reveal the metabolic impairment and hence identify the disease [121].
Likewise, the estimation of fasting or random circulating levels of other metabolites may not 
reveal a physiological impairment in a metabolic pathway. To detect such an impairment the 
level of metabolite must be compared to a "normal” population of healthy individuals and the 
impairment may not be sufficient to place the circulating level outside the range of levels 
expected in a normal population ("reference range"). The excretion of the products of 
metabolism and the circulating metabolite levels are quite often within the expected statistical 
limits of a healthy individual, and would not reflect any abnormality or malfunction. A 
metabolic loading test on the other hand will stress the pathway. An increase in circulating 
metabolites after a load can indicate whether an individual can cope with this stress to the 
same extent when compared to the reference or normal population [43].
The Trp loading test was one of the first metabolic loading tests to be developed. In 1942 
Lepkovsky and Nielson [39] observed that vitamin B6 deficient rats excreted a yellow-green 
compound (later identified as XA [65]) in their urine, which increased considerably when a
Table 4.1 Published Use of Trp Loading
TRP LOAD PURPOSE OF LOAD REFERENCE
300 mg/kg to measure 8 metabolites in urine by TLC.
2 g indole levels in CSF H291
50 mg/kg trp & kyn in senile cataract [1131
2 g pyridoxine deficiency ______[411
100 mg/kg effect of 4-desoxypyridoxine after trp load _____ [1301
not stated blue-diaper syndrome - no trp abnormalities [1311
3 g measurement of kyn in plasma (colourimetric) [901
100 mg/kg pharmacokinetics of trp, renal handling of kyn [1321
5 g presenile cataract [1331
50 mg/kg review article [ « i
3 g menstrual cycle effects on trp loads [134]
50 mg/kg comparison of 2 g, 50 mg/kg & 75 mg/kg _____ [421
2 g comparison with kyn as the load substance [1351
2 g recommendation of max. dose for trp load [401
100 mg/kg determination in untreated urine [103]____
50 mg/kg serum levels of trp in cataracts [001_____
100 mg/kg hereditary B6 xanthurenic aciduria [136]____
£
43 mg/kg serum kyn by HPLC [1071
2 g low oestrogen and low progestogen on trp metab. [1371
20 mg/kg serum trp metabolism in senile cataract [741
20 mg/kg serum trp metabolism in senile cataract [731
28.5 mg/kg* metabolism of DL-trp [1381
114 mg/kg quantitative studies on rat, cat, dog and man [1391
2 g IAA in newly abstinent alcoholics [1401
100 mg/kg invest, of trp metab. excretion in adults & children [341
50 mg/kg trp metabolites in senile cataract [1411
30 mg/kg serotonin & tryptamine analysis [1421____
Dosage amount converted from a different unit of measure.
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loading dose of tryptophan was administered.. They used this observation to develop the 
loading test for the assessment of vitamin B6 nutritional status. The role of pyridoxine in the 
metabolism of tryptophan was discussed in Chapter 1.
Tryptophan 2,3-dioxygenase is induced by the presence of several factors, one of which is 
an excess of its substrate, Trp. Because of this, several suggestions have been proposed to 
standardise the amount of Trp administered in the test dose. Coursin [40] suggested that 2 g 
would cause only a negligible increase in the rate of Trp oxidation and this should be the test 
dose. Coon [41] also suggested 2 g pointing out that 1 g was insufficient to stress the Trp 
pathway and therefore would not detect subclinical deficiencies or abnormalities in 
metabolism. Coon also stated [41] that 5 g or more could not be accommodated by the 
pathway unless large doses of pyridoxine were also given.
The problem associated with a constant dose meant that subjects of different weight were 
receiving different unit doses of Trp. For example, a 50 kg man would receive 40 mg Trp 
for every kg body weight for a 2 g dose, whereas an 80 kg man would receive only 25 mg 
per kg body weight for the same dose. For this reason, Allegri proposed a standard dosage 
rate of 50 mg/kg [42].
However, despite these calls for a standard loading dose, several different doses have been 
reported in the literature as is listed in Table 4.1
In order to standardise the dose between subjects of different weights, and to provide 
sufficient metabolic stress, but not overload the Trp pathway, the loading dose used in this 
study was set at 50 mg Trp for every kg body weight. The use of 500 mg tablets made exact 
dosage difficult. For both a 65 kg person and a 74 kg person, 7 x 500 mg tablets were given 
resulting in 54 mg/kg given to the former and 47 mg/kg given to the latter subject. This
F igure 4.1
Slit-Lam p A pparatus and Cam era
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meant there was an error in the dosage rate of 50 mg (+/. 4 mg)/kg. This was not considered 
to make a significant difference in the metabolic stress imposed, or to deviate greatly from a 
standardised technique.
4.2 Materials
All materials used for specimen collection are described in Chapter 3, section 3.2
All materials and chemicals used in the assay of Trp and its metabolites are described in 
Chapter 2, section 2.2.
The slit-lamp apparatus (Figure 4.1) was a Topcon Photo Slit Lamp, Model SL-5D (Tokyo 
Optical Co. Ltd, Tokyo, Japan) located at the Ophthalmology Department of the University 
of Sydney, Sydney Eye Hospital and also at the rooms of Dr. Vernon, Market Street, 
Wollongong. Photographs were obtained using Kodachrome 200 for Transparencies.
Pupil dilatation was achieved with 2 drops of 0.5% Tropicamide (Mydriacyl, Alcon 
Laboratories (Australia) Pty. Ltd.) applied topically about 20 minutes prior to slit-lamp 
examination.
L-Tryptophan (Vita-Glow, Blackmore Laboratories) was given orally in tablets containing 
500 mg of the amino acid. The L-tryptophan was in a tablet base of calcium phosphate (80 
mg), microcrystalline cellulose (100 mg), silica (8 mg), and magnesium stearate (8 mg). 
Tablets used for all patients and control subjects were from the same production batch (Lot 
No. 21447A)
The analysis for blood biochemistry and haematological parameters is outlined in Chapter 
13.
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4.3 Methods
4.3.1. Consent Form.
It was an essential part of clinical research on human subjects that the objectives of the 
research project plan be submitted to the appropriate ethics committees in each of the 
hospitals providing patients. Permission was granted on the basis that an integral part of the 
research plan was the provision of a consent form detailing the procedure and its 
extenuations to each volunteer. The volunteer subject or patient was to read and sign the 
Consent Form prior to submission to the procedure. A copy of the Consent Form is 
reproduced in Appendix A.
4.3.2 Loading Data Sheet.
To facilitate the uniform collection of data from each patient, a data sheet was designed. A 
copy of the Tryptophan Loading Data Sheet is reproduced in Appendix B.
Several epidemiological studies have been reported which have implicated several factors 
associated with the incidence of cataract formation [2,122]. It was considered necessary to 
record for future reference, the existence of any of these possible factors, which may have 
influenced the formation of cataract in the volunteer. This study, however, was not intended 
as an epidemiological investigation, and the Data Sheet was not a comprehensive 
epidemiological questionnaire.
The form consisted of 7 pages, for the recording of the following information:
Patient Demographics - name, sex, date of birth, weight, height, occupation, area of 
residence.
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Ophthalmic Examination - any abnormal eye pathology, cataract type and grade, visual 
acuity.
Slit Lamp Photography - details of the instrument magnification, pupil dilatation, and 
dimensions of opacities in cortical, nuclear and post subcapsular regions were recorded. 
Also the presence or absence of vacuoles.
Medical History - details of smoking habits [123], alcohol consumption [123], diet,
myopia, diarrhoea, analgesics, other medications, familial diseases [124].
Tryptophan Loading Dose - date and time of loading, loading dose, tablet batch 
number, collection times.
Analytical Data - serum Trp metabolite results, serum biochemistry results, urine Trp 
metabolite results, aqueous humor metabolite results, lens weight and Trp metabolite results.
4.3.3 Loading Protocol
4.3.3.1 Cataract Patients
1. The patient was recruited for the study on the evening prior to surgery. The protocol 
was explained (usually by the admitting medical officer) and the Consent Form 
completed. The criteria for selection were based on the fact that the patient had a 
cataract severe enough to impair vision. Patients with cataract due to other 
causes (eg. trauma, radiation, galactosaemia, etc) were excluded. Diabetics were also 
excluded because of the problem with blood glucose control during an overnight fast 
followed by a further 6 hr of no carbohydrate intake.
2. On the morning of surgery (or sometime prior to removal of the cataractous lens) the 
patient was examined clinically by the Ophthalmology Registrar and a slit-lamp 
photograph taken (see slit-lamp photograph procedure). The results of the 
examination, including grading of cataract, were recorded on page 1 of the Loading 
Data Sheet.
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3. The patient's lens was removed surgically and some aqueous humor collected (at 
least 0.1 mL). Both specimens were stored frozen by operating theatre staff.
4. The patient had an evening meal, but was then fasted from 9.00 pm.
5. The following morning a urine specimen was collected by the ward staff and the 
specimen kept cold.
6. Tryptophan loading was commenced usually at about 7.30 am. During the loading 
test period the questionnaire was completed by asking the subject the questions on 
Page 2 of the Loading Data Sheet.
7. 10 mL of blood was withdrawn from the patient and allowed to clot.
8. L-Trp was administered orally (500 mg tablet) at a dosage rate of 50 mg/kg body 
weight, followed by 250 mL water. The dosage was recorded on page 3 of the Data 
Sheet.
9. Blood (10 mL) was withdrawn at intervals of 1 hr, 2 hr, 4 hr, and 6 hr after the Trp 
load. Water (200 mL) was given after each blood collection to facilitate subsequent 
urine collection. Urine was collected as often as needed and the time of voiding 
recorded on page 3 of the Data Sheet. 10
10. Specimens were processed as outlined in Chapter 2, section 3.5.1.
T able 4.2
Nuclear Opacity Grading Definitions
(According to Taylor and W est*)
GRADE GRADING DEFINITION
0 No opacity. Less dense or less extensive 
than standard photograph 1.
1 Nuclear opacity at least as dense and as 
extensive as standard photograph 1 but 
less dense and extensive than standard 
photograph 2
2 Nuclear opacity at least as dense and as 
extensive as standard photograph 2 but 
less dense and extensive than standard 
photograph 3
3 Nuclear opacity at least as dense and as 
extensive as standard photograph 3 but 
less dense and extensive than standard 
photograph 4
4 Nuclear opacity at least as dense and as 
extensive as standard photograph 4.
* Taylor, H. and S. West. The clinical grading of lens opacities. in Australian and New 
Zealand Journal of Ophthalmology 1989. 4
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4.3.3.2 Control Subjects
1. While attending the Outpatient Ophthalmology Clinic the subject was assessed as 
having a clear lens with no cataract involvement. The subject was then 
asked if they would volunteer to take part in the study.
2. If the subject agreed he/she was informed that the test would take six hours and 
require that the subject fast for 10 hours prior to attending for the test
3. The test was started at approximately 8.00 am and finished at about 2.30 pm. The 
subject was given some sandwiches and tea or coffee at the end of the test.
4. During the test the subject had pupil dilatation of one eye and a slit-lamp photograph 
taken of one lens for grading. Also during the loading test period the questionnaire 
was completed by asking the subject the questions on Page 2 of the Loading Data 
Sheet.
5. The testing procedure was the same as that followed for cataract patients (section
4.3.3.1, steps 7 to 10)
4.3.4 Slit-Lamp Photography
The patient to be loaded first had a photograph taken of the affected eye, with a slit-lamp
camera, before lens removal. The slit-lamp procedure was that of Taylor and West [12].
1. After dilatation of the pupil (0.5% Tropicamide), patients were examined with a slit 
lamp using 16x magnification. The pupil had to be dilated to 6 mm to allow for 
adequate examination. If it was impossible to dilate the pupil to greater than 6 mm 
after repeated use of mydriatics, the pupil diameter was recorded on the data sheet to
Table 4.3
Cortical Opacity Grading Definitions
(According to Taylor and W est*)
GRADE GRADING DEFINITION
0 No opacities
1 Opacities, which when combined, occupy 
less than 1/8 of the circumference.
2 Opacities, which when combined, occupy 
less than 1/4 of the circumference.
3 Opacities, which when combined, occupy 
less than 1/2 of the circumference.
4 Opacities, which when combined, occupy 
more than 1/2 of the circumference.
* Taylor, H. and S. West. The clinical grading of lens opacities, in Australian and New 
Zealand Journal of Ophthalmology 1989.
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indicate inadequate examination and the best possible assessment was made of the 
lens.
2. The nucleus was examined with a thin (0.1 mm) slit beam of 8 to 9 mm in height set 
at an incident angle of 30 degrees. The slit passed through the anatomic centre of the 
lens and the clarity of the optical section of the nucleus was compared to a standard 
set of photographs for grading (Table 4.2). A photograph was taken at this stage and 
examples (reproduced from transparencies) of a normal lens and a cataractous lens 
are shown in Figure 4.2 and 4.3 respectively.
3. The cortex was examined using retro-illumination. The slit beam was relatively wide 
(0.5 to 1 mm) and short (4 to 5 mm) in height. It was angled through, first one side 
of the pupil and then the other so that the entire cortex could be examined in clear 
retro-illumination. The focus of the slit lamp had to be altered so that both the 
anterior and posterior cortical regions were each examined in clear focus. The 
cortical opacity was graded according to Table 4.3 4
4. Posterior subcapsular opacities were also assessed by using retro-illumination and 
their overall vertical and horizontal dimensions measured using the calibration of the 
slit beam height Both the vertical and the horizontal dimensions were recorded and 
multiplied together to give and approximation of the "area".
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Figure 4.2
Slit-Lamp Photograph of Normal Lens.
Figure 4.3
Slit-Lamp Photograph of a Cataractous Lens.
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A  few patients (13%) were not able to be graded. Cataract patients were sourced from the 
Sydney Eye Hospital, The Liverpool Hospital, The Lidcombe Hospital and The Wollongong 
Hospital. The Sydney Eye Hospital was the only hospital which had a slit lamp with a 
camera attachment. The photography, therefore, and the grading of the cataractous lenses 
was dependent on the ability and proficiency of the ophthalmology registrar at the time. In 
some cases a photograph was not taken nor was the cataract graded or collected. The 
Liverpool Hospital, The Lidcombe Hospital had slit lamp apparatus, but without a camera 
attachment. In these cases it was reliant on the ophthalmic surgeon to grade the lens by slit 
lamp examination. The Wollongong Hospital did not have a slit lamp apparatus, nor were 
the surgeons willing to grade the cataract. In those cases where a slit-lamp grading could not 
be obtained, grading was subsequently achieved by the Pirie classification (see Section 
4.3.5) of the extracted lens.
Control subjects from the Sydney Eye Hospital (Refractory Clinic) were confirmed cataract- 
free by the ophthalmology registrar and photographed before or during the loading protocol. 
Control subjects from Wollongong were all photographed and confirmed cataract-free by 
slit-lamp photography.
4.3.5 Lens Photography
Patients who had volunteered to take part in the study had their cataractous lens removed 
surgically and the lens was immediately frozen. The lens was kept at -20°C until required 
for analysis.
Prior to analysis the lens was thawed at room temperature, weighed and photographed. The 
apparatus used to photograph the lens was a light box fitted with a 100 watt tungsten lamp 
for retro-illumination. A diffuser was placed above the light source. The lens was placed in 
a petri dish which was resting on a metric grid on top of the diffuser. A coloured strip was
Loading Protocol Page 69
placed near the lens to standardise the variations in colour which occurs between different 
batches of colour film. A second light source was used illuminate the lens from above. A 
photograph of lens following extraction from the eye is shown in Figure 4.4.
Figure 4.4
Extracted Cataractous Lens
The severity of cataract was graded according to the method of Pirie. In most cases, the 
Pirie grade confirmed the grade obtained from the slit-lamp examination. As mentioned, it 
was not always possible to obtain grading by slit lamp examination, and for this reason the 
Pirie classification was used as the method of grading comparisons. It was necessary, 
however, to confirm all control subjects by the method of Taylor and West [12].
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The preparation of the lens for analysis is discussed in Chapter 14.
4.3.6 Data Presentation
Serum samples were prepared as outlined in Chapter 3, section 3.5 and analysed by HPLC 
according to the method outlined in Chapter 2.
Each patient had five samples (fasting, 1 hr, 2 hr, 4 hr and 6 hr post-load) which were 
analysed consecutively. Each batch of HPLC runs was calibrated with four standard 
solutions freshly prepared by diluting stock solutions of the individual metabolites. From 
the standard curves for each metabolite, the concentration of each metabolite in the serum 
samples was calculated, allowing for the dilution factor introduced when preciptitating the 
plasma protein with TCA.
The results for each metabolite were then plotted as a response curve; concentration of 
metabolite against the time after the loading dose. Graphs were constructed for each patient, 
placing the metabolites into four arbitrary metabolic groups for convenience (see Appendices 
C and D). The "Trp" graph included total and free Trp; the "main-pathway" graph included 
Kyn and 30HA; the "branch-pathway" included KA, XA and AA; and the "related" included 
50HA and 5QHT.
The value at each time point for each metabolite was tabulated together with the age and sex 
of the subject and also the type and grade of cataract. The data was divided into two main 
groups CATARACT (the cataract patients) and CONTROL (the non-cataract volunteers). 
From this tabulation the data could be categorised according to age, sex and grade of 
cataract, allowing comparisons to be made between and within the cataract and control
groups.
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Values from the serum biochemical analysis were also tabulated and the data divided into the 
two main groups, cataract and control. Values from haematological analysis were similarly 
tabulated.
Statistical analysis was performed on the tabulated data.
4.3.7 Statistical Methods
The choice of the appropriate statistical tests used was dependent on a number of 
assumptions about the condition of that data and the design of the experiment. The use of 
the more powerful parametric tests requires that the data are independently selected, that 
variances of the data be homogenous, and the distribution of the data is Gaussian or at least 
symmetrical [125].
Although every effort was made initially to select the patients and controls on a random 
basis, the small number of willing participants made strict random selection difficult. The 
selection based on the presence of cataract, the absence of diabetes, and the absence of a 
known aetiology (eg. trauma, radiation cataract, congenital cataract), limited the number of 
participants. The fact that the majority of the willing participants were public health patients, 
also prevented complete randomisation.
A frequency distribution ("stem & leaf' plot) was constructed for each metabolite to examine 
the spread of values and the median of each set of data. It was evident from these plots that 
the data did not follow a Gaussian distribution, nor were the variances equal in each 
metabolite group. It was decided that the statistical analysis would have to employ non­
parametric techniques. These tests are not dependent on assumptions concerning a given 
distribution, nor with specific parameters, but only with the distribution of the variates.
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Firstly, the data were examined for Trp and each of the Trp metabolites for statistical 
variation between the cataract and control groups. Comparisons were made at each time 
point (0, 1, 2, 4 and 6 hr) after the loading dose, using the X2 approximation test [125]. 
Because the X 2 test compares categories of data, the values at each of the five time points 
had to be ranked and divided into relevant categories prior to statistical analysis. The results 
of the comparisons between the cataract and control groups for each metabolite are discussed 
in the relevant metabolite chapters (Chapters 5 to 12).
The X 2 test makes virtually no assumptions about the distribution from which the data are 
drawn, making it a suitable test since the dispersal of the metabolite data was, in most 
instances, skewed and not normally distributed. An important requirement for the X2 test, 
however, is that the size of the expected frequencies be large enough in each category. A 
conservative requirement is for all expected frequencies to be at least five [126]. The size of 
each of the cataract and control group was large enough to use this test with confidence.
Secondly, the data were separated and compared according to the age-groups (listed in Table 
4.3) within each of the cataract and control groups. Comparison was within the cataract 
group and within the control group. The question asked was, for the cataract group, whether 
there was a difference between the age brackets for each time point. The same question was 
asked of the control group. Because age brackets in the cataract group did not correspond 
with the control group, comparison of age brackets between cataract and control was not 
possible for each age bracket. As it was, the scarcity of volunteers in some of the age-groups 
presented some challenges in the choice of statistical tests. Unfortunately, the data when 
categorised became too few in some groups to allow the use of the X 2 test. In these cases 
the non-parametric Wilcoxon rank-sum test [126] was used. The results of these 
comparisons discussed in sections of the relevant metabolite chapters.
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The Wilcoxon rank-sum test makes few assumptions about the distribution of the data and 
can be used on two independent sample populations. It is especially sensitive to population 
differences in central tendency and is not affected by a few very extreme values [126]. If 
parametric tests such as the t-test were used, the extreme values for some of the metabolites 
seen in this study, could increase the variance (and increase the standard error) as well as 
seriously affect the mean. This would make the t-test less powerful, overall.
Thirdly, the data were separated according to gender within the cataract and control groups 
and the data compared. Like the age bracketed data, the sex bracketed data were compared 
male verses female within the control group, and male to female within the cataract group. It 
was not considered necessary initially to compare male cataract to male control and female 
cataract to female control, although on examination of the results of the earlier testing, this 
comparison was performed later, and is discussed in Chapter 15. Like the age bracketed 
data, the sex bracketed data were tested using the Wilcoxon rank-sum test. The results of 
these comparisons are reported on in the separate chapters on each metabolite.
Finally, the data were arranged according to cataract grade. The data were plotted as bar 
graphs grouped according to time after dose. The question asked was, whether the median 
values of the grades differed significantly within each time point. In other words, at 0 hr 
values were the values of Grade 1 patients significantly different from the values of the 
Grade 2 patients, the Grade 3 patients and the Grade 4 patients? This was also applied to the 
1 hr values, the 2 hr values, etc. These differences within each grade were tested using the
T able 4.4
A ge & Sex D istribution  betw een
C ataract & Control Groups
CATARACT CONTROL
AGE GROUP FEMALE MALE FEMALE MALE
20-29 0 0 2 3
30-39 0 0 1 6
40-49 0 1 0 4
50-59 0 6 0 _0_____
60-69 7 5 7 11
70-79 6 9 1 2
80-89 5 3 0 0
GROUP 18 24 11 26
TOTALS 42 37
Figure 4.5
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Wilcoxon rank-sum test* . The results of the analysis are also discussed in the relevant 
metabolite chapters.
4.4 Demographics
Table 4.4 summarises the distribution of age and sex between the cataract patients and 
control subjects. The distribution is graphically represented in Figure 4.5. Obviously, it 
was difficult to find any controls over the age of 80 yr who did not have any cataract 
involvement, and for this reason there are no controls in this age-group. Conversely, by 
definition there were no senile (age-related) cataract sufferers below 40 yr of age. As a result 
it was extremely difficult, if not impossible, to base the selection of subjects on age- and sex- 
matched criteria.
Many patients were requested to take part in the study, but when confronted with an 
overnight fast, followed by a 6 hr test period without food and the added burden of 5 venous 
blood collections, many potential volunteers declined to participate. The use of a cannula 
inserted in a vein for the duration of the test was considered in order to minimise the trauma 
associated with 5 collections. However, owing to the difficulties often encountered with 
blockages through clot formation and the risk involved when injecting a heparin 
anticoagulant to keep the cannula patent, it was decided to use 5 separate collections (see also 
Chapter 3, section 3.4.1 for further discussion on choice of sample)
The age-groups in the control subjects was extended down to 20 yr to check for any age- 
related trends in Trp metabolism.
* The Wilcoxon rank-sum test is sometimes referred to as the Kruskal-Wallis one-way analysis of variance 
when used in the manner employed here; ie. when three or more independent groups (cataract grades) are tested
[126].
F igure 4.6
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Only 1 patient, a male, was found in the 40-49 yr cataract group with 4 males in the control 
group. No females were represented in the 40 yr age bracket. There were no 50-59 yr old 
volunteers without cataract involvement.
The age-group best represented was the 60-69 yr control group with 18 volunteers and this 
may be due to a greater motivation toward age-related health matters in this group. The same 
motivation may have existed in the 70-79 yr group, but the number of clear lenses in this age 
bracket was lower and therefore lowered control group numbers. This may explain why 
there were larger numbers of volunteers in the 70-79 yr cataract group, in other words the 
motivation was there and also the disease.
Figures 4.6 and 4.7 illustrate the distribution of the 4 cataract grades and normal controls 
between the male and female groups. As mentioned above, it was not possible to age and 
sex-match the cataract and control groups. Control subjects are the greater proportion 
(60.5%) of male group, while the female group is dominated by cataract patients (57.7%). 
The dominant cataract grade is understandably Grade 1 in both sexes, with number of 
subjects varying inversely with the grade. Most patients suffering from cataract would, with 
the relative availability of health care in Australia, seek a surgical solution to the disease 
before the cataract progresses to total blindness. For this reason, only a small number of 
patients (11.5% females; 9.3% males) were seen with Grade 3 cataract, and even fewer 
(3.8% females; 2.3% males) with Grade 4.
It is interesting to note that there were equal numbers (9.3%) of Grade 2 and Grade 3 males, 
whereas there were more than twice the number of Grade 2 females (26.9%), than Grade 3 
females (11.5%). The numbers in this study are small, but they may suggest that females 
seek treatment for cataract at an earlier stage in the development of the disease than do males.
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Harding [7] indicates that there is a higher incidence of cataract extraction in English females 
than occurs in the corresponding male population. The same was true for European Israelis, 
but the opposite occurred in Oriental Israelis, with males having a higher incidence of 
cataract extraction than females.
Although information was collected as to occupation and area of residence of each subject, 
the total number of subjects (cataract and control) were too few to graph any trends or infer 
any vocational or environmental influence on cataract formation. Similarly, the number of 
subjects did not allow for a valid examination of the influence of associated medical 
conditions or family medical history on the status of cataract formation. It was not however 
the aim of this project investigate the epidemiology of cataract and this information was only 
collected in case any common influence (eg occupation) was evident in the data.
4.5 Grading of Cataract
The grading of cataract has received some attention in the literature and two different 
classification systems are favoured and their use depends primarily on the type of cataract 
investigation. Cataract investigations are of two types, biochemical and epidemiological. 
Epidemiological studies favour the use of slit-lamp photography mainly because of the non­
invasive nature of the technique, and the fact that the patient is available for examination and 
questioning [13, 14, 127]. Biochemical studies often involve an examination of the lens in 
vitro and as such a classification of the cataract based on its appearance outside the eye is 
favoured by those investigators [16, 22, 66,128]. Quite often in these studies the patient is 
not available, and only the lens is presented for examination.
In this study, it was planned to use both the slit-lamp technique and an in vitro classification 
and compare the two systems.
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Patients were selected according to the scheme outlined in section 4.3.3 (Loading Protocol) 
with the view to a slit-lamp examination prior to surgery and Trp loading in the case of the 
cataract volunteers. The lens classification would take place prior to biochemical 
examination. Control volunteers would have to be examined by slit-lamp only, since 
extraction of the lens was not possible.
Several systems have been developed in recent years [12, 13], most of which are based on a 
slit-lamp examination of the lens for nuclear colour and opacity, and retroillumination of the 
lens for cortical and subcapsular opacities.
The procedures for slit-lamp examination need to be standardised between examiners and the 
agreement between examiners, carefully monitored [14, 127]. Slit-lamp examination and 
photography of the cataract patients was dependent on the ophthalmologist or an 
ophthalmology registrar, and examination techniques were not universal nor were all the 
examiners skilled in the operation of the slit-lamp apparatus and photography. The standard 
and quality of the photographs varied so much between ophthalmologists that it was not 
possible to grade all the lens opacities against the standard photograph.. This fact did not 
become apparent until most patients had been examined and photographs developed. It was 
not possible to use the same ophthalmologist for the examination of all patients. Therefore, 
in the interest of uniformity, cataract classification had to rely primarily on an in vitro 
classification system of the extracted lens.
Control subjects were all examined by slit-lamp apparatus and since the classification 
required only the assessment that the lens did not contain any opacities, it was not necessary 
for the ophthalmologist to categorise cataract involvement. Where possible the control 
subject lens was photographed in vivo using the slit-lamp camera.
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5.1 Introduction
5.1.1 Biochemistry and Physiology
The major metabolic fate of Trp was outlined in Chapter 1 (Figure 1.3) with the principal 
metabolic route through Kyn to nicotinamide described (Figures 1.4 & 1.5). The 
biochemical reactions of the Trp molecule are summarised in Figure 5.1. Trp can be 
hydroxylated  to 50HTrp (eventually forming serotonin and melatonin); 
decarboxylated to tryptamine (important in bacterial metabolism); transaminated to 
indolepyruvic acid (minor mammalian pathway); cleaved of the side chain to form 
indole (bacterial metabolism); or undergo oxidation to N-formylkynurenine. Products 
of bacterial metabolism can result from the action of intestinal flora and may be absorbed 
into the vascular system. Of these reactions, the most important reaction of Trp is the 
oxidative cleavage of the indole ring and, as indicated in Chapter 1, the subsequent 
formation of essential metabolic products such as nicotinamide nucleotides. Oxidative 
cleavage is catalysed by two distinct enzymes, tryptophan 2,3 dioxygenase in the liver 
and indoleamine 2,3 dioxygenase in many other tissues. Tryptophan 2,3 dioxygenase 
(E.C. 1.13.11.11) is also known as Trp oxygenase and was formerly known as Trp 
pyrollase [143]. The enzyme is an iron porphyrin protein and is found in 
microorganisms, insects, birds, amphibia and the mammalian liver [144]. The enzyme is 
not found in the foetal liver, but its activity is present soon after birth [145]. The extent 
of Trp oxidation can be precisely controlled by the important characteristics and activities 
of this rate-limiting enzyme.
Tryptophan 2,3 dioxygenase has a relatively short half-life of only 2 hours, but in the 
presence of excess substrate the enzyme is stabilised against proteolytic degradation. It 
has been suggested [146] that there is a second binding site for Trp on the enzyme 
which, when occupied, protects the enzyme against catabolism. Unlike the catalytic site, 
which is specific for L-Trp, the second site is less specific and can bind some Trp 
analogues such as a-methyl Trp [146].
Figure 5.2
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Tryptophan 2,3 dioxygenase, as a iron porphyrin enzyme is dependent on the availability 
of haem and in this respect the production of tryptophan 2,3 dioxygenase is linked to the 
haem biosynthetic pathway and the activity of 6-aminolaevulinate synthetase [31]. This 
association has been proposed as an explanation for the involvement of Trp metabolic 
dysfunction in porphyria [147, 148].
The enzyme is induced by hormones. Glucocorticoids can increase the rate of synthesis 
of the apoenzyme and also the rate of production of the m-RNA for the enzyme. Excess 
formation or administration of these hormones causes increased catabolism of Trp, 
limiting protein synthesis and results in an excess of the other amino acids as substrates 
for gluconeogenesis. This mechanism is important in maintaining circulating glucose 
levels [31, 149].
Glucagon, is effective, not alone, but in the presence of Trp or glucocorticoids. The rate 
of tryptophan 2,3 dioxygenase synthesis is increased by glucagon at the m-RNA 
(translational) level. In other words, the m-RNA has to be "in production" as a result of 
induction of the enzyme by other means [31].
The enzyme exists as a tetramer, with a total molecular weight of 103,000 Daltons. 
There are two haem groups per tetramer [150]. The activation of the enzyme (Figure 5.2) 
occurs by a series of reactions starting with the synthesis of the apoenzyme induced by 
corticosteroids. The apoenzyme is then conjugated with haematin in the presence of L- 
Trp or an analog, forming the oxidised (ferric porphyrin protein) holoenzyme. This 
inactive oxidised holoenzyme is then activated by a reducing agent such as ascorbate or 
superoxide in the presence of L-Trp, to the reduced form (ferrous porphyrin protein). 
The reaction is reversible in the absence of Trp and in the presence of molecular oxygen, 
to the inactive holoenzyme. The rate of induction appears to be dependent on the 
presence and concentration of the apoenzyme (and corticosteriods), Trp, haematin, and a
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reducing agent [150, 151]. In vitro at least, this reaction is initiated, in the presence of 
all components, within 5 mins [151].
Some controversy is evident in the literature as to the effect of oestrogens on the activity 
of tryptophan 2,3 dioxygenase. Several studies have suggested that the effect of 
oestrogens on Trp metabolism is similar to that of corticosteroids [137, 152] with 
increases in the excretion of Trp metabolites in those women taking oral contraceptives. 
However, other reports [31] indicated that the increases observed were the result of the 
indirect effect of displacement of the corticosteroids from binding proteins and therefore 
caused an increased uptake of the corticosteroids by the liver [153].
Inhibition of tryptophan 2,3 dioxygenase is achieved by high concentrations of the 
nicotinamide dinucleotide coenzymes, particularly NADPH. The coenzymes cause both 
repression of synthesis and inhibition of activity of the tryptophan 2,3 dioxygenase. 
[150]
The second Trp catabolic enzyme, indoleamine 2,3 dioxygenase, (E.C. 1.13.11.17) 
[150] is also haem dependent, but has a broader specificity, acting not only on L-Trp but 
also D-Trp and to a lesser extent on 50HTrp and tryptamine. Unlike tryptophan 2,3 
dioxygenase, it uses superoxide as oxygen donor rather than molecular oxygen. It is 
found in a number of tissues including heart, lung, adrenal glands, brain, intestinal and 
gastric mucosa. Indoleamine 2,3 dioxygenase also appears to respond to pathological 
stress (eg.8 -interferon [154], bacterial lipopolysaccharides [155]) rather than 
physiological factors. It is not clear, however, to what extent it contributes to the 
degradation of a Trp load, in the absence of induction by these other factors.
5.1.2. Background
There has probably been more articles written about Trp than any other amino acid [31]. 
This maybe because the amino acid has been implicated in a large number of diseases,
F igu re 5.3
T otal T ryptophan R esponse  
to the T ryptophan Load
- 1 1 3  5 7
H ours A fter Dose
N umber of Values constituting each time point
0 hr 1 hr 2 hr 4 hr 6 hr
C ontrol 37 34 36 34 37
Cataract 40 38 36 37 29
Table 5.1
C hi-Square Probability  Scores* : 
C ataract - Control D ifferences  
for Total T ryptophan
0 hour 1 hour 2 hour 4 hour 6 hour
0.005 0.036 0.003 0.001 0.027
* A probability score of less than 0.050 indicates a significant difference.
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such as hepatic porphyrias [148], carcinoma of the bladder [156], inborn errors of 
metabolism [157], haematoblastic disorders [158], depression [159], and alcoholism 
[99]. Involvement of this amino acid in such a wide variety of diseases may be due to the 
fact that Trp is converted into a larger number of metabolites than any of the other amino 
acids [145].
The discovery [30] of Trp's unique ability among the amino acids to bind specifically to 
albumin led to several other studies [160-162] on the effect this phenomenon on the 
metabolism of Trp. One of these studies [161] has indicated that other plasma proteins do 
not interfere with the binding of Trp to albumin. A low serum albumin will lead to an 
increase in the usual free Trp to total Trp ratio of 0.25 and similarly high concentrations 
of competing small molecules (eg. drugs, free fatty acids, other amino acids) will also 
increase the ratio of free to total Trp. As mentioned in an earlier chapter, it was shown 
[162] that salicylate could compete with Trp for its binding site on albumin. Free fatty 
acids [163] also had a similar effect on the binding of Trp. It was also demonstrated 
[161] that free Trp in erythrocytes was in equilibrium with plasma unbound Trp. There 
was no evidence of trp binding to protein within the red cell.
5.2 Discussion of Results
5.2.1 Group Differences
5.2.1.1 Total Tryptophan
Figure 5.3 illustrates the serum mean total Trp response levels (in pmol/L) after an oral 
load of L-Trp, for both the cataract group and the control group. The X-axis shows the 
periods of time before and after the loading dose. The loading dose of 50 mg/kg body 
weight was given at 0 hr after the initial fasting blood sample was taken.
It is clear from Figure 5.3 that there was no overlap in the mean values of the two groups 
and that the total Trp response was obviously different between the two groups. There 
was also no overlap of the error bars at any time period, indicating only a small spread of
Figure 5.4
Free T ryptophan Response 
to the Tryptophan Load
- 1 1 3  5 7
Hours A fter Dose
N umber of Values constituting each time point
0 hr 1 hr 2 hr 4 hr 6 hr
C ontrol 33 32 34 31 30
Cataract 33 32 30 30 23
Table 5.2
Chi-Square Probability Scores* : 
Cataract - Control D ifferences 
for Free Tryptophan
0 hour 1 hour 2 hour 4 hour 6 hour
0.347 0.713 0.229 0.378 0.419
*A probability score of less than 0.050 indicates a significant difference.
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the data at each point. Both groups are similar, however, in the overall shape of the 
curves in that there is a rapid rise to 1 hr and both peak at 2 hr. There was then a decline 
at a much slower rate to 6 hr, with neither group returning to the fasting level in the time 
period of the study.
The control group had a sharp response curve with the 2 hr peak, 3.9 times higher than 
the fasting level. The rate of increase was high in the first hour (233 pmol/L/hr), 
slowing to peak at 2 hr. The rate of decrease was virtually constant from the peak to the 6 
hr point.
The cataract group showed a high rate of increase in the first hour (165 pmol/L/hr), but 
this slowed to a virtual plateau (18 pmol/L/hr) from 1 hr to 4 hr and then the rate of 
decrease became greater (76 pmol/L/hr) to the 6 hr point. A peak at 2 hr (4.2 times 
higher than the fasting level) was only slightly above the 1 hr level.
The graphical differences, shown in Figure 5.3, between the groups was supported by 
the statistical probabilities listed in Table 5.1. There was a statistically significant 
difference between the control and cataract group at each time point. It should be pointed 
out that the statistical difference between the groups at each time point was measured at a 
single time point and did not take account of the influence that the results at the other time 
points had on that particular point.
5.2.1.2 Free Tryptophan
Figure 5.4 outlines the response of serum free Trp levels in response to an oral load of 
L-Trp. The mean responses (in pmol/L) for the cataract group and the control group are 
shown. The scale of the y-axis is the same as for Figure 5.3 so that the levels for free 
Trp levels can be directly compared with the that of the total Trp.
Figure 5.5
Total Tryptophan Response 
to the Tryptophan Load: 
Control Subjects according to Age
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Figure 5.6
Total Tryptophan Response 
to the Tryptophan Load: 
Cataract Patients according to Age
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The mean serum levels for free Trp were approximately 20% that of the total. This level 
of 20% agrees with that of other workers [68,73] who found similar proportions of free 
to total Trp. There was little difference between the cataract group and the control group. 
The fasting levels were virtually identical, as were the levels at 4 hr and 6 hr. The 1 hr 
and 2 hr levels were different and there was no overlap of the error bars. The peak level 
in both groups occurred at 2 hr and the magnitude of the increase above the fasting level 
was about the same (4 x) for both groups. The rate of increase to the peak and the rate of 
decrease was approximately the same in both groups The serum level did not return to 
the fasting level after 6 hr. There does seem to be a difference in the overall shapes of 
the curves.
The statistical probabilities for the differences are shown in Table 5.2. The score at each 
time point showed no significant difference, which supports the graphical presentation in 
Figure 5.3
It was of interest that the total Trp response profile showed a statistically significant 
difference between the two groups but the free Trp levels did n o t.
5.2.2 Age D ifferences
5.2.2.1 Total Tryptophan
Figure 5.5 and Figure 5.6 show the Trp load response bar graphs of the serum total Trp 
grouped according to age. Each set of 5 bars represents the timed response to the load 
for each age group. Each age group represents those patients falling within that decade 
(ie. 20 represents those patients/subjects aged 20 yr to 29 yr). The scales of the y-axes 
of both graphs are the same. The sample size of each group is indicated in parenthesis 
under the x-axes.
Figure 5.7
Free Tryptophan Response 
to the Tryptophan Load: 
Control Subjects according to Age
Age Group (yrs)
Figure 5.8
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Figure 5.5 illustrates the load response of the control group. All age groups exhibited a 
peak at 2 hr and the patterns are remarkably similar over all age groups. The largest 
variation across all the age groups occurred at the fasting and the 4 hr levels, with values 
ranging from 60 to 120 pmol/1 at the fasting level and from 240 to 340 pmol/L at the 4 hr 
level.
There was more of a variation in the pattern of response in the four age groups of the 
cataract group (Figure 5.6). The 4th decade had only one patient and therefore was not 
representative of that age group. The 60 yr group and the 70 yr group showed a similar 
pattern of response. The fasting levels for each age group were very similar, as were the 
1 hr levels. The 2 hr levels however varied considerably and were not always the peak 
level for each group. For instance, the peak levels occurred at 1 hr (50 yr), 2 hr (80 yr), 
and 4 hr (60 yr and 70 yr). All mean 2 hr values in the control groups are >300 pmol/L 
with the exception of the 70 yr old group, which was just below at 278 pmol/L. By 
contrast none of the cataract 2 hr age groups were above 300 |imol/L with the exception 
of the 80 yr old group.
Table 5.3 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Age 
______Total Tryptophan ________
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.1211 0.1228 0.8571 0.2591 0.4693
Cataract 0.9422 0.9729 0.1635 0.1857 0.8619
5.2.2.2 Free Tryptophan
Figure 5.7 and 5.8 illustrate the mean free Trp response for the control and cataract 
groups respectively.
* A probability score of less than 0.050 indicates a statistically significant difference.
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The control group response (Figure 5.7) was consistent in having the peak response 
level at 2 hr for each age group. The response, however, was not consistent in the 
magnitude of response; the peak level of the 40 yr group was almost twice that of the 
other groups. The greatest variation, however, occurred in the fasting (0 hr) levels of 
serum free Trp, which was the lowest in 80 yr group and highest in 40 yr group.
The cataract group response (Figure 5.8) like the control group had a consistent peak at 2 
hr and the free Trp levels at the other time points were very similar except for the 6 hr 
values. Although the 4 hr level was similar in each age group, it appeared that the return 
to the basal level occurred at a faster rate in the oldest age group (80 yr) and in the 50 yr 
group. This did not, however, suggest an age related trend. Overall, the response was 
slightly more homogeneous in pattern than the control group.
Table 5.4 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Age
Free Tryptophan
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.0240 0.8666 0.6310 0.8298 0.9327
Cataract 0.5555 0.8172 0.6050 0.2777 0.1008
Table 5.4 lists the probability scores for significant differences within the age groups at 
each time level. It can be seen that the only data showing any significance was the 
control group at the 0 hr (fasting). This was supported graphically as is shown in Figure 
5.7, and appears to be principally a result of the high fasting levels found within the 20 
yr and 40 yr age group.
The difference found in this comparison of age groups led to an investigation of fasting 
serum total and free Trp from a much larger sample size, but without a loading dose 
given. This data is discussed later in this Chapter (section 5.3).
* A probability score of less than 0.050 indicates a statistically significant difference.
Figure 5.9
Total Tryptophan R esponse  
to the Tryptophan Load: 
Control Subjects according to Sex
500 1
400-
Male Fem ale
n=26 n = l1
a oh
B3 lh
M 2 h
□  4h
□  6 h
Figure 5.10
Total Tryptophan R esponse 
to the Tryptophan Load: 
Cataract Patients according to Sex
M Oh 
m  i h  
■  2 h
□  4 h
□  6 h
Total & Free Tryptophan Page 87
5.2.3 Sex Differences
5.2.3.1 Total Tryptophan
Figure 5.9 illustrates the mean total Trp response in the control subjects grouped 
according to gender. As can be seen from the bar graph, the response for both males and 
females in the control group was remarkably similar. There was a peak in both groups at 
2 hr and the rate of response was similar before and after the peak. The response of each 
sex mimics the response curve of the control group shown in Figure 5.3.
The response of the males and females from the cataract group is illustrated in Figure 
5.10. The results were very similar; both peaking at 2 hr and very similar response rates 
before and after the peak. The flat response shown by both sexes is similar to the flat 
response curve of the cataract group shown in Figure 5.3
Table 5.5 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Sex 
______Total Tryptophan ________
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.2656 0.1266 0.2644 0.3643 0.1264
Cataract 0.3145 0.9883 0.7745 0.8311 0.4321
The similarity of the responses in both groups was confirmed by the statistical tests 
summarised in Table 5.5. There were no statistically significant differences within the 
gender groups from both the cataract patients and the control subjects.
5.2.3.2 Free Tryptophan
Figure 5.11 and 5.12 illustrate the mean free Trp response of the gender groups for the 
control and cataract groups respectively.
* A probability score of less than 0.050 indicates a statistically significant difference.
Figure 5.11
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The response of the control group (Figure 5.11) shows an almost identical pattern for 
both the male and female group. Both had similar fasting levels, both peaked at 2 hr 
with similar levels, and both obtained a similar level at 6 hr. This observation was 
supported by the statistical data summarised in Table 5.6. There were no values below 
0.05 within the control group.
Figure 5.12 presents the response of the males and females of the cataract group. Both 
sexes had similar fasting levels and both peaked at 2 hr. The rate of increase to the peak 
was similar in both groups, but the females showed a more rapid return toward the basal 
level. The males had a slightly lower peak and a more delayed return toward the basal 
level. Once again the statistical analysis (Table 5.6) showed no significant difference 
within cataract group when tested according to sex.
Table 5.6 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Sex
Free Trypltophan
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.6744 0.8427 0.8252 0.3635 0.8741
Cataract 0.8538 0.2933 0.4514 0.9325 0.2184
5.2.4 Cataract Grade Differences
5.2.4.1 Total Tryptophan
Figure 5.13 illustrates the mean total Trp response of the control and cataract groups 
arranged according to the severity of cataract involvement. Grade 0 having no 
measurable cataract involvement, ie, the control subjects. Grade 1 being primarily 
cortical cataract and Grades 2 to 4 having increasing severity of nuclear cataract 
formation (see Chapter 4 for method of classification of cataract).
* A probability score of less than 0.050 indicates a statistically significant difference.
Figure 5.13
Total T ryptophan Response  
to the Tryptophan Load:
All Subjects according to Cataract Severity
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0  Grade 3 (n=7)
FI Grade 4 (n=2)
Time After Dose
Table 5.7
W ilcoxon Probability Scores* : 
W ithin-G roup Grade D ifferences  
for Total Tryptophan
0 hour 1 hour 2 hour 4 hour 6 hour
0.5731 0.3683 0.1666 0.2918 0.0956
* A probability score o f less than 0.050 indicates a significant difference.
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The five grade groups shown in Figure 5.13 differed in their response patterns. Not all 
grades peaked at 2 hr, and not all exhibited the same rate of return toward basal levels. 
The fasting levels showed a slight increasing trend from Grade 1 to Grade 4, with the 
control group (Grade 0) with the highest level.
Grade 0 (control group), had the highest fasting level and the highest peak response, and 
is, in fact, a bar graph representation of the control response curve shown in Figure 5.3. 
The remaining bar graphs are a break down of the groups making up the cataract 
response curve shown in Figure 5.3.
Grade 1 (primarily cortical cataracts) showed a lower response pattern than did the 
control and had a mean peak at 4 hr rather than 2 hr.
Grade 2 showed an even lower response pattern than Grade 1, but had a peak at 1 hr 
rather than 2 hr, and the return toward basal level appeared delayed.
Grade 3 appeared almost identical in response pattern to Grade 0 but with a slightly 
lower fasting level.
Grade 4 (advanced nuclear cataract) had a somewhat aberrant pattern but had only a small 
group size (n=2), which made it difficult to make any valid observations about this grade 
group.
Table 5.7 presents the statistical data of the comparison of each grade when tested at each 
time period. In other words, were there any differences according to Grade at 0 hr, at 1 
hr, etc? The times were tested as independent events and did not take into account the 
influence of values adjacent to it. There were no significant differences within the 
grades at each time point.
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Figure 5.14
Free Tryptophan Response 
to the Tryptophan Load:
All Subjects according to Cataract Severity
U  Grade 0(n=37) 
E3 Grade 1 (n=12) 
Ü  Grade 2 (n=ll) 
E3 Grade 3 (n=7) 
□  Grade 4 (n=2)
Time A fter Dose
Table 5.8
W ilcoxon Probability  Scores* : 
W ithin-G roup Grade D ifferences  
for Free Tryptophan
0 hour 1 hour 2 hour 4 hour 6 hour
0.5953 0.3508 0.2744 0.6701 0.1588
* A probability score of less than 0.050 indicates a significant difference.
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5.2.4.2 Free Tryptophan.
Figure 5.14 illustrates the mean free Trp response of the control and cataract groups 
arranged according to the severity of cataract involvement. The y-axis is scaled to 
correspond with that for total Trp response in Figure 5.13.
Grade 0 showed an "symmetrical” response with the 1 hr and 4 hr having the almost the 
same value. The 6 hr value does not reach the basal level. This response represents the 
response pattern of the control group, and is a bar graph presentation of the control 
response curve shown in Figure 5.4. It should be noted that the time interval of the bar 
graphs is not to scale, whereas the time interval in Figures 5.3 and 5.4 correctly 
represents the time of the response.
Grade 1 had a peak at 4 hr and still had a high level of free Trp at 6 hr. The fasting level 
was similar to the control group (Grade 0).
Grade 2 had a pattern almost identical to the control group (Grade 0).
Grade 3 had similar fasting levels to the control but had the highest mean peak level and 
the slowest return towards the basal level.
Grade 4 peaked at 4 hr with an aberrant value at 2 hr, probably because of the small 
number of patients in this group.
Table 5.8 presents the statistical data of the comparison between grades when tested at 
each time period. There were no statistically significant differences within the grades at 
each time period.
It is interesting to note the differences between the total and free Trp patterns in Figures 
5.13 and 5.14. Grade 0 had similar response patterns with time in both the total and free
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Figure 5.15
Total Tryptophan - cataract
F igure 5.16
Free Tryptophan - cataract
Figure 5.17
Total Tryptophan - control
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Trp. Grade 1 also had similar pattern of response for both total and free Trp. Grade 3 
had a slight variation in response at the 1 hr period; the free level was proportionally 
lower than the total level at the same time period, but otherwise the pattern was similar 
for both fractions. Grades 2 and 4, however had different responses for total Trp than 
for the unbound fraction.
5.3 Fasting Total and Free Tryptophan Levels 
in an Adult Population
As mentioned in section 5.2.2.2, there was a difference found between the age groups 
for fasting serum free Trp. This finding led to the investigation of a larger sample of 
individuals (which included those subjects from both the cataract and control groups) in 
order to ascertain if there was an age related trend in fasting levels of Trp.
Figures 5.15 to 5.22 show the scatter graphs of the fasting total and free Trp levels from 
the three categories of subjects. Figures 5.15 and 5.16 were those values from the 
cataract group. Figures 5.17 and 5.18 were those from the control group. Figures 5.19 
and 5.20 were those from the extra group selected specifically for the determination of 
fasting levels only. No Trp load was given to the "non-load" group and no further testing 
for other metabolites was undertaken. The graphs have identical y-axes for the Total Trp 
and also identical y-axes for the Free Trp to allow for comparison between the three 
groups. This necessarily excluded one high point from the control total and free graphs, 
however this point was included when the trend lines were constructed.
The cataract group (Figures 5.15 and 5.16) shows tight horizontal (age) clustering, but 
the spread of points vertically (pmol/L) resulted in poor correlation (R2 = 0.003 for total 
Trp and R2 = 0.099 for free Trp) for both analytes. The trend line indicates a slight
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decreasing trend for free Trp with age, but because of the poor correlation was not 
considered to be significant
The control group (Figures 5.17 and 5.18) showed a larger spread of points both 
horizontally (age - an adult range from 20 to 90 yr was deliberately selected) and 
vertically (pmol/L) with a correlation score of R2= 0.023 for total Trp. There is tighter 
distribution of data points for free Trp and this is reflected in the higher correlation score 
of R2=0.129 (fig 5.18). This trend was noticed and discussed in § 5.2.2.2 (Age 
Differences - Free Trp) as the reason for extending the investigation.
The non-loaded group (Figures 5.19 and 5.20) showed considerable spread of data 
points. Correlation for total Trp was R2= 0.074 with a slight trend decreasing with 
increasing age. There was no correlation for free Trp (R2= 0.000) but the number of data 
points was small.
Although overall the correlation of fasting Trp with age was small, it was interesting to 
note that there was a downward trend of results in all groups, except non-loaded free 
Trp. Furthermore, the distribution of the results became tighter with increasing age. The 
values above 60 yr in the free Trp in the three groups showed a smaller spread of data.
The data were combined from the three groups for both total and free Trp and was 
graphed as shown by Figures 5.21 and 5.22. As expected the combined data showed a 
slight downward trend but with little correlation. It is clear that a much larger sample 
size needs to be taken to establish whether there is an age related decrease in fasting 
serum Trp levels, since it is not obvious from this data.
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The mean values for each age group were then compared in Figure 5.23. The number of 
individuals contributing to each column is shown in the box below the x-axis. Once 
again a decreasing trend was observed, with each age group showing a lower fasting Trp 
(total and free) than its adjacent younger age group. The exception to this observation 
was apparent with the 30 yr age group. There was also a slight increase in the free Trp 
in the 80 yr age group.
5.4 Reference Ranges for Total & Free
Tryptophan
Since there were no significant differences between the sexes and the age groups (except 
free Trp at 0 hr) within the control group a "normal" or expected range (95% of the data 
range, using 2.5th and 97.5th percentiles) can be established for this analytical method 
for both plasma total and free Trp. Ranges (Table 5.9 and 5.10) can also be established 
for each time period after a 50 mg/kg oral load of L-Trp.
Table 5.9
Reference Ranges for Serum Total Tryptophan 
following Tryptophan Load 
______ (p mol/L)
Mean Reference Range
Fasting 85.8 26.7 - 180.8
After 1 h 291.6 119.2 - 446.3
After 2 h 340.6 162.4 - 476.8
After 4 h 292.0 117.1 - 427.2
After 6 h 207.7 71.4 - 301.4
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Table 5.10
Reference Ranges for Serum Free Tryptophan 
following Tryptophan Load
(H mol/L)__________________
Mean Reference Range
Fasting 22.3 5.0 - 102.4
After 1 h 121.4 41.6 - 270.7
After 2 h 171.2 87.7 - 332.4
After 4 h 120.0 52.6 - 259.2
After 6 h 66.5 25.0 - 187.3
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6.1 Introduction
6.1.1 B iochem istry and Physiology
Figure 6.1 outlines the metabolism of the amino acid, kynurenine from Trp and illustrates 
the major metabolic products of Kyn catabolism. The enzymes involved in these reactions 
are briefly discussed below.
L-Kyn (a ,2-diamino- X-oxo-benzenebutanoic acid) is formed from the hydrolysis of formyl 
Kyn by the enzyme, a r y lfo rm a m id a se * , EC 3.5.1.9 [143] This enzyme is also known 
as arylform amine aminohydrolase (systematic name), kyn. formamidase, 
formylkynureninase [143]. Formate is released in the reaction of this enzyme. Although, 
a r y l f o r m a m id a s e  has a low specificity and catalyses the hydrolysis of several 
arylformylamines, it shows a preference for formylkynurenine.[144]. Rat liver 
arylformamidase shows five distinct isoforms on isoelectric focusing with identical catalytic 
and kinetic properties and molecular weight [150].
K yn u ren in e  a m in o tra n sfe ra se  *(E.C. 2.6.1.7) [143] also known as kyn-oxoglutarate 
aminotransferase causes the transamination (and subsequent ring closure) of Kyn to KA 
[36]. This enzyme is dependent on pyridoxal phosphate as a co-enzyme
K y n u ren in a se  * (EC 3.7.1.3) also known as kynurenine hydrolase [143] is a pyridoxal 
dependent enzyme which catalyses the hydrolytic cleavage of the side chain of Kyn to AA 
and alanine [36]. Kynureninase is active in mammalian liver (cytosolic and mitochondrial) 
but is much less active in spleen, lung, brain, heart, and muscle [164]. K yn u ren in ase
* International Union of Biochemistry recommended name - (I.U.B Nomenclature Committee, ed. Enzyme 
Nomenclature. 1984, Academic Press, Inc.: Orlando, Florida.)
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activity has also been measured in lymphocytes and has been found to be lowered in B6 
deficiency and because of the activity of indoleam ine 2 ,3-d ioxygenase  has been suggested 
as a replacement for the trp load test [164].
K y n u ren in e  h yd ro x y la se  (kyn u ren in e 3 -m on o o x yg en a se* ) EC 1.14.13.9 [143] is a 
NADPH(or NADH)-dependent flavoprotein (FAD co-factor) which catalyses the 
hydroxylation of Kyn to 30HKyn. The hydroxylase is a mitochondrial enzyme, localised 
on the outer membrane [165]. This enzyme has been suggested as a secondary rate-limiting 
step when the activity of tryptophan dioxygenase is increased [36].
6.1.2 Background.
Kyn was first isolated in 1925, but its structure was not correctly known until 1940. It was 
observed to be the intermediate between Trp and KA in animals in 1931 [166].
In the 1956 results of research done on the excretion of the metabolites of Trp in urine was 
published. Kyn was found to be present in the urine of patients suffering from a variety of 
pathological conditions, including different forms of haematoblastic diseases. In most 
cases, Kyn was excreted in considerable quantities without the addition of oral Trp 
supplements [167]. Kyn excretion was also positively correlated with bladder tumours 
seven later [65], although cause and effect relationships were not established at that time and 
still remain controversial.
Many of the investigations of Kyn metabolism have involved its measurement after a 
loading dose of Trp. Krstulovic [168] used a loading dose of 2 g Trp so as not to induce 
tryptophan 2,3-dioxygenase but still "eliminate variations resulting from varying Trp 
intake". They found Trp peaked between 1 hr and 2 hr and Kyn increased slowly (as did 
KA), but 5-HIAA levels remained constant
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Bender [36] showed that there was considerable accumulation of Kyn and 30HKyn after a 
2-5g loading dose of Trp when there is a deficiency of vitamin B6. A deficiency of this 
vitamin impairs the activity of kynureninase. Oestrogen conjugates are competitive inhibitors 
of kynureninase, and women on oral contraceptives and oestrogen replacement therapy have 
increased excretion of these metabolites also, although other symptoms of vitamin B6 
deficiency are not apparent.
Increased urinary Kyn levels (after an oral Trp load) were found in a 15 yr old boy who had 
developed cataracts and a pellagra-like photosensitive dermatitis [169].
In 1982 it was suggested that the kynurenines may play a role in cataractogenesis. Urine 
was collected from patients suffering from cataract at various stages of severity. The urine 
was collected for 10 hr after a 50 mg/kg body weight and analysed for 10 Trp metabolites. 
The percentage of metabolites excreted was found to increase with the severity of the 
cataract, and Kyn was the metabolite which was excreted in the largest amount in all groups 
of cataract patients [66].
Grimm et al [133] used a 5 g Trp loading dose to compare the excretion of Kyn and 
xanthurenic acid in presenile (<40 yr old) cataract patients, non-cataract individuals, and 
xanthurenic aciduric individuals. They measured the metabolites concentration in 24 hr 
urine collections by 2-dimensional paper chromatography and found increased levels of Kyn 
in both the cataract group and the xanthurenic aciduria group.
Other workers measured a significant increase in the aqueous humor Kyn in cataract patients 
after a 50 mg/kg load of Trp. They also showed a related increase in aqueous humor and 
plasma Trp and Kyn, 3 hr after the load [113].
F igu re 6.2
K ynuren ine R esponse  
to the T ryptophan Load
H rs A fter Dose
N u m b e r  o f  V a lu e s  c o n s t i t u t in g  e a ch  t im e  p o in t
0 h r 1 h r 2  h r 4  h r 6  h r
C o n t r o l 35 33 35 32 35
C a t a r a c t 38 37 34 35 28
Table 6.1 C hi-Square P robab ility  Scores* : 
C ataract - C ontrol D ifferences
0 hour 1 hour 2 hour 4 hour 6 hour
0.167 0.535 0.051 0.028 0.145
* A probability score o f less than 0.050 indicates a statistically significant difference.
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Serum fasting Kvn has been positively correlated with both free and total Trp and serum 
glucose [170]. No explanations for this relationship were given.
6.2 Discussion of Results
6.2.1 G roup D ifferences
The serum Kyn levels in response to the Trp load are shown in Figure 6.2. The mean levels 
for both the cataract group and the control group are shown. There is a difference between 
cataracts and controls for Kyn at all time points The standard error ranged from 7 pmol/L at 
the cataract fasting levels to 30 nmol/L at the 6 hr level. The standard error for the control 
group is much smaller at all the measured time periods.
Consistent with the graphical presentation, statistical analysis of the data (Table 6.1) 
indicates that there is significant difference between the cataract groups and the control 
group for Kyn at the 2 hr and 4 hr time periods. The 6 hr values are not significant (0.145), 
and reflects the dispersion of data for that period.
With a few exceptions both groups had levels peaking at either 4 hr or 6 hr. The exceptions 
were controls #6, #8, #12 and cataracts #21, #29, and #42 peaking at 2 hr; while controls 
#26 and cataract #5 peaked at 1 hr. In general, there was an increasing trend over the test 
period. Only controls #2, #9, #13 and cataract #5 showed a decreasing response.
It is interesting to note that the mean serum Kyn of the cataract group reaches a value four 
times that of the control level at the 6 hr time period. The control reaches a peak level of 20 
pmol/L Kyn at the 4 hr time period and then shows a slight decline to the 6 hr period.
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Other investigators have found similar results to those shown above. Moller [132] in his 
study on healthy subjects showed that Kyn also peaked at 4 hr after a Trp load. This study 
found a peak level of 60 pmol/L, but used a loading dose of 100 mg Trp/kg body weight. 
The cataract group in Figure 6.2, however, reaches the highest level at 6 hr and may even 
peak at a later time. Another study had Kyn peak range at 3 hr with levels of 9.6 - 19.2 
umol/L and reported a marked variation in the rate of Kyn increase [90].
Holmes [107] found that serum Kyn levels increased 4-fold at 3-4 hr after a 3 g Trp load (ie 
40 mg/kg for 75 kg individual). This study, in most cases using a greater loading dose, 
found a increase of 5-fold to 8-fold increase at 2 hr and 4 hr respectively. Holmes found that 
the level remained above the fasting level for the 8 hr test period, as this study found over 
the 6 hr test period in both control and cataract groups.
6.2.2 Age D ifferences
The two test groups were analysed for changes within each group (Table 6.2), and no 
significant differences were found in the cataract group, but a difference greater than that 
which could be expected by chance alone was found within the fasting levels of the control 
group (Wilcoxon probability score of 0.0483). This effect can be seen graphically by 
comparing the 0 hr level of each age group in Figure 6.3, the level for the 20 and 30 yr age 
groups is less than that for the 40 yr, 60 yr, and 70 yr age groups. Although the 0 hr value 
for the 50 yr age group is higher than the older age groups this was not detected as a 
statistically significant difference (Wilcoxon probability score of 0.9453)
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Table 6.2. Wilcoxon Probability Scores* :
Within-Group Differences as a fiunction c>f Age
0 hour 1 hour 2 hour 4 hour 6 hour
Cataract 0.9453 0.8385 0.7206 0.7470 0.4491
Control 0.0483 0.1318 0.2139 0.2252 0.5259
Figures 6.3 and 6.4 show the bar graphs of serum Kyn levels in response to the Trp load. 
Each set of 5 bars represents the timed response to the Trp load for each age group. Each 
age group represents those patients falling within that decade (ie. 20 represents those 
patients/subjects aged 20 yr to 29 yr). In order to illustrate the different age group 
responses the scale of the y-axis of the control graph has been altered.
The 30 yr, 60 yr and 70 yr age groups for the control group show an increasing response 
with time from 0 hr, peaking at 4 hr and then decreasing. The same response pattern as 
shown by the Moeller study [132]. The 20 yr control group by contrast showed increasing 
Kyn value up to the 6 hr period.
The 60 yr and 70 yr cataract groups and show increasing Kyn value with no peak or no 
decreasing trend within the 6 hr period. Only the 70 yr and 80 yr age groups in the cataract 
group show same response but with considerably higher values.
Only the 40 yr control group showed very little Kyn increase to the Trp load, however this 
only represents 4 subjects.
* A probability score o f less than 0.050 indicates a statistically significant difference.
F igu re 6.5
K ynuren ine R esponse  
to the T ryptophan Load: 
Control Subjects according to Sex
n=26 n=l 1
H  Oh 
E3  l h
ES 2 h
0  4h
□  6h
F igure 6.6
K ynurenine R esponse  
to the T ryptophan Load: 
Cataract Patients according to Sex
Ü  Oh 
E3 l h
Ü  2 h 
E3 4 h
Q  6 h
n=24 n=18
Kynurenine Page 102
6.2.3 Sex Differences
Statistical analysis established that there were no significant differences within each group 
according to sex and Figure 6.6 supports this finding for the control group. The cataract 
male group at 4 hr and 6 hr however appears to vary considerably from the cataract female 
group and both control groups. High Kyn values for two male cataract patients (#21 and 
#30) have caused a considerable increase in the mean for that group. Understandably, with 
two patients out of only 13 male, there is a large standard error of the mean indicated by the 
large error bars at 4 hr and 6 hr in Figure 6.5. It is this large standard error that has caused 
the statistical result of non-significance.
Table 6.3 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Sex
0 hour 1 hour 2 hour 4 hour 6 hour
Cataract 0.9298 0.3851 0.6521 0.6311 0.2894
Control 0.4968 0.2984 0.8983 0.9666 0.9549
By grouping the cataract males and females, and thus increasing the sample size, the 
standard error is reduced and the difference between the cataract group and the control group 
approaches significance at 4 hr (0.0988) and 6 hr (0.0648) (Table 6.1) The lack of 
significance is probably due to the high values for the two patients mentioned earlier. 
Although the data points for the two high patients were 2 and 3 times higher than the other 
values in the male group, they could not be excluded on the basis of outliers without having 
to eliminate all the data concerning these two. All the Trp metabolite data at each time period 
were obtained from the same chromatographic run, and there was no valid reason to exclude 
any of the chromatograms on either patient. Furthermore the value from each time period
* A probability score o f less than 0.050 indicates a statistically significant difference.
F igu re 6.7
K ynurenine R esponse  
to the T ryptophan Load: 
all subjects according to Cataract Grade
Time After Dose
H  Grade 0 (n=37) 
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T able 6.4
W ilcoxon  P rob ab ility  Scores* :
W ithin-G roup D ifferences as a function  o f C ataract Grade
0 hour 1 hour 2 hour 4 hour 6 hour
0.2909 0.6629 0.8397 0.7250 0.0330
* A probability score o f less than 0.050 indicates a statistically significant difference.
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was obtained from a separate sample, so each sample, although from the same patient, was 
independent and thus served as a check on the other samples from the same patient.
6.2.4 Cataract Grade Differences
When the cataract group is arranged according to the grade of cataract (see Chapter 4 for the 
cataract grading protocol) at each time interval, the serum Kyn response shows no 
statistically significant difference between cataract grades for all times except the 6 hr point, 
with a probability of 0.0330 (Table 6.4).
Examination of Figure 6.7 reveals a much higher response in the peak levels in the cataract 
patients (Grades 1 to 4) when compared with the control subjects (Grade 0). The peak 
levels of the cataracts, although varying from 2 hr to 4 hr, are higher than the control 4 hr 
peak level. Even Grade 4, which show the lowest cataract group overall response, is still at 
the peak than the control.
Furthermore, the 6 hr values alone provide an interesting comparison. The values for the 6 
hr serum Kyn levels show a trend which increases with severity of cataract up to Grade 2. 
Both Grade 1 and Grade 2 levels at 6h are higher than that for Grade 0. However, the 6 hr 
level for Grade 3 and Grade 4 are much lower than either Grade 2 or 3, and more 
significantly, the control level at 6 hr.
Grade 4 also shows a high fasting Kyn level, much higher than the control and Grades 1 
and 3. However, it is important to note that the standard error is relatively small at each time 
period for Grade 4, and the small probability figure of 0.0330 (Table 6.4) is in part due to 
this fact and also because of the small sample size (n=2) for this grade group. (See Chapter 
4, Section 4.4 Group Demographics for the distribution of grades, ages and gender within 
the cataract and control groups).
Table 6.5
Reference Intervals for Serum Kynurenine 
following Tryptophan Load 
(limol/L)
Mean Reference Range
Fasting 4.0 0.08 - 18.5
After 1 h 11.1 0.02 - 60.2
After 2 h 19.9 0.11 - 120.1
After 4 h 25.0 0.05 - 106.4
After 6 h 20.2 0.26 - 71.3
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It is interesting that for each grade, the Kyn response has a peak level at 2hr or 4hr with a 
decreasing value at 6 hr. This contrasts with the pattern of response shown when the data is 
examined according to age and sex (Figures 6.3 to 6.6).
6.3 Reference Range for Kynurenine
Since there were no significant differences between the sexes and the age groups within the 
control group a "normal" or expected reference interval (95% of the data range, using 2.5th 
and 97.5th percentiles) can be established for this analytical method for plasma Kyn. An 
interval (Table 6.5) can also be established for each time period after a 50 mg/kg oral load of 
L-Trp.
Other investigators have found lower mean fasting levels for serum Kyn. Holmes [107] 
using a HPLC method found the fasting range for both males and females to be from 1.30 
to 3.32 [imol/L with a sample population size of 40. Joseph [90] found a similar range for 
plasma samples, 1.94 to 2.91 mmol/1 but this was established on only 8 male subjects and 
using a colorimetric diazotisation method.
CHAPTER 7
3-HYDROXY-
ANTHRANILIC
ACID
M etabolism  o f
F igu re  7.1
3 -H yd roxyan th ran ilic  A cid
c x
o
II
c - c h 2 c h - c o o h  
n h 2 
n h 2
OH
3-Hydroxykynurenine
02 3-Hydroxyanthranilate oxygenase
HOC
COOH
H O O C ^  NH2
2-Amino-3-carboxy-muconic semialdehyde
a
N  o n -e n zy m ic  
c y c l i s a t io n HOC*
N COOH
Picolinic acid
HOOC NH2 
2-Aminomuconic 
semialdehyde
se m i a ld e h y d e  
d e h y d r o g e n a s e
Acetyl CoA 
and CO2
HOOC
HOOC NH2
2-Aminomuconic
acid
N o n -e n z y m ic
c y c l i s a t io n
COOH
COOH
Quinolinic acid
Q u in o la te
p h o s p h o r i b o s y l
t r a n s f e r a s e
o
COOH
^  N A D *  and 
N A D P *
Ribose-P
Nicotinamide
nucleotide
3-Hydroxyanthranilic Acid Page 106
7.1 Introduction
7.1.1 Biochemistry and Physiology
3-Hydroxyanthranilic acid (30HA) or 2-amino-3-hydroxybenzoic acid is an 
aminophenol which is involved in the tanning of proteins in insect cocoons, and the 
formation of some pigments in marsupials [83].
Figure 7.1 indicates that 30HA is formed from the hydrolysis of 30HKyn by the 
enzyme, kyn u ren in a se*  (E.C. 3.7.1.3) This enzyme was discussed in section 6.1.1 
in relation to the conversion of Kyn to AA. In a similar reaction, the alanine moiety is 
cleaved from 30HKyn to produce 30HA.
30HA is cleaved by the enzyme, 3-hydroxyanthranilate oxygenase  also known as 
3 -h yd ro x ya n th ra n ila te  3 ,4 -d ioxygen ase*  (EC 1.13.11.6) to form an unstable 
intermediate, 2-amino-3-carboxymuconate semialdehyde (syn. 2-acroleyl-3- 
aminofumarate). The enzyme requires oxygen, ferrous ions and free thiol groups for 
activity, and is inhibited by ferric ions [144].
The semialdehyde cyclises to a Schiff base, resulting in a pyridine dicarboxylate, 
quinolinic acid. The rate of reaction is probably limited by the isomerisation of the double 
bond to bring the amino group near the aldehyde.
Quinolinic acid is decarboxylated in the presence of 5-phosphoribosyl 1-pyrophosphate 
(PRPP) to form nicotinamide mononucleotide, by the action of q u in o lin a te  
p h o sp h o -r ib o sy ltra n sfe ra se  (E.C. 2.4.2.19) also known as n ico tin a te-n u cleo tide  
pyrophosphorylase*. This enzyme is localised in the liver and the kidney.
* International Union of Biochemistry recommended name - (I.U.B Nomenclature Committee, ed. 
Enzyme Nomenclature. 1984, Academic Press, Inc.: Orlando, Florida.)
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Nicotinamide mononucleotide can then react with ATP to yield nicotinamide adenine 
dinucleotide (NAD), catalysed by NAD-synthase* (E.C. 6.3.1.5)
It is unusual for a biosynthetic pathway such as this to have a non-enzymatic step, (to 
quinolinic acid and NAD) and regulation of this section of the pathway is possibly 
controlled by diversion through the other (enzymatic) pathway to acetyl CoA. The 
enzyme, picolinic carboxylase* (aminocarboymuconate-semialdehyde decarboxylase 
- E.C. 4.1.1.45) removes the carboxyl group from the first semialdehyde to form 2- 
aminomuconic semialdehyde. This second semialdehyde is then converted by an 
aldehyde dehydrogenase (2-hydroxymuconic-6-semialdehyde dehydrogenase) to 2- 
aminomuconic acid, however it can be non-enzymically cyclised to picolinic acid [171]. 
Since most carboxyl-labelled 30HA yields labelled-C02 in vivo it appears most 30HA is 
metabolised via this route. Picolinic acid has been found to be excreted quantitatively as 
its glycine conjugate in rats [172].
The 2-aminomuconic acid can also be further degraded through oc-ketoadipate via 
glutarate to acetyl CoA and CO2 , a metabolic fate which was first described in 1959
[173]
7.1.2. B ackground
30HA was first identified as an intermediate in the tryptophan-nicotinic acid pathway 
firstly in Neurospora sp. in 1948, and then in mammals in 1956. In 1957 it was 
demonstrated that the first intermediate in the conversion to quinolinic acid was 2-amino- 
3-carboxymuconic semialdehyde [174]. As well as undergoing spontaneous cis-trans 
isomerisation and cyclisation to form quinolinic acid, this intermediate was shown in 
1956, to be enzymatically converted to picolinic acid. [172].
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30HA is very sensitive to oxidation and has been shown to auto-oxidise at both acidic 
and alkaline pH to form cinnabarinic acid and a p-quinone dimer respectively. It also can 
react to form these compounds, although at a more sluggish rate, at neutral pH [83].
The high reactivity of this metabolite has been demonstrated by several workers. 30HA 
has been found in the urine of leukaemics and bladder tumour patients [167,175, 176]. 
Chromosomal aberrations (breakages, translocations) are found in haemopoietic cells 24­
48 hr after subcutaneous injection of 10 mg/L. Mutagenicity is probably the mechanism 
of the blastogenic activity of 30HA [177]. Proteins when incubated with 30HA in an 
oxidising environment become rapidly tanned (coloured, crosslinked and insoluble) and 
this has been suggested as a model for the formation of senile nuclear cataract in man 
[84].
An Italian study, examining the hypothesis that Trp is involved in the development of 
senile cataract, examined the urine of 45 cataract patients and 26 controls by 2­
dimensional paper chromatography. They found increased urinary levels of Kyn, o- 
aminohippuric acid and 30HA in the cataract patients but not in the control individuals 
[66]. 30HA was not present in the urine of the most severe cataract patients.
30HA has recently been demonstrated [87] to have antioxidant properties. The authors 
described 30HA as being more efficient as an antioxidant than ascorbic acid and a water- 
soluble vitamin E analog. They suggested that the antioxidant property may be due to the 
phenolic moiety, since all the phenolic Trp metabolites showed antioxidant activity. It 
was also shown that an influenza infection which is known to cause a 50% decrease in 
superoxide dismutase activity [87], also was associated with a dramatic increase in lung 
indoleamine dioxygenase activity [87,178].
F igure 7.2
3-H ydroxyanthran ilic  R esponse
to the Tryptophan Load
Hours A fter Dose
Number of Values constituting each time point
0 hr 1 hr 2 hr 4 hr 6 hr
C on tro l 37 34 36 34 36
Cataract 36 35 32 33 26
Table 7.1
C hi-Square Probability  Scores* : 
Cataract v. Control D ifferences
0 hour 1 hour 2 hour 4 hour 6 hour
0.595 0.076 0.058 0.037 0.398
* A probability score o f less than 0.050 indicates a statistically significant difference.
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7.2 Discussion of Results
7.2.1 G roup Differences
Figure 7.2 shows the mean serum 30HA response for both groups to the Trp load. 
Table 7.1 indicates the probability value for differences between the cataract group and 
the control group for each time period.
The serum 30HA response, shown in Figure 7.2, for cataract patients is higher overall 
than that for the control subjects, but as the error bars indicate there is considerable 
overlap between the two groups. Therefore, the degree of difference is probably not 
significant. This finding is supported by the Chi-Square probability scores shown in 
Table 7.1, where only the 4 hr value (0.037) indicates greater difference between the two 
groups than could be expected by chance. The graph also shows the greatest separation 
of means at this time period.
Three patients (Cataracts #36, #41) had high basal levels which remained constant over 
the measurement period and both had high total trp peak levels (ie. >300 pmol/L at 2 hr 
post-load). Similarly, the control subjects showed little or no response to the load and as 
with the cataracts some displayed high total trp (Controls #1, #2, #28, #29).
7.2.2 Age Differences
Figure 7.3 and 7.4 show the Trp load response bar graphs of serum 30HA levels 
grouped according to age. Each set of 5 bars represents the timed response to the load 
for each age group. Each age group represents those patients falling within that decade 
(ie. 20 represents those patients/subjects aged 20 yr to 29 yr). The scale of the y-axes of 
both graphs are the same. The sample size of each group is indicated under the x-axes.
Table 7.2 lists the probability scores for differences within each group for each time 
period.
Figure 7.3
3-H ydroxyanthranilic A cid  R esponse  
to the Tryptophan Load: 
Control Subjects according to Age
n=5 n=7 n=4 n=18 n=3
M Oh 
B  l h  
Ü  2 h 
' □ 4 h  
□  6 h
Age Group (yrs)
Figure 7.4
3-H ydroxyanthranilic acid R esponse  
to the Tryptophan Load: 
Cataract Patients according to Age
n-6  n=12 n=15 n=8
Age G roup (yrs)
m oh
@ l h
m  2 h
□  4 h
□  6 h
3-Hydroxyanthranilic Acid Page 110
Table 7.2
W ilcoxon Probability Scores* : 
W ithin-Group Differences as a function of Age
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.0001 0.0721 0.0179 0.0031 0.0002
Cataract 0.9956 0.9713 0.6029 0.9355 0.3184
The probabilities for the control group show significant differences at each time period 
except for the 1 h period. Although the height of some of the columns in Figure 7.3 
suggest minimal variation in the values, particularly when comparing the 20 yr age group 
with the 30 yr age group, the very low results in the 60 yr group and the small standard 
error probably account for the statistical significance.
The probabilities for the cataract group, on the other hand, show there is no significant 
difference in the cataract group for any time period. Figure 7.4 shows very little variation 
in the height of the bars except for the 2 hr bar. The standard error for this period is also 
very large and would account for the result of Mno statistical significance".
Perhaps the most curious finding in this age data is the lower response pattern seen in the 
controls for the 60 yr decade compared with the other control age groups. The older age 
groups (40, 60 and 70 yr) in the control category had mean levels either close to or less 
than 5 |imol/L, compared with the 20 yr and 30 yr groups who had 30HA levels above 5 
Umol/L. The data suggested an almost linear decrease in 30HA with age, up to age 60 yr 
(figure 7.3). The cataract group had values not higher than 5 pmol/L (except for the 2 hr 
point for the 60 yr group). Thus the cataract groups, in general, have response patterns 
similar to those of the 60 yr control group. *
* A probability score of less than 0.050 indicates a statistically significant difference.
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7.2.3 Sex Differences
Figures 7.5 and 7.6 show the Trp load response bar graphs of serum 30HA levels 
grouped according to sex. Each set of 5 bars represents the timed response to the load 
for each age group. The sample size of each group is indicated under the x-axes.
Table 7.3 lists the probability scores for differences within each group for each time
period.
Table 7.3 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Sex
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.9857 0.8937 0.8866 0.8619 0.8292
Cataract 0.2138 0.0446 0.0676 0.1832 0.1296
As Table 7.3 indicates there is no significant difference within the cataract group and 
within the control group on the basis of gender. This is also obvious in Figure 7.5, 
where both the female bar charts and the male bar charts are similar in size and pattern.
Figure 7.6, on the other hand, illustrates that the pattern for the males is overall lower 
than that for the females. The 2 hr male value does not fit the pattern, but the variation is 
large as indicated by the large error bar for this time period.
7.2.4 Cataract Grade Differences
Table 7.4 suggests that there was no significant difference within the cataract group at 
each time period when tested according to severity of cataract. In other words, there was 
no difference between grades 1, 2, 3 and 4 at the basal (0 hr) level, nor any difference 
between them at the 1 hr level, nor the 2 hr level etc.
However, when the data is grouped as shown in Figure 7.7, the response to the Trp load 
produces a very different pattern. There was virtually no response to the load for 30HA
* A probability score of less than 0.050 indicates a statistically significant difference.
F igu re 7 .7
3-H yd roxyan th ran ilic  A cid  R esponse  
to T ryptophan Load:
All Subjects according to Cataract Grade
Time After Dose
13 Grade 0 (n=37) 
E3 Grade 1 (n=12) 
H Grade 2 (n=ll) 
0  Grade 3 (n=7) 
□  Grade 4 (n=2)
Table 7.4 W ilcoxon P robability  Scores* : 
W ithin-G roup D ifferences as a function  o f C ataract G rade
0 hour 1 hour 2 hour 4 hour 6 hour
0.3284 0.3372 0.2264 0.6758 0.4360
* A probability score of less than 0.050 indicates a statistically significant difference.
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in the Grade 3 cataract group. Grade 1 and Grade 2 cataract responses were also lower 
than the control group (Grade 0) response and, although only of small sample size 
(n=2), the Grade 4 group appeared higher than the control group. There was therefore 
no obvious trend in 30HA response with increasing severity of cataract.
7.3 Reference Ranges for 3-Hydroxyanthranilic
Acid
Since there were no significant differences between the sexes and the age groups within 
the control group a reference or expected range (95% of the data range, using 2.5th and 
97.5th percentiles) can be established for this analytical method for plasma 30HA. A 
range (Table 7.5) can also be established for each time period after a 50 mg/kg oral load 
of L-Trp.
Table 7.5
Reference Ranges for Serum  3-H ydroxyanthranilic acid  
follow ing the Tryptophan Load  
( lim o l/L )
Mean Reference Range
Fasting 4.55 0.01 - 20.6
After 1 h 5.01 0.01 - 16.5
After 2 h 5.51 0.01 - 18.4
After 4 h 6.32 0.01 - 20.6
After 6 h 4.91 0.01 - 16.6
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8.1 Introduction
8.1.1 B iochem istry and Physiology
Xanthurenic acid (4,8-dihydroxy-2-quinoline carboxylic acid) is formed from the 
transamination of 30HKyn by the enzyme, kynurenine am inotransferase , 
(kynurenine-oxoglutarate aminotransferase* EC 2.6.1.7). This enzyme is active on both 
L-Kyn and L-30HKyn and it requires pyridoxal phosphate or pyridoxamine phosphate as 
a coenzyme [144].
The aminotransferase is loosely bound to the inner mitochondrial membrane and utilises 
either oc-ketoglutarate or oxaloacetate as the amino receptor. The resulting aromatic oc- 
ketoacid immediately undergoes dehydration and ring closure to form XA. Unlike other 
transamination reactions, the reaction is irreversible since XA cannot be a substrate for 
the aminotransferase [150].
XA, to a small degree, may undergo further metabolism by dehydroxylation to form 8- 
hydroxyquinaldic acid, however XA is mainly excreted unmodified or as the 
glycine conjugate. Alternatively, the 8-hydroxy group of XA may be methylated and 
then excreted as the 8-methyl ether of XA [144]. This compound is excreted in the 
urine of man and monkey, but little is known of the quantitative aspects of its excretion 
[44].
8.1.2 Background
XA was first isolated from urine by Luigi Musajo in 1935 and was shown in 1936 to 
originate from Trp via Kyn. Then, in 1942, XA was associated with vitamin B6 when it 
was found in large amounts in the urine of pyridoxine-deficient rats, and it was this
*
International Union of Biochemistry recommended name (International Union of Biochemistry E n zym e  
N om en cla tu re . 1984, Academic Press, Inc.: Orlando, Florida.)
F igure 8.2
X anthuren ic A cid  R esponse  
to the T ryptophan Load
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Hours after Dose
N u m b e r  o f  V a lu e s  c o n s t it u t in g  e a ch  t im e  p o in t
0 h r 1 h r 2  h r 4 h r 6 h r
C o n t r o l 37 32 35 33 36
C a t a r a c t 38 37 34 34 27
T able 8.1
C hi-Square P robability  Scores* : 
C ataract verses C ontrol
0 hour 1 hour 2 hour 4 hour 6 hour
0.596 0.604 0.040 0.126 0.211
A probability score of less than 0.050 indicates a statistically significant difference.
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association which first attracted attention to the interrelationships between pyridoxine and 
the metabolic enzymes [65].
The early method for the measurement of XA in urine was a colourimetric method 
developed in 1945 which relied on a green complex formed with iron. This procedure 
was modified later to remove the urinary extraction step. The method was not specific 
and actually overestimated the amount of XA in the urine. This method had been used 
extensively in the literature, and as a result previous measurements were invalidated 
when a more specific method [179] became available. The Trp Load Test, the generally 
accepted measure for pyridoxine deficiency in man, relies on the assay of XA as the 
metabolic indicator of the test and the introduction of a more reliable method lead to calls 
for the standardisation of the Trp load [41]
In investigating Trp metabolism and Kyn in senile cataract, Allegri, et al [113] used XA 
estimation as an indicator of vitamin B6 deficiency and reported no increase in urinary 
excretion in the cataract group. Other investigators [66, 133], however have found an 
increase in some patients. It was noted [133] that 1% of healthy individuals do have 
asymptomatic xanthurenic aciduria. This was supported by further work on hereditary 
(autosomal recessive) xanthurenic aciduria [136], a vitamin-dependent inborn error of 
metabolism associated with several clinical entities.
The estimation of serum levels of XA has to my knowledge not been reported previously 
in the literature.
8.2 Discussion of Results
8.2.1 Group Differences
As indicated by the response graph in Figure 8.2, there is considerable overlap of the 
error bars of the control and cataract groups, and there is no apparent major difference 
between the two groups. Except for the probability of the 2 hr period (0.040), this
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difference is supported by the Chi-Square scores for the data comparison shown in Table
8.1. The cataract patients peaked at 4 hr. XA levels in controls, on the other hand, 
increased linearly from 2 hr to 6 hr.
Overall, serum XA does not differ significantly between cataract patients and control 
subjects.
8.2.2 Age D ifferences
The appearance of the bar graph in Figure 8.3 suggests large individual differences 
within the 20 yr age group, but as the error bars indicate, the 4 hr and 6 hr values have a 
very large spread and this is due to a comparatively high value for both these time points 
in one female only (control #32). These values (both results above 15 pmol/L) were not 
sufficient to make the control probability scores statistically significant at 4 hr and 6 hr, 
as can be seen in Table 8.2.
The curves for the 30 yr age group in Figure 8.3 show a higher response than that which 
occurs in the other control age groups. Excluding what would appear to be two aberrant 
values in the 20 yr age group, there is very little difference in the responses of the 20 yr, 
40 yr, 60 yr and 70 yr age groups and overall little XA response to the load.
The cataract group shows a similarly low (below 4 pmol/L) response for each of the 
four age groups. These values were not statistically significant when tested for 
variations within each time period (Table 8.1). There are, however, differences in the 
pattern of responses. Each of the groups peaks at a different time interval - 50 yr at 2 hr; 
60 and 80 yr at 4 hr; and 70 at 6 hr. These differences, although not statistically 
significant, illustrate the varied response possible for some of the Trp metabolites.
There does seem to be a trend towards higher values for XA in the later time periods in 
cataract patients compared with controls.
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Table 8.2
W ilcoxon Probability Scores* : 
W ithin-Group Differences as a function of Age
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.3673 0.1324 0.1855 0.8230 0.7585
Cataract 0.4000 0.8493 0.6195 0.5279 0.6404
8.2.3 Sex Differences
It is clear from Table 8.3 that there are no statistically significant differences in the serum 
XA levels on the basis of sex in either the control or the cataract group. Figures 8.5 and 
8.6 demonstrate that there is considerable similarity for the sexes independent of the 
group. An interesting finding was that the males from both groups exhibited a similar 
pattern, which was slightly different from the females. The males tended to have a lower 
profile and showed a flatter response pattern, whereas the XA levels in the females 
continue to rise to 6 hr. Although apparent from the figures, this pattern was not found to 
be of significance by the statistical analysis.
Table 8.3
W ilcoxon Probability Scores* : 
W ithin-Group Differences as a function of Sex
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.5580 0.3043 0.5588 0.6710 0.6712
Cataract 0.9764 0.2925 0.1096 0.2681 0.2915
The excretion of XA after a Trp load is often used as an index of the vitamin B6 status in 
an individual. In a study of the vitamin B6 requirements of the elderly [180], it was 
found that after a Trp load, the female group excreted larger amounts of XA in their urine 
than did the male group, and this feature developed sooner in a vitamin depletion period *
* A probability score of less than 0.050 indicates a statistically significant difference.
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than it did in the males. The authors reported that a similar finding had also been noted 
by other investigators in younger age groups.
8.2.4 Cataract Grade Differences
Within the cataract group, XA was the only metabolite to exhibit a statistically significant 
difference in the serum levels of the patients between the cataract grades. The Wilcoxon 
probability scores are listed in Table 8.4. There is no statistically significant difference 
between the grades for the fasting XA level and the 6 hr level, however the 1 hr, 2 hr, 
and 4 hr levels exhibit a statistically significant change.
The difference is apparent when Figure 8.7 is examined. The standard errors are 
relatively small compared with the height of the bars for 0 hr, 1 hr and 2 hr time points. 
It is interesting to note that the cortical cataract patients ie. Grade 1 (7 males, 4 females) 
exhibit an increased trend in the magnitude of response compared with Grade 0 subjects. 
A second response pattern was found in Grade 2 patients (5 males, 7 females), who 
displayed a low overall response. Grade 3 and Grade 4 patients were similar to the 
controls.
One metabolic study [133] of Trp metabolites in patients with presenile (18-40 yr) 
cataracts observed an increase ("moderate" to "considerable") in the urinary XA excretion 
in 28% of patients above control levels. They also noted that only 1% of healthy persons 
have asymptomatic xanthurenic aciduria. This study did not classify the cataract group 
into categories of severity. However, an earlier investigation [66] examined the excretion 
of XA in cataract patients after a Trp load (50 mg/kg). This study observed that patients 
with Type I-II cataracts (Pirie classification) had increased XA excretion, 1.8 times the 
control group, while the Type HI-IV cataracts showed a similar level (1.1 x) to the 
control. Although the grade groups are different, and serum rather than urine has been 
analysed, a somewhat similar result is seen in Figure 8.7. The Grade 1 cataract patients 
showed increased XA levels at 1 hr, 2 hr, 4 hr and 6 hr, but Grade 2 - Grade 4 patients 
appeared to have low XA levels or XA levels similar to those of Grade 0.
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8.3 Reference Ranges for Xanthurenic acid
Despite the differences within cataract groups, there were no statistically significant 
differences between the sex and age groups within the control group. Therefore, a 
range (Table 8.2) can be established for this analytical method for plasma XA (95% 
of the data range, using 2.5th and 97.5th percentiles) for each time period after a 50 
mg/kg oral load of L-Trp.
Table 8.3
Reference Ranges for Serum Xanthurenic Acid 
following the Tryptophan Load 
(pmol/L)
Mean 95% Reference Range
Fasting 0.62 0.03 - 3.09
After 1 h 1.16 0.06 - 4.76
After 2 h 1.07 0.06 - 4.95
After 4 h 1.49 0.05 - 10.95
After 6 h 1.88 0.01 - 13.4
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9.1 Introduction
9.1.1 Biochemistry and Physiology
Figure 9.1 illustrates the metabolism of kynurenic acid. KA (4-hydroxyquinoline-2- 
carboxylic acid) which is formed through the transamination of Kyn via the catalytic 
activity of kyn u ren in e  am ino transferase  (k y n u re n in e -o x o g lu ta ra te  
aminotransferase* E.C. 2.6.1.7). This enzyme requires pyridoxal phosphate or 
pyridoxamine phosphate (PPi) as a coenzyme. Kynurenine aminotransferase is also 
active towards 3-hydroxykynurenine (30HKyn) [144].
The transamination of Kyn would be expected to yield o-aminobenzoylpyruvic acid, but 
spontaneous cyclisation occurs with such rapidity, that the intermediate has never been 
isolated [144]. The reaction is not reversible since the intermediate does not accumulate, 
and KA cannot be a substrate for the aminotransferase.
Kynurenine aminotransferase is found only in the liver and kidney, but other mammalian 
enzymes capable of catalysing the transamination of Kyn to KA are known, and 
conversely other amino acids are substrates for kynurenine aminotransferase, but it 
appears that Kyn is the preferred substrate [150].
In vitamin B6 deficiency there is a greater increase in urinary XA than in KA and this has 
formed the basis of the tryptophan loading test. There is also a correspondingly greater 
decrease in kynureninase than there is in kynurenine aminotransferase which explains the 
former observation [144]. This phenomenon is most likely due to the protected location 
of kynurenine aminotransferase on the inner membranes of the mitochondria, compared 
to the more vulnerable location of kynureninase in the cytosol [150].
*International Union of Biochemistry recommended name (International Union of Biochemistry E n zym e
N om en cla ture. 1984, Academic Press, Inc.: Orlando, Florida.)
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KA can be further metabolised to quinaldic add which is not degraded further, and is 
excreted as the free acid or as a conjugate of glycine. As much as 29% of a single oral 
dose of KA has been recovered in human urine [144].
9.1.2. Background
KA was discovered in 1853 by Lieberg, before tryptophan was known. In 1904, before 
its structure was known, KA was demonstrated to be a metabolic product of tryptophan 
in the dog [65].
In 1956, small but varying amounts of KA were found in the urine of patients with 
various diseases and in controls, but no specific correlations could be made for KA 
excretion with any particular disease or symptom [167].
Much of the earlier analytical work on KA in urine utilised a method of chlorinating KA 
with phosphorus pentachloride and oxychloride and then adding quinoline until a red- 
violet substance was produced quantitatively. XA, which also produces the coloured 
product, was first oxidised with potassium permanganate (KA does not oxidise), and 
then the KA extracted at pH 2 with amyl alcohol, chlorinated and reacted with quinoline 
[65].
A study of tryptophan metabolism in patients with senile cataract in 1982, found 
increased amounts of KA in the urine of cataract patients after a 50 mg/kg oral dose of 
tryptophan. A group of patients having either Type I or II cataracts had urinary KA levels 
1.6 times the control group and those with Type HI or IV had levels twice that of the 
control group [66].
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9.2 Discussion of Results
9.2.1 Group Differences
A comparison of the response curves for the cataract and control groups in Figure 9.2 
shows the control group exhibiting a larger response to the tryptophan load than the 
cataract group. Furthermore, there is no overlay of the curves at any time point, but the 
error bars do overlap at the 6 hr point. A similar pattern was observed in the serum 
response curves for total trp, 30HA, and AA, but the latter two showed considerable 
overlap of error bars at various time points. The other metabolite response curves were 
higher in the cataract group.
The peak level in both groups occurs at 4 hr, with the cataract patients exhibiting a steady 
rate of increase from the basal level. On the other hand, the control subjects show a more 
rapid rise from basal to 1 hr and a slowing down of the rate of increase to peak at 4 hr. 
There is a correspondingly rapid decrease to 6 hr, whereas the rate of decrease is much 
slower for the cataract group.
Figure 9.2 demonstrates a clear difference in the degree of response between the two 
groups. There were 3 controls (#27, #32, #35) with peak values above 25 nmol/L and 2 
cataracts (#6, #30) with peak values above 25 limol/L. Cataract #6 had a 4 hr peak level 
of 60 |imol/L. Table 9.1 indicates that with the exception of the 6 hr point, there is a 
significant difference between the groups at each time point
9.2.2 Age Differences
Figure 9.3 and 9.4 show the response curves for each decade for the control and cataract 
groups respectively.
The control groups have a similar magnitude of response in each age group, with the 
exception of the 40 yr olds. The 40 yr olds have a peak response below 5 |imol/L, 
where as the other groups have the peak response between 5 and 10 jimol/L. The mean
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peak response for the control group was 4.6 pmol/L at 4 hr (Figure 9.2), but the age 
groups vary in their peak response from either 2 hr or 4 hr, with the 40 yr olds differing 
by peaking at 6 hr. There appears to be no trend in the actual time of the peak in the 
control group.
The cataract groups, like the controls, have a similar magnitude of response in each 
group but all are below 5 pmol/L (except the 80 yr 4 hr peak). This lower response of 
the cataract groups as a whole was reflected in the mean response shown in Figure 9.2. 
(The 40 yr cataract group only had 1 patient and this patient was only sampled 1 hr after 
the dose and has been excluded from this graph.) Unlike the control group, the peak 
response in the cataract group occurred at either 4 hr or 6 hr, which would account for 
the shallower mean-cataract-response curve shown in Figure 9.2.
It would appear then that the lower response of the cataract group is reflected across all 
the four age groups. Likewise the higher response of the control group is reflected 
across four of the age groups, with the 40 yr group standing out by being similar to the 
cataract age groups.
Table 9.2 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Age
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.0745 0.3250 0.3884 0.1633 0.3437
Cataract 0.9719 0.4075 0.9486 0.2893 0.3272
Table 9.2 lists the probability scores for comparisons at each time period for the cataract 
and the control group. The scores, for example, indicate there is no significant 
difference in KA levels between the subjects in the control group at the 1 hr period
* A probability score of less than 0.050 indicates a statistically significant difference.
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according to age group. The table shows that there is no significant difference between 
KA levels for the cataract group at each period.
9.2.3 Sex Differences
Figures 9.5 and 9.6 illustrate the KA response curves for males and females as sub­
groups of the control and cataract groups.
There does not appear to be any significant difference between the male and female 
groups amongst the controls as shown in Figure 9.5. Both sexes peak at 4 hr and have 
similar basal levels. The rate of response appears somewhat steeper and higher in the 
female than in the male group (for further discussion, see Chapter 15).
The cataract group response, on the other hand, does exhibit a contrast between the 
sexes. The male response, although steeper in rate, is similar in magnitude to the male 
control response. The cataract female group is much lower in magnitude and flatter in 
rate than the cataract males, and is even more of a contrast to the control females, who 
showed the higher peak value in that group. It would seem then that the difference 
between the cataract and control response curves seen in Figure 9.2, is due largely to the 
low response shown by the females in the cataract group.
Table 9.3 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Sex
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.6871 0.7127 0.8100 0.3997 0.7543
Cataract 0.4954 0.2322 0.0769 0.0881 0.8901
* A probability score of less than 0.050 indicates a statistically significant difference.
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Table 9.3 indicates that there is no significant variation at each time interval for both the 
cataract and control groups that can be attributed to gender using this statistical analysis. 
Using Fisher's Exact Test to compare cataract males verses control males, and cataract 
females verses control females a statistically significant difference was found and this is 
discussed in Chapter 15.
9.2.4 Cataract Grade Differences
Figure 9.7 shows the KA response curves when separated according to cataract grade. 
Grade 0 is the control group. In all grades except Grade 4 , the peak occurred at the 4 hr 
period. Grade 4 has a peak response at 2 hr, and a mean 4 hr level lower than the 6 hr, 
but this group only has a sample size of 2. Grades 1 and 2 are almost identical in size 
and shape, indicating a similar response. Grade 3 is similar to 1 and 2, but with a higher 
1 hr and 2 hr response.
All three cataract groups (excluding Grade 4) are different from the control (Grade 0). 
This may reflect the difference shown by the female cataract group although the 0 hr, 1 
hr and 2 hr points are also lower in the male cataract group. There is a larger proportion 
of females in the cataract group (75% females) than there is in the control group (42% 
females), and their influence is seen when the cataract group is divided into smaller 
groups as shown in Figure 9.7. The females in the control group (Grade 0), however, 
demonstrated the highest response of the gender groups (Figures 9.5 and 9.6) and would 
also contribute to the higher response of the Grade 0.
Grade 1, 2 and 3 response patterns appear lower than that of the controls (Grade 0), 
however, Table 9.4 indicates that there is no significant difference in the serum KA 
levels within the cataract group (Grades 1 to 4) according to grade of cataract.
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9.3 Reference Ranges for Kynurenic Acid
Since there were no significant differences between the sexes and the age groups 
within the control group a "normal" or expected range (95% of the data range, using 
2.5th and 97.5th percentiles) can be established for this analytical method for plasma 
KA. A range (Table 9.5) can also be established for each time period after a 50 mg/kg 
oral load of L-tryptophan.
Table 9.5
Reference Ranges for Serum Kynurenic Acid 
following the Tryptophan Load 
(p m ol/L )
Mean Reference Range
Fasting 1.81 0.43 - 5.6
After lh 5.35 0.44 - 20.0
After 2 h 6.46 0.18 - 20.6
After 4 h 7.51 0.77 - 26.0
After 6 h 5.22 0.68 - 19.5
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10.1 Introduction
10.1.1 Biochem istry and Physiology
Alanine is cleaved from Kyn to form AA through the catalytic action of kynureninase * 
(EC 3.1.1) also known as kynurenine hydrolase.
Figure 10.1 illustrates the metabolic products of AA metabolism, which in mammals 
appear to be mainly those reactions that are associated with detoxification of metabolic 
end-products and for increasing the solubility of the more hydrophobic molecules in 
order to assist excretion.
Significant amounts of AA are conjugated with glucuronic acid (anthraniloyl 
glucuronide) and glycine (o-aminohippuric acid) after a trp load, and because 
conjugation is often associated with detoxification, the cleavage of kyn to AA has even 
been suggested by some [150] to be a waste-removal mechanism.
Small amounts of anthranilamide can be found in the urine after a loading dose of trp, 
but it has been suggested [150] that it is formed in the bile ducts by a non-enzymic 
amidation reaction of anthraniloyl glucuronide and ammonium and bicarbonate ions. 
From here it enters the intestine and is reabsorbed into the portal circulation and 
eventually appears in the urine [150].
Hydroxylation has been demonstrated to result when rabbit liver microsomes were 
incubated with AA to form 50HA [181]. The enzyme responsible, anthranilate 5- 
hydroxylase, was characterised and was believed by the authors to be a metal-containing 
sulphydryl enzyme. Some 30HA is reported [37] to be formed by the activity of 
microsomal hydroxylation, although this has been disputed by others [38].
* International Union of Biochemistry recommended name (International Union of Biochemistry, Enzyme
Nomenclature. 1984, Academic Press, Inc.: Orlando, Florida.)
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Hydroxylation of the anthranilamide by liver microsomes forming the 3- and 5- 
hydroxyanthranilamide can also occur, the hydroxylated forms undergoing O-sulphation 
before excretion [38].
10.1.2. B ackground
It has been known since the 1930s that A A was an intermediary metabolite of Trp. The 
glycine conjugate of A A, o-aminohippuric acid was discovered in 1953 and rats injected 
with A A were able to form anthranilamide and excrete it in urine [37]. These authors 
reported that the conjugate of AA with glucuronic acid had been found in urine much 
earlier [37]. AA, its glucuronide and o-aminohippuric acid have been found in the urine 
following administration of trp [44, 66]. Although this was not believed to be a 
precursor for nicotinamide nucleotides [38], Ueda and co-workers reported that NAD 
accounted for 2.6% of labelled AA [37]. They showed that both 30HA and 50HA were 
formed from AA in rat liver by microsomal hydroxylation.
10.2 Discussion of Results
10.2.1 Group Differences
A comparison of the response curves for the cataract and control groups in Figure 10.2 
shows the control group exhibiting a larger response to the trp load than the cataract 
group at all time points. The maximum response for both groups is only about twice the 
basal level and only the control group returns to the fasting level after 6 hr. Except for 
the dip in the cataract curve at the 2 hr time point and a sharper decline of the cataract to 
the 6 hr point, both curves show a similar pattern of response. This suggests a similar 
rate of metabolism of AA for the two groups. The reason for the dip in the cataract curve 
at 2 hr could not be explained.
There is considerable overlap of the error bars at three time points, fasting, 1 hr, and 4 
hr. The 2 hr and the 6 hr points do not overlap but the values are low and the standard 
error for the control values is small at both these points. The fasting level is also low
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and the error small, but the low control fasting mean has a larger error and overlaps the 
cataract mean value. The standard error for the cataract group is considerably smaller 
than that for the control group at all time points.
It is this large standard error in the control group which has caused the probability scores 
shown in Table 10.1 to indicate no significant difference of four of the time points. The 
score at the 6 hr time point shows a value (0.008) of high significance which is 
consistent with the graphical presentation in Figure 10.2. Had the variation in the 
control values been the same as in the cataract group, there would still be overlap of the 
error bars at the three points mentioned above and therefore no significant difference 
between the groups. It is interesting, however, that the control group shows a greater 
variation in serum AA values than does the cataract group.
10.2.2 Age Differences
Figures 10.3 and 10.4 illustrate the response curves for each decade (eg 20-29, 30-39, 
etc) for both the control group and the cataract group. The profiles reflect the differences 
between the two groups that was shown in Figure 10.2. It would appear from these 
profiles that age may have some influence on the serum AA response.
The control group shows higher values in the 3rd, 4th and 5th decades. The 7th decade, 
although having 18 subjects in that age group had virtually no AA response to the trp 
load. The 8th decade had a response similar to that found in the corresponding age 
group in the cataracts. (The x-axis has been expanded in Figure 10.4 to better illustrate 
the response pattern.)
The cataract group has no representatives in the younger age groups, and the overall 
response is low but relatively consistent for all four decades. The 2 hr level in the 60 yr 
group is not consistent with the pattern of response for that group, and this low value 
would influence the mean value (ie, the dip) at the 2 hr point in Figure 10.2.
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Table 10.2 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Age
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.0113 0.2309 0.0217 0.0270 0.0395
Cataract 0.5555 0.8172 0.6050 0.2777 0.1008
Table 10.2 lists the probability scores for the variations within the control group and 
within the cataract group. The controls show a significant difference according to age 
except for the 1 hr point and this is due to the large standard error at that point in the 30 
yr group which would counteract the large difference shown by the 60 yr and 70 yr 
group. The cataract group, on the other hand, is represented by those over 50 yr and 
show no significant difference from 50 yr to 89 yr. It would seem then that the AA 
response is greater in those aged under 50 yr, and shows only minimal response in those 
over 50 yr.
10.2.3 Sex Differences
The separation of the control and the cataract groups according to sex are illustrated in 
Figures 10.5 and 10.6. Both figures have the same scale for the x-axes. Again the 
lower values are shown by the cataract group, and except for the 4 h mean for the female 
group, are not remarkably different. However, the fasting level for the cataract male 
group is half the level of the female group, and considering the relatively consistent 
fasting means over the age groups (Figure 10.4), this may be an important feature of the 
response of this metabolite in this group.
Furthermore, the fasting level for the control male group is approximately double the 
level of the control female group (Figure 10.5). This is, therefore, the converse of the 
finding in the cataract group.
* A probability score of less than 0.050 indicates a statistically significant difference.
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Table 10.3
W ilcoxon Probability Scores* : 
Within-Group Differences as a function of Sex
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.3684 0.8869 0.6823 0.7567 0.7342
Cataract 0.1193 0.9704 0.9836 0.4703 0.1679
Table 10.3 lists the probability scores for the differences within each group according to 
sex and as demonstrated by the bar graphs, show that gender has no significant bearing 
on the AA response to a tryptophan load.
10.2.4 Cataract-Grade Differences
Figure 10.7 illustrates the mean AA response pattern for the data grouped according to 
cataract type. Grade 0 is all the control group and reflects the responses seen in Figure 
10.2,10.3, and 10.5, ie. generally higher values than that seen in the cataract group.
The outstanding feature in Figure 10.7 is the high values seen in the Grade 4 group. 
This group has only a small sample size (n=2) and the high mean is contributed to by 
only one of the female patients (#63), aged 69 yr. It becomes apparent that this patient 
has contributed the high mean and large standard error for the 4 h point seen in Figure
10.4 (60 yr age group) and Figure 10.6 (female group). It is unfortunate that only 2 
subjects are present in this rare group of cataract patients.
Table 10.4 lists the probability scores for the response differences due to cataract grade at 
each time interval. Only the fasting level shows any significant difference. The effect of 
the Grade 4 patients is small because the sample size of this group is very small and 
although the mean value is large it exerts very little influence on the statistics.
A probability score of less than 0.050 indicates a statistically significant difference.
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10.3 Reference Ranges for Anthranilic Acid
Since there were no significant differences between the sexes and the age groups within 
the control group a "normal" or expected range (95% of the data range, using 2.5th and 
97.5th percentiles) can be established for this analytical method for plasma AA. A range 
(Table 10.5) can also be established for each time period after a 50 mg/kg oral load of L- 
trp.
Table 10.5
Reference Ranges for Serum  A nthranilic Acid  
follow ing Tryptophan Load  
( lim o l/L )
M ean Reference Range
Fasting 0.19 0.01 - 2.30
After 1 h 0.39 0.01 - 3.34
After 2 h 0.41 0.01 - 3.26
After 4 h 0.47 0.01 - 3.24
After 6 h 0.37 0.01 - 2.41
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11.1 Introduction
11.1.1 Biochemistry and Physiology
50HA is reported to be formed by the action of anthranilate 5-hydroxylase on AA 
[37, 181]. Anthranilate 5-hydroxylase was first characterised from the microsomal 
fraction of rabbit liver and was found to require NADPH cofactor, and was believed to 
be a metal-containing sulphydryl enzyme [181]. Figure 11.1 outlines the formations and 
reactions of 50HA.
50HA is excreted directly in the urine or may converted to the O-sulphate [150].
11.1.2. Background
Reports in the literature on the biochemistry of 50HA are very few and apart from some 
obscure Japanese references, amount to those cited above. Despite the lack of reports in 
the literature the 50HA has sometimes been included as a metabolite in methodology 
experiments involving the estimation of Trp metabolites [182,183].
One report appearing in 1957 [64], and also discussed in Chapter 1, Section 1.3, proved 
to be an interesting finding in relation to the relationship of Trp metabolism to senile 
(age-related) cataract formation. The authors found 50HA in the urine of senile 
cataractous patients, but not in that of normal persons. They isolated 50HA in crystalline 
form after an elaborate concentration and extraction procedure using 12 litres of pooled 
urine obtained from cataract patients. The quinonimine carboxylic acid supposedly 
formed by bromine oxidation of the 50HA produced cataracts when injected into 
scorbutic guinea pigs. A review [65] appearing in 1964 reported that these authors were 
unable to find 50HA in the urine of 45 subjects with incipient or mature senile cataract. 
The review also reported that another Japanese group (Tojo and Uenoyama, Japanese 
Journal of Biochemistry, 5 (1961) 67-75) was unable to find 50HA or its conjugates in 
the urine of senile cataract patients. All three groups however used extraction 
procedures, followed by two-dimensional paper chromatography as their detection
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method. The controversial nature of the these findings, together with other factors (eg its 
reactive properties), lead to the inclusion of 50HA as a metabolite for investigation in 
this current work.
11.2 Discussion of Results
11.2.1 Group D ifferences
The difference between the mean response for the control subjects and the cataract 
patients is shown in Figure 11.2. The two response curves are clearly separated with no 
overlap of the standard error bars.
The control response is relatively flat, revealing very little increase in serum AA after a 
Trp load. The mean peak response (3.8 pmol/L) barely rises above the mean fasting 
level of 3.0 pmol/L, a rise of only 20% after 4 h.
The cataract patients, on the other hand, show an increasing response to 4 h, which then 
levels out to peak at 6 hr with a level of 9.7 pmol/L. This represents an increase above 
the fasting level (4.3 pmol/L) of 125% after 6 h.
The pattern shown by the two response curves is very similar to that shown by Kyn 
(Figure 6.2). Kyn also showed higher levels in the cataract group, with the 6 hr level 
still showing an increase. In both Kyn and 50HA the control group peaks at 4 hr and 
then slowly decreases to 6 hr. Unlike the Kyn response, 5 OH A shows no overlap of 
error bars, at any time between the two groups.
Table 11.1 reveals a high level of statistically significant difference between cataract and 
controls at all time points. The greatest degree of significance is shown at 2 hr, 4 hr and 
6 hr, supporting the separation of the two groups shown in Figure 11.2.
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11.2.2 A ge Differences
Figure 11.3 and 11.4 illustrate the mean response values for each decade (eg. 20-29 yr, 
30-39 yr, 40-49 yr, etc) in the control subjects and the cataract patients respectively. The 
values in parentheses are the number of subjects in each group.
The response of the control group according to age-grouping is shown in Figure 11.3 
and reflects the "flat" curve seen in Figure 11.2. This is especially the case in the 3rd, 
5th, and 7th decades where the response (or non-response) is almost identical. The 80­
89 yr old groups is slightly higher in value, but still has a relatively flat response. The 
30-39 yr olds, however, show a definite peak response at 2 hr and 4 hr, but there is a 
larger variation in the values in this group compared with the other age grouped controls. 
This is evident from the extent of the error bars.
The cataract group response according to age is shown in Figure 11.4. The response 
graphs for each age group show a more varied response. The 50-59 yr age group have 
the highest fasting mean, with a peak at 4 hr and 6 hr. The 60-59 yr age group show an 
increasing response to peak at 6 hr, while the 70-79 yr group has a lower mean response 
overall with a peak at 4 hr.
Only the 80-89 yr age group has a similar response to the control age groups (20-29 yr, 
40-49 yr, and 60-69 yr), so it would appear that this age group contributes little to the 
larger response shown by the cataract group as a whole (Figure 11.2) The large 
difference between the groups therefore is provided principally by those cataract patients 
in the 50-59 yr and 60-69 yr age groups.
The differences within the groups were tested statistically and the results tabulated in
Table 11.2.
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Table 11.2 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Age
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.3412 0.1574 0.1736 0.3232 0.2397
Cataract 0.3901 0.7488 0.2494 0.3872 0.1178
It can be seen that at no time period, in either group, is there a statistically significant 
difference. This lack of significant difference can be partly explained by the many 
values, close to 0 nmol/L in all the age groups.
11.2.3 Sex Differences
The differences between the sexes in each group are shown in Figures 11.5 and 11.6. 
The values in parentheses are the number of subjects from each gender. The columns in 
each group represent the mean response in pmol/L at each time point after the Trp load. 
The scale of the y-axis is the same for both groups.
Both male and female responses in the control group (Figure 11.5) reflect the small 
response to the Trp load seen in the control group as a whole (Figure 11.2). Both sexes 
have similar basal levels and both groups peak at 4 h, although that peak is not much 
higher than the basal level.
By contrast, the cataract group (Figure 11.6) shows a similar pattern of response for 
both the males and the females with both showing a steady increase to a peak at 6 hr.
It is clear from both Figure 11.5 and 11.6 that the cataract group has the higher response 
to the Trp load, but there is no apparent difference in that response between the female 
cataracts and the male cataract patients. Table 11.3 supports this observation by scoring
A probability score of less than 0.050 indicates a statistically significant difference.
Figure 11.7
5-H ydroxyanthranilic Acid R esponse 
to the Tryptophan Load: 
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Table 11.4
W ilcoxon Probability  Scores* :
W ithin-G roup D ifferences as a function of Cataract G rade
0 hour 1 hour 2 hour 4 hour 6 hour
0.2770 0.3957 0.2388 0.3851 0.0782
*
A probability score of less than 0.050 indicates a statistically significant difference.
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non-significant probabilities within each group at the same time points. For example, a 
score of 0.9853 for the control group at 1 hr indicates that there is no significant 
difference between all the 1 hr values for all the control subjects as a function of sex. 
Similarly, the cataract group at this time point show a greater variation in the values with 
a value of 0.4366, but nonetheless this variation is still not significant within that group.
Table 11.3 Wilcoxon Probability Scores* : 
Within-Group Sex Differences
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.3626 0.9853 0.5826 0.6231 0.7023
Cataract 0.3769 0.4366 0.8623 0.9868 0.9085
11.2.4 Cataract Grade Differences
Figure 11.7 illustrates the differences in Trp load response for each grade of cataract 
severity. The values in parentheses are the number of subjects in each grade. The 
control group is classified as Grade 0. The columns in each grade represent the mean 
response in pmol/L at each time point after the Trp load.
Patients from Grades 1, 2, and 3 all contribute to the high values of the 4 hr and 6 hr 
values seen in Figure 11.2. The Grade 1 group, however, includes patients with the 
highest 50HA values at 4 hr and 6 hr, but the number of high values within the group is 
small, increasing the mean, but also resulting in large error bars. The values in this 
Grade for 0 hr, 1 hr and 2 hr are the same as for controls. Grade 2 has the highest fasting 
level of all the grades and has a gradual rise to peak at 6 hr. Grade 3 has a slower rise to 
peak at 4 hr and returns to below fasting levels at 6 hr. Grade 4 represents only a small 
number of patients and if these are excluded all cataract grades show an increased 
response compared with normal controls at some point.
* A  probability score of less than 0.050 indicates a statistically significant difference.
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11.3 Reference Ranges for 
5-Hydroxyanthranilic Acid
Since there were no significant differences between the sexes and the age groups within 
the control group a "normal" or expected range (95% of the data range, using 2.5th and 
97.5th percentiles) can be established for this analytical method for plasma 5-OHA. A 
range (Table 11.7) can also be established for each time period after a 50 mg/kg oral load 
of L-Trp.
Table 11.7
R eference R anges for Serum  5-H ydroxyanthranilic Acid
follow ing T ryptophan Load  
( lim o l/L )
Mean Reference Range
Fasting 4.31 0.76 - 8.27
After 1 h 4.89 0.90 - 10.52
After 2 h 6.14 1.04 - 10.22
After 4 h 9.22 1.25 - 13.42
After 6 h 9.72 1.20 - 18.88
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12.1 Introduction
12.1.1 Biochemistry and Physiology
Figure 12.1 illustrates the other important pathway of Trp metabolism, the formation of 
5-hydroxytryptamine or serotonin, a neurotransmitter in the central nervous system. 
Under normal conditions only 1% of Trp is metabolised in this pathway [36].
Trp is hydroxylated in a rate limiting step to produce 50HT. The enzyme responsible for 
this catalysis is tr y p to p h a n  h y d r o x y la s e  * (E.C. 1.14.16.4) [143], a
tetrahydrobiopterin-dependent enzyme and the reaction requires molecular oxygen [36]. 
The dihydrobiopterin is reduced back to tetrahydrobiopterin by dihydrohiopterin 
reductase (E.C. 1.14.16.4) and NADPH [31].
Tryptophan hydroxylase  normally operates in the CNS below saturation and any 
increase in the availability of Trp results in an increase in the rate of hydroxylation and 
rate of serotonin synthesis. To enter the CNS Trp must first cross the blood-brain 
barrier. The exact transport mechanism is still the subject of some conjecture, but appears 
to be dependent on the competitive concentrations of other large neutral amino acids 
(phenylalanine, tyrosine, threonine, leucine, isoleucine and valine). The rate of uptake of 
any of these amino acids (including Trp) across the blood-brain barrier is high, with 
about 30-50% being taken up in a single pass through the brain capillary bed. 
Simultaneously, there is a counter-transport of amino acids, both carrier mediated and 
active, from the brain into the circulation [31]. The amount of binding of Trp to albumin 
will also affect the availability of free Trp to the brain.
5-hydroxytryptamine (serotonin) is formed from the decarboxylation of 50HT which is 
catalysed by a ro m a tic  am in o  a c id  deca rb o x y la se  (E.C. 4.1.1.28). The 5-
* International Union of Biochemistry recommended name - (I.U.B Nomenclature Committee, ed. Enzyme
Nomenclature. 1984, Academic Press, Inc.: Orlando, Florida.)
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hydroxytryptamine is deaminated oxidatively by monoamine oxidase to 5-hydroxyindole 
acetaldehyde which is oxidised further to 5-hydroxyindoleacetic acid by aldehyde 
dehydrogenase . (E.C. 1.2.1.3). Small amounts of 5-hydroxytryptophol may be 
formed (particularly after the ingestion of alcohol) through the catalytic activity of 
alcohol dehydrogenase (E.C. 1.1.1.1) [31].
12.1.2. Background
Considerable literature exists on the metabolism of Trp in the CNS and its role in the 
synthesis of neurotransmitters. For a review of the 5-hydroxyindole pathway of Trp 
metabolism, see Bender [31].
50HT was included in this study as a possible indicator of the metabolism of Trp by the 
5-hydroxyindole (serotonin) pathway and its behaviour in the circulation after an oral Trp 
load. Although serotonin has been reported in the aqueous humor [184], at 
concentrations about three times lower than that found in serum, there has been no 
evidence that metabolites from this pathway have been implicated in age-related cataract 
formation.
12.2 Discussion of Results
12.2.1 Group Differences
Figure 12.2 illustrates the comparison of the responses to the Trp load The two curves 
are clearly separate with no overlap of the error bars. The serum levels of 50HT of the 
cataract group are higher than that of the control group.
The control group response is virtually "no response" and amounts to what is 
experimental variation. The mean fasting level is 1.0 pmol/L which "decreases" to 0.96 
|amol/L at 1 hr and "peaks" at 4 hr with a level of 1.07 pmol/L - a variation from 4% to
7%.
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The cataract group similarly shows little change in the mean serum values over the 6 hr 
period. The fasting level is 1.83 nmol/L which then "decreases" to the lowest mean 
value of 1.50 pmol/L at 1 hr and does not reach the fasting level again throughout the 6 
hr period. This represents a total variation of only 18% over the 6 hr period, and this all 
occurs within the first hour.
Although the curves for the two groups are separate, there is very little change in either 
group in response to the Trp load. Table 12.1 lists the probability scores for the 
differences between the two groups at each time point. The scores indicate that there is 
no significant difference between the groups at any time point
12.2.2 Age Differences
The differences in 50HT response to the Trp load according to age is shown in Figures 
12.3 and 12.4. The scales of the y-axes for both graphs are the same. The values in 
parentheses are the number of subjects in each group. The columns in each group 
represent the mean response in pmol/L at each time point after the load.
Figure 12.3 illustrates the mean response for each decade. As with the overall response 
for the control group shown in Figure 12.2, there is very little change in the serum levels 
within each age group. It is interesting that the 20 yr age group has higher levels than 
any of the other control age groups. The 30 yr age group is the only group to show a 
slight increasing trend of values from 0 hr to 6 h.
The cataract group response according to age is shown in Figure 12.4. As with the 
control groups there is little change in mean levels within the age groups, with the 
exception of the 80 yr age group. The error in the fasting period is large as is the mean 
value. This due to one cataract patient (#42) with a high fasting 50HT, which is not 
consistent with the other values for this patient and with the other patients in this age
um
ol
/L
 
um
oI
/L
F ig u re  12 .5
5 -H y d ro x y try p to p h a n  R esp on se  
to  the T ryp top han  L oad: 
Control Subjects according to Sex
0  Oh 
E9 l h
1  2 h 
0  4 h
□  6 h
(n=26) (n = ll)
F igu re  12.6
5 -H yd ro x y try p to p h a n  R esp on se  
to the T ryptophan  Load:
Cataract Patients according to Sex 
3 n
2 -
1 “
m 0 h
0 1 h
n 2 h
0 4 h
□ 6 h
0
Male
(n=24)
Female
(n=18)
1
5-Hydroxytryptophan Page 146
group. The 50 and 60 yr age groups are both similar their values, whereas the 70 yr 
group is lower and similar to the lone 40 yr old.
It is apparent that the cataract group has higher 50HT values than the control group. The 
70 yr group and the 40 yr old are similar to the control groups, and the increased values 
for the cataract group as a whole (Figure 12.2) appear to result from the 50 yr, 60 yr and 
perhaps the 80 yr age groups. There is no definite trend with age apparent for serum 
50HT levels.
Table 12.2 indicates that there is no significant age difference between the values within 
the control group at each time point.. There is also no significant difference as a function 
of age between the values within the cataract group at each time point
Table 12.2 Wilcoxon Probability Scores* : 
Within-Group Differences as a function of Age
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.3412 0.1574 0.1736 0.3232 0.2397
Cataract 0.4458 0.3112 0.5505 0.4802 0.7575
12.2.3 Sex Differences
Figure 12.5 illustrates the mean response levels for the control group when the data is 
grouped according to sex. As can be seen the response is virtually "no-response", as 
was seen in the control group as a whole (Figure 12.2). The fasting level was 
approximately 1.0 pmol/L for both male and female and this value does not change 
significantly over the 6 hr period.
Figure 12.6 illustrates the mean response levels for the cataract group when the data is 
grouped according to sex. There is virtually no response for either the male or female
A probability score of less than 0.050 indicates a statistically significant difference.
Figure 12.7
5-H ydroxytryptophan  R esponse  
to the Tryptophan Load:
All Subjects according to Cataract Grade
©
S3
Ohr 1 hr 2 hr 4 h r 6hr 
Time A fter Dose
EU Grade 0 (n=37) 
BJ Grade 1 (n=12) 
HI Grade 2 (n=ll) 
0  Grade 3 (n=7) 
□  Grade 4 (n=2)
Table 12.4
W ilcoxon P robability  Scores*
0 hour 1 hour 2 hour 4 hour 6 hour
0.5047 0.2496 0.2963 0.3287 0.1390
* A probability score of less than 0.050 indicates a statistically significant difference.
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group. Although there is a decrease in the values after the fasting level, the decrease 
appears slightly greater in the females.
The cataract group has a higher overall serum level (almost twice the control) than the 
control group, as was evident in Figure 12.2. Also the greater variation of the values 
within the cataract group as shown by the larger error bars is also evident in these 
graphs.
Overall there does not appear to a trend in 50HT levels according to sex, and both sexes 
seem to contribute equally to the mean values of each group.
Table 12.3 indicates that there is no significant difference within the control group at each 
time point when analysed according to sex. Also there is no significant difference within 
the cataract group at each time point when analysed according to sex.
Table 12.3 Wilcoxon Probability Scores"
0 hour 1 hour 2 hour 4 hour 6 hour
Control 0.8501 0.8829 0.6928 0.7768 0.7903
Cataract 0.8597 0.4812 0.9492 0.8492 0.8538
12.2.4 Cataract Grade Differences
Figure 12.7 illustrates the differences in Trp load response for each grade of cataract 
severity. The values in parentheses are the number of subjects in each grade. The 
columns in each grade represent the mean response in |imol/L at each time point after the 
Trp load.
* A probability score of less than 0.050 indicates a statistically significant difference.
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The pattern of response for each of the grades is reasonably consistent with previous 
comparisons of this metabolite, in that all grade groups have a relatively "flat response".
The 50H T values of the Grade 1 group levels are approximately twice those of the 
Grade 0 (control) and slighdy higher than Grade 2. The high mean for 0 hr in Grade 3 is 
due to the one 80 yr old female (Cataract #42) mentioned in the age and sex 
comparisons. If this value (Grade 3, 0 h) is ignored a slight trend in the overall mean 
response level is noticeable from Grade 1 descending through to Grade 4. The is 
probably not a reflection of a response to oral Trp, but rather a variation in basal serum 
50HT levels, since it is apparent that there is no significant increase in 50HT levels after 
a Trp load.
Table 12.4 lists the probability scores for the differences within the grade groups over 
the individual time periods. There is no significant difference within the grades. This 
does not test the significance of the trend discussed in the previous paragraph.
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12.3 Reference Ranges for 
5-Hydroxytryptophan
Since there were no significant differences between the sexes and the age groups within 
the control group a "normal" or expected range (95% of the data range, using 2.5th and 
97.5th percentiles) can be established for this analytical method for plasma 5-OHT. A 
range (Table 12.5) can also be established for each time period after a 50 mg/kg oral load 
of L-Trp.
T able 12.5
R eferen ce R anges for Serum  5-H yd roxytryp top h an  
fo llow in g  T ryp top h an  L oad (50 m g/kg)
( l im o l/L )
Mean Reference Range
Fasting 1.00 0.27 - 2.38
After 1 h 0.96 0.25 - 2.41
After 2 h 1.01 0.27 - 2.24
After 4 h 1.07 0.25 - 2.31
After 6 h 1.03 0.26 - 2.22
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13.1 Introduction
The aim of analysing blood and serum biochemical and haematological parameters on the 
cataract patients and control subjects was three fold. Firstly, trp metabolism has been 
reported to be involved in several disease states, including haematoblastic diseases [167, 
175, 176], renal disease [107], alcoholism [99, 140, 185] and diabetes [186]. It was 
important to exclude the influence of any of these diseases or at least, record the possible 
influence of the disease on the levels of metabolites. Secondly, the control subjects, by 
definition, were required to be individuals in a reasonable state of health and, a full 
medical examination notwithstanding, the only way to confirm this was by questionnaire 
(see Appendix A family medical history) and by blood screening for possible disease 
processes. Thirdly, the incidence of age-related cataract and associated risk-factors, have 
been published in several epidemiological studies [2,122,124, 187-190].
13.2 Materials & Methods
As outlined in Chapter 4, extra blood (10 mL) was collected before the trp load was 
given and allowed to clot. This fasting specimen was prepared as outlined in that 
protocol and frozen at -20°C, until biochemical analysis was undertaken in the 
Biochemistry Department at The Wollongong Hospital. Whole blood (5 mL) was also 
collected into disodium EDTA for haematological analysis and examination within twelve 
hours of collection. The analysis was performed in the Haematology Department of The 
Wollongong Hospital.
13.2.1 Serum Biochemistry
Serum biochemical analysis was performed on the serum of each subject using a Kodak 
Ektachem 700XR Biochemical Analyser (Kodak Australia). The following serum 
constituents were measured: sodium, potassium, chloride, carbon dioxide, urea, 
creatinine, glucose, total protein, albumin, bilirubin, alkaline phosphatase, 8-glutamyl 
transferase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase,
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calcium, phosphate, magnesium, uric acid, creatine kinase, amylase, cholesterol, 
triglyceride.
If sufficient serum was available, zinc [191-193] was also assayed using a PE-3100 
Flame Atomic Absorption Spectrophotometer (Perkin-Elmer (Australia) Ltd).
Where possible, serum was assayed for free thyroxine and thyroid stimulating hormone 
using the Abbott IMx Free T4  assay and the Abbott IMx Ultrasensitive hTSH assay. 
Both assay systems used a microparticle enzyme immunoassay (MEIA) principle.
The results from each group (cataract and control) were collated and the arithmetic mean 
and the standard error were calculated. The groups were not subdivided by age, sex or 
cataract type. The data were compared using the Wilcoxon rank-sum test. Student’s t- 
test was also used to analyse the data, but since the trp metabolite data was tested non­
parametrically (because of non-normal distribution), it was considered relevant to report 
the non-parametric statistic for this data as well. The t-test data produced the same 
decision level (ie. <0.050 or >0.050) as the Wilcoxon score in each case.
13.2 .2  H aem ato log ica l E xam ination .
A blood film was made and stained with May-Grtinwald Giemsa stain and examined for 
abnormal red cell morphology and a differential white cell count. The blood was 
analysed in a Coulter Counter S-Plus IV for the following parameters: haemoglobin, 
erythrocyte count, leucocyte count, platelet count, haematocrit. Some computed 
parameters (mean cell volume, mean corpuscular haemoglobin, mean corpuscular 
haemoglobin concentration, red cell distribution width, and mean platelet volume) were 
also recorded. The erythrocyte sedimentation rate (ESR) was also measured if there was 
sufficient blood collected.
Table 13.1 Biochemical Parameters
# The statistical score is the probability obtained by Wilcoxon rank-sum Test
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The haematological data was analysed statistically by the same method as the biochemical 
data.
13.3 Results
13.3.1 B iochem istry
The mean and standard error of each of the biochemical parameters is listed in Table
13.1. The Wilcoxon probability score for the comparison of the two groups is also 
listed. The parameters which showed a significant difference between cataract and 
control means are highlighted in the Table by shading.
1 3 .3 .1 .1  A b n o r m a l  M e a n  V a lu e s
With a few exceptions, the mean values for each parameter listed are within the expected 
reference range for an adult population (reference ranges for all parameters tested are 
listed in Table 13.2). Those falling outside the reference range were cataract creatinine, 
cataract and control zinc, cataract CK, and cataract and control cholesterol.
Creatinine - (60 - 110 mmol/L) The cataract mean was slightly elevated (113.8 
mmol/L) but this may have reflected the higher mean age of this group. The cataract 
group mean urea on the other hand, although higher was not abnormal, nor was it 
significantly different from the control group mean.
Zinc - (13 - 19 mmol/L) The serum zinc level was abnormally low in both groups, but 
the difference between the two means was not significant. There was no obvious 
explanation for the low zinc in both these populations.
Cholesterol - (2.5 - 5.5 mmol/L) Mean cholesterol levels in both cataract and control 
groups were slighdy raised above the reference range and this probably reflected the level 
found in the general population on a western style diet. The reference range for plasma 
cholesterol is based on an ideal or a desirable range rather than a range established from a
Table 13.2 Biochemical Reference Ranges
Parameter U nits Reference Range
Sodium mmol/L 137 -1 4 5
Potassium mmol/L 3.1 - 4.6
Chloride mmol/L 102 111
C02 mmol/L 21 - 30
Urea mmol/L 3.11 -7 .4 9
Creatinine pmol/L 6 0 - 1 1 0
Glucose mmol/L 3.8 - 7.8
Protein g/L 6 3 - 8 2
Albumin g/L 3 5 - 5 0
Bilirubin pmol/L 0 -  19
ALP units/L 27 - 107
GGT units/L 1 0 - 6 9
AST units/L 4 - 5 6
ALT units/L 1 0 - 5 6
LD units/L 170 - 400
Calcium mmol/L 2.00 - 2.52
Phosphate mmol/L 0.77 - 1.42
Magnesium
Urate
mmol/L
Umol/L
0.70 - 0.91 
208 - 506
Zinc pmol/L 1 3 -  19
CK units/L 57 - 374
FreeT4 nmol/L 9.1 - 23.8
TSH nmol/L 0.32 - 5.00
Amylase units/L 3 0 - 1 1 0
Lipase units/L 23 - 203
Cholesterol mmol/L 2.5 - 5.5
Triglyceride mmol/L 0.1 - 2.1
Iron Umol/L 8 - 3 1
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reference population. Thus it is common in Western societies to have 40% of the aged 
population classified as hypercholesterolaemic [121].
1 3 .3 .1 2  Significantly Different Mean Values
The plasma constituents which produced statistically significant results are discussed 
below.
Chloride - although both chloride values are within the reference range for serum 
chloride (95 to 110 mmol/L), there was a significant difference (0.0001) between the 
mean serum chloride for the controls and cataract groups.
Carbon Dioxide (Total CO2 ) - a prolonged delay in processing and subsequent 
exposure of a blood or serum specimen to atmospheric air can result in a loss of CO2 . In 
the presence of red cells this can lead to a concomitant rise in the serum chloride [194]. 
This, however, was unlikely since specimens from both groups were prepared under 
similar conditions using the same procedure and processing times (refer to Chapter 3). A 
study into risk factors associated with cataract [187]also found a significant difference in 
serum Total CO2  with the lower mean also in the cataract group. This study did not
report serum chloride levels.
Albumin - serum levels for both groups were within the reference range but the cataract 
group had a significantly lower serum albumin than did the control group. It is known 
that the serum concentration is lower in a prone individual compared to when ambulant 
[121]. Most of the cataract patients in this study were post-operative and lying in bed for 
at least twelve hours prior to testing, while the controls were all ambulatory. This may 
account for the significance seen in the different results. Clayton [187] also found a 
significant difference in serum albumin, also with the lower albumin in the cataract group 
This study also used cataract patients who were hospitalised (duration not stated) and 
controls from day clinics and presumably were ambulatory.
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Magnesium - both the cataract and the control group had serum magnesium levels 
within the reference range. Serum magnesium exists as the ionised species (55%), 
albumin bound (30%) or complexed to anions (15%) [121], but the method used in this 
study measured total serum magnesium. The difference between the means of the two 
groups was significant with the cataract group mean higher than the control group. There 
is no evidence in the literature of a similar finding. However, increased magnesium has 
been reported in the aqueous humor of patients with senile cataract compared with 
patients with choroidal melanoma. The ratio of aqueous magnesium to serum magnesium 
was also significantly higher in the cataract group. The ratio was especially evident in the 
"mature cataract" group [195].
Calcium is similarly distributed in serum, bound to albumin, associated with ion 
complexes and in the ionised form, however the differences between the mean serum 
calcium levels for the cataract and the control group were not significant Therefore it is 
unlikely that the differences seen in the magnesium levels are due to the differences in the 
albumin concentration. It is also unlikely that the difference in serum albumin seen 
between the two groups had any appreciable effect on the binding of trp to albumin. 
There was no significant difference in the concentration of serum free trp between the 
cataract and control group (see Chapter 5).
Creatine Kinase - the cataract group mean was below the lower limit of the reference 
range and was significantly different from the control group mean. One subject (Control 
#23) had an elevated CK of 508 units/L (clinical reason unknown) which was more than 
twice the level of the next highest control value. This high value, however, does not 
account for the increased mean and the larger standard error for the control group, since 
the median CK for the cataract group was 27 pmol/L and the median for the control 
group was also higher at 53 pmol/L. A possible reason for the significant difference in 
the CK means is the instability of CK activity in serum especially when stored frozen. 
CK activity in serum is reported to be stable for up to 12 hr at 4°C, but only for 3 days
Table 13.3 Haematological Parameters
C A T A R A C T C O N T R O L
Parameter U n its N o . M ean Std.Error N o . Mean Std.Error Scored
Haemoglobin ! g/dL 19 14.1 0.30 24 14.32 0.21 0.4304
Erythrocytes j x 1012/L 18 4.67 0.11 24 4.71 0.07 0.7865
Haematocrit j 18 0.41 0.01 24 1 0.42 o.di 0.5140
MCV fL 18 88.3 1.15 24 88.5 0.52 0.9705
MCH pg 18 30.2 0.43 24 1 30.4 0.24 0.7864
MCHC 18 342 1.91 24 343 1.74 0.5295
RDW 18 14,3 ...Û.34 24 ! 13.4 0.19 1 0.0067
Platelets x 109/L 18 302 17.99 24 274 11.56 0.1718
MPV 17 8.22 0.20 24 8.66 0.26 0.2230
L eucocytes xiO^/L 18 8.25 0,34 24 6,47 0.29 0.0005
Neutrophils % 18 64.9 2.43 24 58.5 | 2.31 0.0647
Lymphocytes % 18 27.3 2.37 24 33.4 ! 2.12 0.0782
Monocytes % 18 5.5 0.57 24 4.9 ! 0.63 0.4370
Eosinophils % 10 2.9 0.65 24
!
2.7 ! 0.60 0.5188
Basophils % 5 1.0 0.00 24 0.2 ! 0.09 *
ESR mm/hr 9 16 3.49 12 io ! 1.49 0.2008
A bbreviations U sed in  Table 13.3
MCV = mean corpuscular volume expressed in femtolitres (fL) 
MCH = mean corpuscular haemoglobin expressed in picogram (pg) 
MCHC = mean corpuscular haemoglobin concentration (g/L)
RDW = Red cell distribution width (arbitrary units)
MPV = mean platelet volume (arbitrary units)
ESR = erythrocyte sedimentation rate measured over 1 hr (mm)
* = insufficient values to produce accurate statistics.
# The statistical score is the probability obtained by Wilcoxon rank-sum Test
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when stored frozen [196]. It was not always possible to assay the serum biochemistry 
within 3 days, and although stable for other constituents, the delay in assaying for CK 
would cause artefactually lowered results. A larger number of specimens from the 
cataract group were delayed in assaying for serum biochemistry. For this reason the CK 
results in Table 13.1 are not highlighted even though the statistic is significant.
Thyroid Stim ulating Horm one (TSH) - One patient (Cataract #2) had results 
consistent with primary hypothyroidism (high free T4 of 35.9 nmol/L and low TSH of
0.10 nmol/L), but this result could not account for the significant difference between the 
two groups. A similar finding could not be found in the literature.
13.3.1.3 Correlation of Kynurenine and Glucose.
A positive correlation between fasting serum Kyn and fasting serum glucose has been 
previously reported [170]. Serum Kyn was determined by the colourimetric method of 
Joseph [90]. The authors found a correlation coefficient (r) between serum kynurenine 
and serum glucose of 0.623 in 59 individuals with a glucose range from about 5 to 10 
mmol/L. They suggested that glucose was an inhibitor of tryptophan 2,3-dioxygenase 
and an inhibitor of interferon, which has been reported to induce indoleamine 2,3- 
dioxygenase. No such correlation between glucose and Kyn was found in this study 
with the cataract group (n = 37) producing a correlation coefficient of r = -0.13; the 
control group (n = 31), a value of r = 0.004. The correlation coefficient for the 
combined groups (cataract + controls: n = 68) was r = -0.073. The glucose range for the 
combined groups in this study was 4.2 to 17.1 mmol/L.
13.3,2 H aem atology
The mean and standard error of each of the haematological parameters is listed in Table 
13.3. As with Table 13.1, the Wilcoxon probability score for the comparison of the two 
groups is also listed and shading highlights the parameters with a significant difference 
between cataract and control means.
Table 13.4 H aem atology R eference Ranges
Parameter U n its Reference Range
Haemoglobin* S/dL 14.0 - 16.7
Erythrocytes x 1012/L 4.60 - 5.81
Haematocrit* 0.357 - 0.504
MCV fL 80.8 - 97.7
MCH pg 27.0 - 32.2
MCHC g/L 3 1 9 - 3 5 1
RDW 12.0 - 14.3
Platelets x 109/L 168 - 365
MPV 7 . 4 - 1 1 . 7
Leucocytes x 109/L 4 . 0 -  11.0
Neutrophils % 4 0 - 7 5
Lymphocytes % 2 0 - 5 0
Monocytes % 2 - 1 0
Eosinophils % < 2
Basophils % < 2
ESR mm/hr 3 - 5
* Reference Range includes male and female to accommodate the mixed nature of the groups.
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13.3.2.1 Abnormal Mean Values
With the exception of the ESR, the mean values for each parameter listed are within the 
expected reference range for an adult population (reference ranges for the all parameters 
tested are listed in Figure 13.4). Although some haematology parameters are sex 
dependent (eg. haemoglobin, haematocrit) the references ranges stated have been 
combined to accommodate the combination of males and females into the cataract and 
control groups.
Erythrocyte Sedimentation Rate (ESR) - is usually raised in inflammatory 
diseases, but it is a non-specific test and is often used to monitor the progress of organic 
disease. Only 9 cataract patients had sufficient blood collected to perform the ESR, and 
the same was true for only 12 control subjects. The ESR increases with age and 
considering the mean age of both the cataract (70.4 yr) and control group (514 yr) the 
ESR value of 16 mm/hr for the cataract group and 10 mm/hr for the control group is not 
surprising and cannot be regarded as abnormal. The difference between the two groups 
for ESR was not significant
13.3.2.2 Significantly Different Mean Values
Only two haematological parameters exhibited a significant difference between the 
cataract and control means.
Red cell distribution width (RDW) - is a quantitative assessment of the degree of 
variation in red cell size or volume (anisocytosis) provided by the Coulter Counter. It is 
the coefficient of variation of erythrocyte volume distribution (ie. standard 
deviation/mean) [197]. The mean values are not abnormal but the difference between the 
cataract and control groups is significant. Although the variation of RDW is greater 
within the cataract group, there was no significant anisocytosis noted in the blood film 
examination of any individual patient or subject.
Leucocyte count - is well within the reference range (4.0 - 11.0 x 10^/L) for both 
groups and therefore does not indicate any inflammatory process, infection, or
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haematological malignancy. The difference between the groups, however, is significant 
with the cataract group showing the higher value.
No cataract epidemiological study in the literature has reported the measurement of 
haematological parameters.
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Figure 14.1
Diagram of Dynamic Flow and Drainage of 
Aqueous Humor
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14.1 Introduction
The optical integrity of the anterior portion of the eye is dependent on its shape (refraction) 
and its transparency to visible light The shape of the cornea is partly maintained by the 
hydrostatic pressure of the aqueous humor. The chemical composition of the ocular fluid, 
being in constant flux, is important in sustaining the optical properties of the lens and cornea. 
High concentrations of albumin or other proteins in the humor will alter the refractive index 
of the fluid and directly affect vision. The humor acts as the source of nourishment and 
oxygen to the avascular lens. It must also effectively remove any metabolic wastes generated 
by the lens. Any alterations in its composition may cause metabolic aberrations in the lens, 
such as occurs in galactosaemia where high levels of galactose in the humor lead to increased 
amounts of sugar alcohols (polyols) in the lens and subsequent formation of cataracts [198, 
199]. The presence of metabolites or compounds in the aqueous humor will have a direct 
effect on the metabolism of the lens which it nourishes. It was important, therefore, in a 
study of Trp and cataract to quantify this amino acid and its metabolites in the aqueous humor 
and the lens itself.
14.1.1 Production of Aqueous Humor
The aqueous humor fills the anterior and posterior chambers of the eye. These chambers are 
anterior to the lens and are illustrated in Figure 14.1. The anterior chamber is formed from (i) 
the posterior surface of the cornea, (ii) the iridocorneal angle containing the trabecular 
meshwork. (iii) the anterior surface of the iris and (iv) the anterior surface of the lens 
capsule. The posterior chamber lies between the posterior surface of the iris and the anterior 
surface of the vitreous and the equatorial regions of the lens capsule. The ciliary body lies 
within the posterior chamber. Aqueous humor is produced by the non-pigmented 
parenchyme of the ciliary body. It is secreted through the ciliary epithelium (double-layered 
cubic epithelium) into the posterior chamber at a rate of 2 to 3 pL per hour. Some of the
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aqueous humor in the posterior chamber is absorbed by the vitreous body and the epithelium 
of the anterior surface of the lens. It then passes through the pupillary aperture into the 
anterior chamber which holds about 200 to 250 }iL of the fluid. Drainage occurs through the 
trabecular meshwork at the iridocorneal angle, where it enters Schlemm's Canal to be 
excreted through collector channels into the venous system of the eye. The turnover time for 
aqueous humor is about 1.5 hr [200]
14.1.2 The Blood-Aqueous Barrier
The suppression and selective diffusion and infiltration of solutes from the blood to the 
ocular tissues is controlled by a mechanism known as the blood-aqueous barrier. This 
barrier is essentially a functional concept, but it does have a structural analogy with the 
vascular endothelium and its basement membrane, the stroma of the ciliary body and two 
layers of ciliary epithelium in the posterior chamber. The anterior chamber "barrier'’, consists 
of the vascular endothelium and the iris stroma, but has no epithelial component. These blood 
vessels also are non-fenestrated and have an unusually thick basement membrane. By 
comparison the capillaries of the ciliary body are fenestrated and do not completely exclude 
the larger protein molecules [200].
Evidence that Trp metabolism does take place in the anterior segment of the eye has been 
presented by a number of workers. The presence of indoleamine 2,3-dioxygenase (IDO) 
activity has been demonstrated in the ciliary body and in the aqueous humor [201]. Since 
IDO uses superoxide as a cofactor, it was suggested that this enzyme may act as free radical 
scavenger in the eye. Ascorbate is present in high concentrations in the aqueous humor 
[200], and its presence may be necessary to maintain the protoheme of IDO in the active 
ferrous form and preserve the activity of the enzyme. Malina also found evidence for the 
presence of kynureninase in the (bovine) eye [201]. Surprisingly, evidence for the presence
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of tryptophan 2,3-dioxygenase activity in the ciliary body has been reported [67], but the 
enzyme has not been found in the lens.
14.2 Materials & Methods
As outlined in Chapter 4, a sample of aqueous humor and the lens were collected by the 
ophthalmic surgeon from the cataract patients at the time of lens extraction. The aqueous 
humor specimen was collected into a 1 mL syringe and the specimen and syringe were frozen 
at -20°C, until HPLC analysis. The whole lens was placed in a 5 mL plastic tube (without 
any additive or prior preparation) and the tube stored at -20°C until it could be weighed and 
analysed.
14.2.1 Aqueous humour
Aqueous humor is a clear solution with relatively little protein and therefore no specimen 
preparation was necessary prior to HPLC analysis. As was illustrated in Chapter 3, Figure 
3.11, the specimen was thawed, mixed and transferred to a HPLC vial and 100 |iL injected 
directly onto the HPLC column. HPLC conditions were identical to those described in 
Chapter 2. Electrochemical and fluorescence chromatograms of an aqueous humor sample 
from a patient having lens extraction are illustrated in Figures 14.2(a) and 14.2(b) 
respectively.
14.2.2 Lens
The lens was thawed and its wet weight recorded and graded. The lens was then 
photographed according to the procedure described in Section 4.3.5 (Lens Photography).
Lenses were homogenised twice in 0.5 mL cold 80% ethanol. The extracts were centrifuged 
(15 mins, 15,600g) and the supernatants combined. The supernatants were then filtered 
through a 10,000 molecular weight cut-off membrane filter. The filtrates were then freeze- 
dried.
Figure 14.2(a)
Chromatogram illustrating the separation of compounds in aqueous humor by 
HPLC with electrochemical detection at 990 mV 
(20 mM acetate buffer, pH 4.5 and flow rate 0.6 mL/min)
Figure 14.2(b)
Chromatogram illustrating the separation of compounds in aqueous humor by 
HPLC with programmable fluorescence detection.
(20 mM acetate buffer, pH 4.5 and flow rate 0.6 mL/min)
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The dried extracts were re-constituted in 200 \iL  20 mM sodium acetate buffer. An aliquot 
(100 |iL) was injected onto a C18 column using 20 mM sodium acetate buffer (Section 
2.2.4) as mobile phase and a Knauer variable wavelength UV-detector as described by Wood 
and Truscott [86]. UV detection (365 nm) was used to detect and quantify 30HKyn and 
30HKyn glucoside. 5-OHT (0.01 mg/mL) was added to the re-constitution buffer as a 
internal standard.
Of course, lenses were not obtainable from the control group, so randomly selected normal 
lenses obtained from the Sydney Eye Bank were used for a comparison of metabolite levels.
14.3 Results & Discussion
14.3.1 Aqueous Humor
Figure 14.2 shows a typical ECD and fluorescence chromatogram of an aqueous humor 
sample taken from a cataract patient at the time of extraction of the lens. The large broad 
peaks at the beginning of the ECD chromatogram (Figure 14.2(a)) contain tyrosine and 
ascorbic acid. Ascorbic acid is not fluorescent
Table 14.1
Levels of Metabolites in Aqueous Humor from Cataract Patients
(Umol/L)_______________ _
50HA 50HT Kyn XA Tfp
Mean 0.16 0.24 0.60 0.29 31.8
Std. Error 0.05 0.03 0.11 0.16 5.26
Number 8 11 10 8 12
Table 14.1 indicates the mean levels and standard error for those metabolites detected in the 
cataract patient aqueous humor. Trp and Kyn were the only metabolites detected from the 
main route of the Kynurenine Pathway, while XA and 50HA were the only representatives
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Table 14.2
Mean M etabolite Concentrations in Aqueous Humor 
and Fasting Serum from Cataract Patients
A q.H um or
( l i m o l / L )
Serum
( U m o l / L )
Ratio
( A H : S )
Total Trp 31.8 57.7 0.55
Free Trp (31.8) 16.9 1.88
5 0 H A 0.16 4.31 0.04
5 0 H T 0.24 1.83 0.13
K yn 0.60 8.44 0.07
XA 0.29 0.54 0.54
Figure 14.3
Bar-chart o f Mean Serum and Aqueous Humor 
M etabolite Concetrations
8 0-,
T r p
□
Aq.Humor
Serum
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from the branch pathways. 50HT, a metabolite of the serotonin pathway was also detected. 
As seen in Figure 14.2 the concentrations of the Trp metabolites are small in comparison to 
the tyrosine and ascorbic acid peaks which are detected by ECD. These compounds were not 
quantified. Lerman reported that the levels of tyrosine were six times the level of Trp in the 
aqueous humor of the Rhesus monkey [198].
Trp has been found by others to be lower in aqueous humor (40 nmol/L) than in plasma and 
even lower in the humor of aphakic patients [67]. The value found in this study was slightly 
lower, but the relative serum/aqueous humor value was similar. Kyn levels of 1 Jimol/L were 
reported in aqueous humor by van Heyningen [202].
No control aqueous humor was available for comparison, therefore the ratio of serum level to 
aqueous humor level was calculated. This measure has been used previously [200]. Table
14.2 lists the mean concentrations of Trp and metabolites found in the aqueous humor of the 
cataract patients compared to the mean concentration of the same metabolites found in the 
fasting serum specimens of the cataract group. The aqueous to serum ratio is also tabulated. 
The mean total Trp value found in the aqueous was a little over half (0.55) the mean total Trp 
found in the serum of the cataract patients. This finding is in agreement with that of Lerman 
[198], who reported a ratio of 0.62 in the aqueous and serum of the Rhesus monkey§.
Figure 14.3 is a graphical representation of the ratio of the mean concentration of metabolites 
found in the aqueous humor compared to the mean concentration found in the serum of the 
cataract group. It can be clearly seen from this graph that even though Trp and Kyn have a 
similar molecular weight the aqueous humor to serum ratio is quite different. This is
§ The study reported by Lerman does not state whether total or free trp was measured, but it was assumed to be a value
for total trp
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indicative of the selective permeability of the blood-aqueous barrier. Albumin is in very low 
concentration in the aqueous humor (0.055 to 0.065 g/L [8]) compared to a serum level of 
about 34 g/L [8]. It therefore seems likely that most of the Trp in the aqueous is in the free 
form. If Trp diffused passively into the aqueous it would be expected to have a similar 
concentration to that of serum. This finding therefore suggests that Trp is actively 
transported into the aqueous across the blood-aqueous barrier.
The correlation of the aqueous levels of metabolites with the serum levels in the 
corresponding patients was plotted and the scatter graphs are shown in Figure 14.4. The 
correlation coefficient (r2) is indicated on each graph and the linear regression line is shown 
as the dotted line. It is clear from the diagrams that there was very little correlation between 
serum and aqueous levels for any of the metabolites. The lack of correlation further suggests 
that the transport of metabolites, even relatively small molecules such as these, from serum to 
aqueous humor is an active and complex process.
14.3.2 Lens
Lens extracts were examined principally for the presence of Trp and levels of 30HKyn and 
its glucoside using a UV detector in preference to the ECD-fluoresence combination. 
30HKyn glucoside, a major metabolite of Trp in the human lens was first identified in 
human lens by van Heyningen in 1971 [203]. This compound is an efficient lenticular UV- 
filter.
The mean wet weight of 32 cataractous lenses and the results of the analysis are listed in 
Table 14.3. XA, 50HA, and 50HT were not detected either because of their low 
concentrations (if any) and the low sensitivity of UV detection for these compounds. The 
results are in agreement with those found by Wood and Truscott [86].
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Table 14.3
Weight & Leve‘Is* of Mi îtabolite in Lens
Weight
<g)
30HKyn
(nmol/lens)
30HKgl
(nmol/lens)
Trp
(nmol/lens)
Mean 0.1135 1.29 49.03 2.00
StcLError 0.0201 0.31 10.45 ! 0.35
Number 32 17 22 ! 32
30HKgl = 30HKyn glucoside
The concentration of Trp in the lens was plotted against the age of the patient as were the Trp 
levels from the lenses of eye-bank donors, to determine if a relationship existed between 
these two variables. The scatter graph, Figure 14.5 indicates that there is very little 
correlation (r2 = 0.004) between age and Trp concentration in the lens irrespective of 
presence of cataract
The degree of cataract involvement does, however, appear to influence the concentration of 
Trp in the lens. Figure 14.6 compares the concentration of Trp with the grade of cataract The 
eye-bank donors are shown as Grade 0. It can seen that there is an apparent progressive 
reduction in the concentration of lenticular Trp as the cataract increases in severity (ie. as the 
Grade increases) This finding, however, is not consistent with that observed by Bessems, 
et al [204] who reported that there was no significant differences in lens Trp concentration 
between increasing severity of cataract
As with Trp, there was little correlation (r2 = 0.024) between age of the patient and the lens 
concentration of 30HKyn. The scatter graph is shown in Figure 14.7 Figure 14.8 shows 
the concentration of 30HKyn in lenses grouped according to cataract grade. There does not
£Weight of lens is the wet-weight, and metabolites are expressed as nmoles per lens.
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appear to be the decrease in concentration of the metabolite with increasing severity as was 
seen with Trp, although more data points in Grades 3 and 4 would be needed to verify this.
The concentration of 30HKyn glucoside, when plotted against the age of the patient (Figure 
14.9) indicates little correlation with increasing age. This is reflected in the correlation 
statistic (r2 = 0.018). The lens concentration of 30HKyn and 30HKyn glucoside have been 
found to decrease with age in a study incorporating a greater number of lenses [86, 205].
Except for two outliers the 30HKyn glucoside (Figure 14.10) does appear to decrease in the 
lens with increasing severity of cataract. This finding must be interpreted with caution (as 
with the other lens metabolite data) because of the small number of data points for each 
metabolite, perhaps with exception of Trp.
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15.1 Overview
It was the objective of this thesis to determine if cataract patients metabolise the amino 
acid tryptophan (Trp) differently from normal controls. The key finding to emerge from 
this study is that a large percentage of cataract patients appear to have a dysfunction in the 
somatic metabolism of Trp when compared to normal controls.
This difference in metabolism seems to be more pronounced for some Trp metabolites 
than others. For example 50HA, KA, Kyn, and Trp were found to be clearly separated 
in terms of their response profiles to the Trp load whereas others such as 30HA, free 
Trp, XA and 50HTrp showed little change in cataract patients verses normal controls.
The discovery of such a clear difference in somatic Trp metabolism in cataract patients 
was surprising. It is highly unlikely that the cataract lens itself is responsible for such a 
finding even though the primate lens does metabolise Trp. It is possible that the two 
features of cataract and Trp metabolic disturbance occur together as a result of a quite 
separate endogenous or acquired defect. It appears more plausible that an alteration in Trp 
metabolism may in fact be a primary feature of the aetiology of this disease. This results 
from the fact that some Trp metabolites are particularly reactive in the presence of oxygen 
and readily bind to proteins. Since the modified proteins, which result from such 
interactions, closely resemble those isolated from cataract lenses [84, 85] a "reactive 
metabolite theory" for cataract formation has been proposed [88].
The metabolites of importance in this regard are the aminophenols, which are particularly 
prone to oxidation, forming ortho- or para quinonimines [83]. Simply bubbling these 
with air at neutral pH is sufficient to induce such oxidation [206] which is rapidly 
followed by self-condensation and/or covalent binding to proteins, if they are present.
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In terms of Trp metabolism, 30HA, 50HA and 30HKyn are o-aminophenols and each is 
capable of binding to proteins, including lens proteins, under the conditions described 
above [84, 85]. Thus, it may be postulated that in an oxidative environment, an excess of 
one or more compounds in the lens, resulting from a dysfunctional Trp metabolism, may 
trigger the post-translational protein changes which are observed clinically as senile 
cataract. For this to be a feasible proposal it must be demonstrated that these 
aminophenols can enter the lens. This has been done for one of the aminophenols, 
30HKyn, which readily enters intact human lenses in organ culture [205].
In terms of the results in this thesis, the metabolite 50HA was found to be elevated in 
cataract patients following a Trp load. As mentioned earlier this compound was proposed 
as a cataractogenic agent in 1957 on the basis of urinary data although this finding has not 
been confirmed [65]. Our data on serum levels would lend support to the original finding 
of Ogino and Ichihara [64] . 30HA levels were found not to be statistically different 
although the serum concentration in cataract patients were higher at each time point 
following the load. Unfortunately, it was not possible to measure 30HKyn in the serum 
samples by HPLC due to co-elution of interfering substances. This metabolite may be of 
importance as it is also biosynthesised in the lenses of primates [205] as an intermediate 
in the pathway leading to the major human lens UV filter compound, 3- 
hydroxykynurenine glucoside.
Due to the relatively small sample size and overlap of the responses in the two groups, it 
was not possible to gain accurate data on the percentage of cataract patients who may 
have a dysfunction in Trp metabolism. It did appear however that patients with high 
5 OH A serum concentrations following the Trp load formed a separate group from those 
characterised by elevated Kyn and Trp and decreased KA levels. This may indicate that 
more than one metabolic defect of Trp may be present in cataract patients.
Table 15.1
Summary of Statistically Significant Differences 
within the Metabolic Groups
Metab. Group Group
Differences!
Age
Diff.5
Sex
Diff.S
Grade
Difference*
Trp Cataract 0,1 *2*4,6 fot NS NS NS
Control NS NS
Free
Trp
Cataract NS NS NS NS
Control ■ 1 86 NS
K yn Cataract 2*4 lit NS NS 61sronly
Control Ohr NS
3 0 H A Cataract 4 hr only NS »jute™ . NS
Control 8,2,4,6 NS
XA Cataract 2 hr only NS NS 2* 4 hr
Control NS NS
KA Cataract 0,1,2.4 hr NS NS NS
Control NS NS
AA Cataract 6 hr only NS NS Obronly
Control 0.2,4,6 NS
5 0 H A Cataract 0,1*2,4,6 far NS NS NS
Control NS NS
5 0 H T Cataract NS NS NS NS
Control NS NS
NS = Difference is not statistically significant 
t = Data analysed by Chi-Square Test 
§ = Data analysed by Wilcoxon Ranked Scores
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Finally it should be noted that a study of this type, aimed at following the serum levels of 
all the major Trp metabolites following a Trp load in humans, has not been performed 
previously. Thus important data on somatic metabolism of Trp in normals and the 
temporal relationship of various metabolites has been obtained for the first time. As 
expected, considerable individual variation was observed (see Appendices C and D), 
however when analysed as a group the data were found to yield quite reasonable standard 
errors for most metabolites.
15.2 Introduction
Seven earlier chapters (Chapters 5 to 12) have compared the response of Trp and seven 
individual metabolites to an oral Trp load, and measured the effects of age, sex and type 
of cataract in a group of cataract patients and a control group. The serum biochemistry 
and haematology of both groups were also compared in a preceding chapter (Chapter 13). 
The appearance of Trp metabolites in the aqueous humor and lens were presented in 
Chapter 14.
Each of the metabolite chapters was structured similarly; group differences, age 
differences, sex differences and grade differences were oudined. Graphical and statistical 
comparisons were made for (i) each time point between cataracts and controls, (ii) each 
time point within defined age groups for cataracts and controls, (iii) each time point 
within the sex groups for cataracts and controls, (iv) each time point between each of the 
cataract groups. Table 15.1 summarises the statistical results for these comparisons.
15.3 Discussion of Statistical and Graphical
Results.
15.3.1 Group Differences in Total Tryptophan Response
The shaded areas of Table 15.1 indicate those comparisons where a statistically 
significant difference occurred. The differences found in the mean response curves for
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each group are listed in the Group Differences column. It should be emphasised at the 
outset that the data shown in this thesis includes the serum levels of metabolites only. 
Urine specimens were collected and processed at the time patient loading (as oudined in 
Chapter 3), however they were not able to be analysed at the time of writing. In the 
absence of the urinary data, therefore, very little can be said about the clearance of the 
metabolites examined. This does not, however, detract from the observations made 
about the two groups.
The metabolites Trp, Kyn, KA and 50HA exhibit a statistically significant difference 
in more than one time point (Table 15.1), and also have a difference which is obvious 
from the graphs. The metabolite response curves (from the respective chapters) are 
repeated in this chapter (Figures 15.1, 15.2, 15.3, 15.5) for the purpose of discussion.
15.3.1.1 Total Tryptophan
Total Trp (Figure 15.1) showed a difference in cataract and control responses. These 
differences may represent real changes in metabolism, since it seems unlikely from the 
data that the differences observed are due to variations in the intestinal absorption rate of 
the oral Trp. The rate of increase in the concentration of serum Trp should reflect the rate 
of absorption of the amino acid from the gut. The rate of increase in mean serum Trp 
from fasting level to peak level is marginally higher (by 27%) in the control group (rate = 
127 pmol/L/hr or 0.025 mg/mL/hr) than in the cataract group (92 |imol/L/hr or 0.018 
mg/mL/hr). The absorption rates being similar, any alterations which are observed in 
metabolites may represent real changes in metabolism.
Trp loading has been used by several workers for studies on various pathological 
conditions (see Table 4.1). Much of the work done, however, has involved the urinary 
excretion of Trp metabolites, or an examination of the serum levels of Trp itself. No 
authors have studied the response of the spectrum of Trp metabolites in serum to Trp 
loading in either normals or patients with age-related cataract.
Table 15.2
Basal Serum Tryptophan Levels 
(pmol/L) *
C o n tro l C ataract
F a stin g T ota l Free T ota l Free M ethod R e f.
Yes 65.9 6.1 70.1 9.1 fluorometric [73]
Yes 68.4 6.1 68.3 9.1 fluorometric Í741
No 63.1 12.2 117 30.8 Not stated [67]
Yes 67.9 11.3 63.0 12.0 HPLC [113]
No 55.8 12.7 126.8 35.7 fluorometric [307]
Yes 55.3 54.8 fluorometric [70]
Yes 54.4 9.1 86.1 15.2 fluorometric [69]
Yes 65.7 10.5 63.2 10.6 fluorometric 1661
Yes 85.8 22.3 57.7 16.9 HPLC *
* This study.
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Thus no information is available on the serum responses to Trp loading for AA, 50HA, 
KA, XA. A limited number of authors have studied serum responses for Kyn [90, 107, 
113] and 30HA [130].
Most of the reports in the literature involve only serum levels of Trp. Table 15.2 lists the 
basal levels of serum Trp determined in some of those reports. Workers in Italy [66] 
found that the serum levels of free and total Trp showed no significant difference between 
cataract patients and controls, both before and 2 hr after a 50 mg/kg load of L-Trp. The 
fluorometric method of Denckla and Dewey [71] was used to determine levels of serum 
Trp. Using a similar fluorometric procedure, Cotlier and Sharma [207] found increased 
levels of both free and total Trp in non-fasting cataract subjects compared to controls.
Another group of authors in Italy [73,74] measured free and total Trp levels in the serum 
of cataract patients and controls. In their first report Libondi, et al [73] determined 
fasting levels in 53 cataractous patients and 27 controls. They concluded as have others 
[66,68, 70] that there was no significant difference between cataract and control patients. 
They used the spectrofluorometric method based on the formation of the non-harman 
derivative according to Hess and Udenfriend [208]. The distribution of both total and free 
Trp values were skewed to the left.
Using the same method, an oral dose of 20 mg/kg L-Trp was administered to 30 
cataractous patients and 15 controls [74]. They found no significant difference for serum 
Trp between cataract patients and controls before and after the Trp load. They did, 
however, find a significant increase in free Trp after 1 hr. The total Trp peak also 
occurred at 1 hr. This time differs from that found in the current study and that found by 
other authors [99, 107, 132]. The authors hypothesised that by using a lower dose of Trp 
(ie. <50 mg/kg) they did not exceed the serum albumin binding capacity for Trp. Any 
excess Trp, they maintained was "rapidly excreted and/or taken up by tissues". Moller
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[132], however, showed that oral doses of L-Trp up to 100 mg/kg are completely 
absorbed by healthy subjects, and that the urinary excretion of Trp was negligible. He 
also maintained that the uptake of Trp into the tissues and metabolism by tryptophan 2,3- 
dioxygenase in the liver was largely responsible for the removal of the amino acid from 
the circulation. The linear disappearance of Trp suggested that the amino acid is 
transported into the tissues, while an exponential disappearance implied enzymic removal 
of Trp. In other words, only a small amount of ingested Trp, he suggested, is 
metabolised via tryptophan 2,3-dioxygenase and the disappearance of plasma Trp occurs 
via transport into the tissues. This implies that a large amount of the ingested Trp may be 
metabolised by indoleamine 2,3-dioxygenase in tissues other than the liver.
15.3.1.2 Kynurenine & Kynurenic Acid
Figures 15.2 and 15.3 show that in general the cataract response is relatively high for 
Kyn and low for KA. The reason for the characteristic high Kyn yet low KA response to 
the load is unclear. Overall, the expected response would be to have a high Kyn 
producing a high KA, since very high levels of kynurenine would be expected to be 
metabolised by the side pathway through the aminotransferase.
If it is assumed that the kynurenine aminotransferase apoenzyme levels in the two groups 
are similar, then it is possible that this disparity may be due to a B6 deficiency in cataract 
patients. Vitamin B6 levels were not assayed (and more than one biochemical index is 
recommended [180] to assess a deficiency of this enzyme), however there was no 
evidence to suggest that any of the patients and subjects studied had a pyridoxal 
deficiency. All those loaded and sampled satisfied criteria for adequate dietary 
requirements as determined by questionnaire. Furthermore, the serum biochemistry 
results that were performed (Chapter 13) did not reflect any B6 deficiency. For example, 
the serum activity of the vitamin B6-dependent enzyme, aspartate aminotransferase, has 
been used previously [209] as an index of deficiency of that vitamin. There was no 
significant difference seen between the AST activities of cataract group and the control
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group (Table 13.1), nor were the mean activity levels low (refer to Table 13.2), which 
would have suggested a B6-deficiency. In fact only one cataract patient (Cataract #38) 
and one control subject (Control #15) had low enzyme activity. Similarly, except for a 
few individuals (Controls #9 and #27), the activities of another B6-dependent enzyme, 
alanine aminotransferase, were also normal and with no significant difference between 
the two groups.
The location of kynureninase (Figure 15.4) in the cytosol makes it more vulnerable to 
vitamin B6 deficiency than the mitochondrial-bound kynurenine aminotransferase [150], 
Enzyme compartmentalisation is not unusual since other aminotransferases exhibit this 
phenomenon. For example, alanine aminotransferase is present only in the hepatocellular 
cytosol, while aspartate aminotransferase is found in both cystosolic and mitochondrial 
cellular fractions [121]. This being the case, one would expect to find an increase in Kyn 
(and 30HKyn) levels in B6 deficiency, and subsequently, XA and KA (refer also to 
Figure 1.6). The increase of the latter metabolites in urine forms the basis of the Trp 
loading test for B6 deficiency. No such an increase in serum KA and XA was observed 
in the present work. This does, however, ignore the clearance rates into the urine, but the 
rate of clearance would have to be extremely rapid in order not to see some significant 
increase in the serum XA and KA levels. The fact that Cataract #21 and #30, had very 
high levels of Kyn and KA indicates that the rate of clearance is not that rapid at least in 
these patients. Neither of these two patients had impaired renal function, as indicated by 
their normal levels of serum urea and creatinine results.
It has been suggested that since oc-oxoadipate has been shown to inhibit the activity of 
kynurenine aminotransferase, it is possible that the activity of the this enzyme is reduced 
by such inhibition after a Trp load [210]. oc-oxoadipate is formed by the reductive 
deamination of aminomuconic acid (Figure 1.5). A mechanism similar to this has been 
proposed to explain a hereditary lethal pellagra-like syndrome which results in the 
increased excretion of Kyn (and 30HKyn) but not KA and XA, and an increased flux
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through the pathway [169]. One may speculate that kynurenine aminotransferase could 
be more susceptible to such inhibition in cataract patients.
As pointed out above there was no increase in 30HA, a metabolite further down the 
pathway from kynurenine (Figure 15.3). This suggests that any rate-limiting step would 
occur prior to this metabolite. Figure 7.2 illustrates that 30HA is higher in cataracts, but 
this was not statistically significant and the spread of data (standard error) was 
considerable.
15.3.1.3 5-Hydroxyanthranilic Acid
The response curves for 50HA (Figure 15.5) are very similar in pattern to those of Kyn, 
but on a lower absolute scale. Many of both cataracts and controls showed very little 
variation in response to Trp loading and most had values below 5 pmol/L. Peak times 
varied from 1 hr to 6 hr. However, thirteen cataract patients had peak levels above 10 
pmol/L. Only one control (#4) had a peak 50HA value above 10 pmol/L.
It would not be unreasonable to expect that the reported precursor of 50HA, AA, would 
also have been increased in cataract patients. As mentioned earlier this was not the case, 
and in fact the AA levels in controls were slightly higher. The mean level at each control 
time-point was higher than the corresponding cataract time-point, and the two curves do 
not cross at any point although the difference was not statistically significant. The mean 
response curves for 30HA similarly, do not cross at any point even though the difference 
in the means of the two groups is also not statistically significant.
The occurrence of the exceptions noted above and in the separate metabolite chapters, 
highlights the individual variation seen in the metabolism of Trp.
30HA, XA and AA, on statistical analysis (Table 15.1), showed only one time point 
where there was a significant difference between the cataract and control groups and in
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each case this point did not appear out of context on the response curve (refer also to 
Figures 7.2, 8.2 and 10.2). Overall, it did not appear that there was an observable 
difference in the metabolism of these three compounds between the two groups.
15.3.1.4 3-H ydroxyanthranilic  Acid
There was little 30HA response to the Trp load in the cataract group, but the mean levels 
were higher in the cataract group at every time point including fasting (or 0 hr). There 
seemed to be no clear relationship between serum Trp and serum 3 OH A levels (see 
graphs 15.1 and 7.2)
15.3.1.5 A nthran ilic  Acid
Both cataract and controls groups showed very little difference in the AA response to 
Trp, and with a few exceptions (control #2, control #3 and cataract #35) remained either 
undetectable or near constant levels, at or below 2 pmol/L. In contrast to the case of 
30HA all the mean control values for AA were higher than those of cataract patients.
15.3.1.6 X anthurenic Acid
XA showed a significant difference only at the 2 hr point (refer to Figure 8.2) even 
though graphically there was considerable overlap of the error bars. The control subjects 
on the whole remained relatively constant after the load, peaking at 2 or 4 hr but generally 
the level remained below 3 pmol/L. There was, however, a statistically significant 
difference observed in levels of serum XA between the cataract groups (see section 
15.3.3.2).
No significant difference in metabolite levels for 50H T  and for Free T rp were found 
for the cataract and control groups.
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15.3.1.7 5-Hydroxy tryptophan
The values for 50HT do vary between subjects but generally show no marked response 
to the load of Trp. This is understandable since only 1% of ingested Trp is metabolised 
to serotonin via 50HT (refer to Figure 12.1), most of which takes place within the central 
nervous system [31]. The finding by Anderson et al [211] that whole blood levels of 
serotonin, a metabolite of 50HT, did not increase after a meal (even though there was an 
increase in serum Trp), partially supports the finding here that 50HT does not increase 
after a Trp load.
15.3.1.8 Free Tryptophan
The response curves for Free Trp (Figure 5.3) in both cataract and controls were virtually 
identical. The average (or mean) values were 20% of the total Trp value, a figure which is 
similar to that found in the literature [31]. The free Trp values, however, were not 
reflected by the different response seen for the total Trp values between the two groups. 
This may be a result of the fact that free Trp is more rapidly taken up by hepatocytes than 
is albumin-bound Trp [160]. The difference seen between control and cataract groups in 
total but not free Trp, may therefore, suggest a difference in the binding of Trp to 
albumin in the two groups. A difference was seen in the serum albumin contents of the 
two groups (Chapter 13) but it does not seem likely that this can account for the observed 
differences in the total and free Trp curves of the cataract and controls. Consequently, 
this may be an indication that the albumin binding sites in cataract patients are somehow 
modified so that less Trp is able to bind.
15.3.1.9 Other Factors.
The possibility that another factor may be influencing the different metabolic pattern 
between the two groups has been mentioned previously and has been considered in the 
light of these differences. Emphasis has been placed on the influence of glucocorticoids 
on tryptophan 2,3-dioxygenase by Rose [159], who suggested that Trp metabolic studies 
not be performed on persons in stressful situations, for example, in the immediate pre-
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and post-operative periods. Contrary to this recommendation, Badaway and Evans [170] 
found no correlation between serum Trp and serum Kyn levels with serum cortisol 
levels. In order to account for this influence, if any, a serum cortisol* [212] was 
performed on randomly chosen control subjects (n = 9) and cataract patients (n = 9). 
There was a significant difference (t = -4.88 at 5% level; P = 0.0002) between the two 
groups using the two-sample t-test (assuming equal variance) with a mean and standard 
error for the control group being 195 (+/- 44) nmol/L and 506 (+/. 46) nmol/L for the 
cataract group. The expected range for serum cortisol at this time of day (all subjects and 
patients were loaded between 7 am and 9 am) is 138 to 499 nmol/L. The fact that the 
control group showed a significant difference compared to the cataract patients in serum 
cortisol levels suggests that this group may have been under more stress that the post­
operative cataract group. If tryptophan 2,3-dioxygenase were induced in either group 
through effects existing prior to Trp loading (viz. raised serum cortisol), one would 
expect to see a more rapid and exponential rate (opposed to the observed, almost linear, 
response seen in Figure 15.1) of disappearance of Trp from the circulation [132].
Thus it appears that there is indeed a difference in the manner with which Trp is 
metabolised in some people with cataract and those without cataract. The cause of, or the 
reason for, the difference is at this stage unclear and cannot be determined solely from the 
experimental evidence described in this thesis.
15.3.2 Sex, Age & Cataract
Differences which were statistically significant were also found when examining the 
effect of age and sex within the cataract group and within the control group. The 
statistical values were presented in the individual metabolite chapters and are summarised 
in Table 15.1 (Age Diff. and Sex Diff). The significant values are represented by the 
shaded areas. Significant Age differences were found in the control group with 30HA
* Serum cortisol estimations were performed using the Abbott TDx system.
Table 15.3
Chi-Square Test for Differences 
between Cataract and Controls according to Sex
M etabolite M ALE FEM ALE 1 M etabolite MALE FEM ALE
50H A  - 0 hr 0.260 0.003 D XA - 0 hr 0.725 0.799
5 0 HA - 1 hr 0.062 0.088 XA - 1 hr 0.655 0.154
50H A  - 2 hr 0.012 0.022 XA - 2 hr 0.444 0.021
50H A  - 4 hr 0.009 0.133 XA - 4 hr 0.186 0.542
50H A  - 6 hr 0.000 0.004 XA - 6 hr 0.322 0.470
50H T  - 0 hr 0.492 0.754 KA - 0 hr 0.038 0.236
50H T  - 1 hr 0.740 0.687 KA - 1 hr 0.256 0.002
50H T - 2 hr 0.419 0.151 KA - 2 hr 0.285 0.024
5 0 HT - 4 hr 0.419 0.024 KA - 4 hr 0.199 0.033
50H T - 6 hr 0.197 0.638 KA - 6 hr 0.263 0.227
Kyn - 0 hr 0.391 0.864 Trp - 0 hr 0.017 0.197
Kyn - 1 hr 0.698 0.288 Trp - 1 hr 0.175 ; 0.018
Kyn - 2 hr 0.139 0.126 Trp - 2 hr 0.012 0.198
Kyn - 4 hr 0.126 0.402 Trp - 4 hr 0.089 \III.001
Kyn - 6 hr 0.169 0.649 Trp - 6 hr 0.180 0.747
30H A  - 0 hr 0.387 0.692 AA - 0 hr 0.558 0.143
30H A  - 1 hr 0.047 0.174 AA - 1 hr 0.192 0.487
30H A  - 2 hr 0.052 0.188 AA - 2 hr 0.684 0.631
30H A  - 4 hr 0.082 0.179 AA - 4 hr Too few 0.593
30H A  - 6 hr 0.242 0.503 AA - 6 hr i l l l i i i i l l i l l l l l ! 0.289
FTrp - 0 hr 0.467 Too few FTrp - 4 hr 0.666 0.619
FTrp - 1 hr 0.624 Too few FTrp - 6 hr 0.913 Too few
FTrp - 2 hr 0.263 1.000
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and AA at 0 hr, 2 hr, 4 hr and 6 hr and with Free Trp and Kyn at 0 hr only. No age 
differences were seen within the cataract group. Sex differences were noted as 
significant in the cataract group for 30HA at 1 hr only, but no such sex differences were 
found within the control group.
The Group Difference (Figure 15.1) between cataract and control groups was found to be 
statistically significant for KA at 0 hr, 1 hr, 2 hr and 4 hr, but there appeared to be no 
correspondingly significant difference within the groups according to age and sex. The 
response profile according to sex, discussed in Chapter 9 and seen in Figures 9.5 and 
9.6, however, did suggest a difference. This disparity between the cataract and control 
groups, (ie female cataract verses female control; male cataract verses male control) led to 
further statistical testing, not only for KA, but for all metabolites when grouped 
according to gender. Again because of the non-normal distribution of the data, it had to 
be categorised and tested using the Chi-square Test. The statistical probabilities are 
tabulated in Table 15.3. Those metabolites which showed a significant difference 
between male or female cataract and the corresponding control gender have the Chi- 
square statistic shaded. Some time-points had a low frequency of values within that 
category, and could not be computed. Those time-points are marked "too few".
Those metabolites which showed a significant difference at several time points are 
50HA, KA, and Trp. These three were also found to exhibit significant differences in 
Group response (Figures 15.1,15.3 and 15.5). 30HA and AA have only one significant 
different time each and both in the male group. XA has only one significantly different 
time point between cataracts and controls for females at 2 hr.
Overall the control group for 50HA had a statistically lower response for both males and 
females as is illustrated in Figures 11.5 and 11.6, for three out of five time points; from 2 
hr, 4 hr and 6 hr in males and at 0 hr, 2 hr and 6 hr in females. KA was significantly 
lower at 0 hr for males, (Figures 9.5 and 9.6), and the females were significantly lower
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Figure 15.6 Kynurenine Response according to Cataract Grade
Xanthurenic
Figure 15.7
Acid Response according to Cataract Grade
Summary Page 181
at 1 hr, 2 hr and 4 hr. The lower KA response in cataract patients was more pronounced 
in females than males.
A reasonable amount of work has been published on the effects of hormones on the 
metabolism of Trp [137, 149, 166, 213]. Most of the reported data, however, has been 
performed on experimental animals and on females who were either pregnant or taking 
oral contraceptives. The average age for the females in this study, however, was 74 yr 
and 55 yr for cataract females and control females respectively. Both mean ages are 
above the age of expected reproductive years. No patients were on hormone replacement 
therapy as established by questionnaire (one male, Cataract #3, was receiving oestradiol 
therapy for carcinoma of the prostate), and it was not determined how many were post­
menopausal. It remains likely, however, that a hormonal influence may be implicated in 
the observed sex-related differences in the metabolism of Trp.
15.3.3 Cataract Grade Differences
The response at each time point for each metabolites is plotted as a function of grade of 
cataract in Appendix E. The response data as a function of cataract type for each of the 
metabolites which showed a statistically significant difference within the cataract grades 
(Kyn, XA) as indicated by shading in Table 15.1 (Grade Differences), were illustrated as 
line graphs in Figures 15.6 and 15.7. The Grade 4 patients, because of their small 
number, were combined with the Grade 3.
Grade 1 are those patients whose lenses were removed as a consequence of cortical 
cataracts. Grade 2 - 4  have an increasing degree of nuclear cataract (with or without 
cortical involvement). The numbers contributing to each grade represented in Figures
15.6 and 15.7 are as follows; Control: n = 37; Grade 1: n = 1 1 ; Grade 2: n = 12; 
Grades 3 & 4: n = 9.
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15.3.3.1 Kynurenine
The Kyn response (Figure 15.6) shows that all the nuclear cataract groups (Grades 
2,3,4) are higher than the controls at time 0 hr. Grade 1 cataracts show no difference 
from the controls at 0 hr. All grades and controls show an increase in Kyn after the load, 
with all the cataract groups increasing at a greater rate than the controls. Kyn levels in the 
Grade 1 and 2 cataracts remained significantly higher at 6 hr (marked with *) than the
controls, but the Grade 3 & 4 group decreased after 2 hr.
15.3.3.2 Xanthurenic Acid
Table 15.1 indicates that there were significant differences between the grades for XA 
response at 1 hr, 2 hr and 4 hr. These times are indicated by the *  in Figure 15.7. It is
apparent from the line graph that the significance is due to the Grade 1 patients who 
display a different response pattern of XA from those of both controls and the other 
cataract groups. As noted in Chapter 8, cataracts of Grade 1 have minimal nuclear 
involvement Interestingly, Grade 2 patients seemed to cluster together tightly and were 
lower than the controls at all time intervals after the commencement of the load. The 
combined Grades 3 & 4 group responded similarly to the controls. The reason for the 
increased XA response seen in the Grade 1 cataracts is unknown.
15.4 Tryptophan Metabolite Levels as Criteria for 
the Separation of Cataract & Normal Subjects
On the basis of the preceding observations, it became apparent that a subgroup of cataract 
patients may exist who exhibit characteristics which could distinguish them both from 
other cataract patients and from controls.
By observing the response curves of the "significant" metabolites (Figures 15.1, 15.2, 
15.3, 15.5) it is apparent that there are some time points which exhibit a greater degree 
of separation of the two groups. For example, the 2 hr point for total Trp (Fig. 15.1) 
represents the greatest separation of cataract and control means with the smallest error
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bars; the 4 hr point for Kyn although showing less separation of means than the 6 hr has 
smaller error bars. Similarly, the 1 hr point seemed discriminatory for KA and the 6 hr 
point for 50HA. Was it possible therefore to ascribe a level of serum metabolite which 
would represent a "diagnostic cut-off separating control and cataract populations? Was 
there a "diagnostic level" of metabolite or group of metabolites which would include a 
significant proportion of cataracts and exclude all or almost all controls (or vice versa)?
Rather than maximising for all four time points (1, 2, 4, 6 hr) for each of the four 
metabolites, it was decided to optimise using only one point (eg. 4 hr). The use of one 
time point as a "diagnostic index" was considered to be of be more use clinically, and if 
such an analysis proved effective, only two blood samples (fasting and 4 hr) and a 
loading dose would be necessary to screen people for a possible metabolic susceptibility 
to cataract
By comparing the data table for each of the four metabolites at any given time point, an 
attempt was made to find values which provided the greatest discrimination (in terms of 
numbers) between the groups (cataract and control). In other words, the data set was 
maximised to include the largest number of cataract patients whilst keeping the control 
group at or near zero. The criteria at the 4 hr time point were persons with a KA < 4 
pmol/L and Total Trp <300 |imol/L and Kyn > 10 pmol/L.
As a result of this exercise, a subgroup was selected which included 12 cataract patients 
and 1 control subject. Twelve patients represents 29% of the cataract group; 1 control 
subject represents 3% of the control group.
Figure 15.5 suggests that a discriminatory value at 4 hr for 50HA of approximately 6 
pmol/L would also be suitable. The data, however, indicated that a value of >8.0 pmol/L 
selected 13 (30%) cataract patients and only 2 (5%) control subjects. Although the high 
50HA value of >8.0 pmol/L selected a third of the cataract patients, only 2 of these 13
Table 15.4 Individuals Fulfilling Selection Criteria*
Group No At 0 hr At 4 hr
Trp+KA 5 0 H A Trp+K A+
K y n
5 0 H A
contro l 8 V i V V
control 6
contro l 4 w
control 3 6 V
cataract 1 V
cataract 2 V
cataract 5
— -,—
cataract 8 Sf
-j
cataract 9
- ,
--------- =7--------- — 3
- J
cataract 13 ............ Sf............ V
cataract 15
—
cataract 33 V V V
cataract 3 4 V
cataract 35 V
cataract 3 7
-y
cataract 3 8 V sf
cataract 6
— -,—
V
cataract 7
cataract 12 i
cataract 16 V
cataract 18
----------------- J ----------------
V
cataract 19 V V V
cataract 21
-j,
V
-,
cataract 2 2 V V
cataract 3 0
— - J —
cataract 31 s/
cataract 4 2
cataract 10 V V
cataract 2 0 3
cataract 3 2 7
cataract 3 9
cataract 17 ............ST............
cataract 29
TOTAL CATARACTS 3 7 4 0 3 6 3 5
TOTAL CONTROLS 3 7 3 6 3 4 3 4
* 0 hr - Trp+KA = trp<60 nmol/L AND KA<0.8 jimoi/L 
50HA = 5OHA>4.0 \i mol/L
4 hr - Trp+KA+Kyn = trp<300 \i mol/L AND KA<4.0 \x mol/L AND Kyn >10 n mol/L 
50H A = 5OHA>8.0 \i mol/L
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were patients selected on the basis of the KA/Trp/Kyn parameter so it would appear that it 
may distinguish a separate subset of cataract patients who are different from the subset 
selected by the above-mentioned criteria.
The method of selection of criteria was also applied to the basal (0 hr) data. There was a 
significant difference between cataract and control response at 0 hr for Trp, KA and 
50HA, but not Kyn. The discriminatory values at this time were determined to be Trp 
<60 nmol/L and KA <0.8 iimol/L. For 50H A  >4.0 nmol/L was used. This precept 
when applied to the Trp and KA selected 45% of the cataract patients and only 8% of the 
controls. Once again the 50HA model was applied as a separate subset, since there 
appeared to be no patient association between the other two metabolites and 50HA. This 
single metabolite selected 30% of the cataract patients with 50HA values above 4.0 
limol/L, but only 8% of the controls had values above this figure.
The other time periods were not tested. The fasting level was determined to be the most 
suitable if a clinical test was to be applied since, if suitable, no loading dose need be 
given. If necessary, a further sample would be taken after a loading dose and the 4 hr 
sample was considered (from the response curves) to be the discriminator with best 
potential. Unfortunately, the choice of two levels (0 hr and 4 hr) did not enhance the 
ability of the original criteria to discriminate between cataract and controls.
The usefulness of applying the criteria to the data can be determined by calculating the 
diagnostic sensitivity, specificity, predictive value and efficiency of the selection rules. 
The sensitivity of the test is a measure of the frequency of positive criteria when cataract 
is present. Specificity is a measure of the frequency of not fulfilling the criteria when 
there is no cataract present. The predictive value of the diagnostic criteria is the frequency 
of cataract occurring in those patients who have the elevated metabolites. The efficiency 
of the criteria indicates the percentage of patients who have been correctly classified by 
the criteria [214].
Table 15.5
The Performance of the "Diagnostic Index" of Cataract
Formation.
C r it e r io n S e n s i t i v i t y S p e c i f i c i t y P r e d ic t iv e E f f i c i e n c y
% % Value (% ) %
Trp/K A/K yn at 4 hr 33 97 92 64
5 0 H A  at 4 hr 37 94 87 65
Trp/K A/Kyn + SOHA at 4 hr 11 97 80 54
Trp/KA at 0 hr 46 95 89 70
5 0 H A  at 0 hr 30 92 80 59
Trp/KA + SOHA at 0 hr 19 97 88 11
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Sensitivity of the Criteria:
No. of Cataracts with the criteria
No. of cataracts with the criteria + No. of controls with the criteria
X 100
Specificity of the Criteria:
No. of Controls without the criteria 
No. of controls with the criteria + No. of controls without the criteria
X 100
Predictive Value of the Criteria:
No. of cataracts with the criteria
No. of cataracts with the criteria + No. of controls with the criteria
X 100
Efficiency of the Criteria:
No. of Cataracts with the criteria + No. of Controls without the criteria 
Total No. of controls + Total No. of cataracts
X 100
In this application, the predictive value of the "diagnostic criteria" is of primary 
importance and Table 15.5 indicates that the best predictive performance (92%) is 
obtained using the data from the Trp/KA/Kyn levels at 4 hr. The sensitivity and 
specificity indicate that this criteria when applied will have a frequency of 33% when 
correctly classifying a (potential) cataract associated with abnormal Trp metabolism, and a 
frequency of 97% in correctiy eliminating such a cataract in a normal individual.
A similar finding is obtained for the Trp/KA criteria at 0 hr. The predictive value (89%) is 
not as good as Trp/KA/Kyn at 4 hr, but the sensitivity is better (46%) with a similar 
specificity (95%). The overall ability to correctly classify those with cataract and those 
without cataract (efficiency) is also better for the two metabolites at 0 hr (70%) compared 
to the three metabolites at 4 hr (64%).
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The levels of 50HA, although producing reasonable predictive values (87% and 80%) 
have much lower sensitivities (11% and 30%) and therefore lower efficiencies. These 
distinctive grouping values and the distribution of the positive criteria shown in Table
15.4 further suggest that two subgroups of cataract patients with abnormal Trp 
metabolism exist
Of course, it should be remembered that this exercise was performed on a small 
population (cataracts « 42; controls «37)* and as such needs to be interpreted with 
caution, but it represents evidence for the existence of a subgroup(s) of cataract patients 
having a dysfunction in Trp metabolism.
15.5 Degree of Response (Serum Tryptophan
Level)
When the difference observed in the serum Trp levels of the cataract and control groups 
was taken together with the variation in response seen in the serum levels of the 3 Trp 
metabolites (Figures 15.2, 15.3, 15.5), it seemed appropriate to group the cataract 
patients into high and low Trp responders to see if these two groups differed in those 
metabolite profiles. Arbitrarily a figure was chosen corresponding to a 2 hr serum Trp 
>300 pmol/L in order to define a group of high responders, and individuals with the 
lowest Trp level at the 2 hr peak (lowest 10 individuals) were then grouped as the low 
responders. Such a broad demarcation was chosen to help determine if the metabolite 
levels were a direct function of Trp levels in blood. The same ranking was applied to the 
control group.
* Not all values were available for each metabolite in the "criteria", and where this occurred that patient or 
subject was eliminated. This is the reason for the variation in the Total number of cataracts and controls 
listed at the bottom of Table 15.4.
Figure 15.8 Kynurenine Levels in High & Low Trp Responders
(Cataracts)
Figure 15.9 Kynurenine Levels in High & Low Trp Responders
(Controls)
Figure 15.10 Kynurenic Acid Levels in High & Low Trp
Responders (Cataracts)
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The mean metabolite levels of each group (low Trp responders and high Trp responders) 
were graphed as a function of time after dose and the results are was shown in Figure 
15.8 to 15.13.
Of the three metabolites, Kyn (Figure 15.8) showed the largest difference between the 
cataract patients who had a high peak Trp level and those with a low peak Trp level. 
Although the degree of spread of data for the high responders is larger than in the low- 
responders, there is no overlap of error bars at any point after the basal level. The 
controls were sorted on a similar basis but no major difference was seen in this group's 
response (Figure 15.9). For those cataract patients whose mean 2 hr Trp level was >300 
pmol/L, the Kyn level was about 80 pmol/L after 2 hr, while the corresponding figure 
from control subjects (Figure 15.9) was approximately 20 to 25 pmol/L. It is of 
particular interest that the low Trp responders in the cataract group (Figure 15.8) appear 
quite normal in their Kyn response (cf. Figure 15.9).
A difference of this magnitude in the response of one metabolite, points to a difference in 
Trp metabolism in a subgroup of cataract patients.
The increase in the Kyn levels in the high Trp cataract group is also reflected to a lesser 
extent in the corresponding KA values (Figure 15.10). Even so, the high KA values (~ 5 
pmol/L) in the cataracts do not equal the control values (~ 7 pmol/L) seen in Figure 
15.11. Thus even if Kyn is elevated four fold in serum compared with the controls, there 
is still a lower KA value than is seen in the controls. This may suggest a relative decrease 
in the activity of Kyn aminotransferase in cataract patients.
By contrast the 50HA levels are not significantly elevated in the high responders (Fig. 
15.12) even in those cataract patients who displayed elevated Kyn levels. This is despite 
the fact that overall 50HA levels in the cataract group are higher than in controls at each 
time point (Fig. 15.12 and 15.13). One possibility is that the constitutive enzyme levels
Figure 15.11 Kynurenic Acid Levels in High & Low Trp
Responders (Controls)
Figure 15.12 5-Hydroxyanthranilic Acid Levels in High & Low
Trp Responders (Cataracts)
Figure 15.13 5-Hydroxyanthranilic Acid Levels in High & Low
Trp Responders (Controls)
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of kynureninase and/or anthranilic acid hydroxylase in cataract patients are higher than in 
controls. This data also implies that the cataract patients who have low 50HA may form a 
separate sub-category from the high Trp, high Kyn group.
In summary, Kyn levels were found to be increased significantly in a sub-group of 
cataract patients. In this group KA was also raised significantly relative to the other 
cataract patients but the levels still remained below those of controls. It should be noted 
that with adequate levels of vitamin B6, a Trp load does not result in a major increase in 
the excretion of KA or XA [31]. Therefore, it may be concluded that very little 
metabolism occurs through the aminotransferase branch of the pathway, under normal 
conditions and that the levels of kynurenine hydroxylase and kynureninase are more than 
adequate to cope with the increased flux.
15.6 Further Points for Consideration
In the controls, the data revealed no major differences in Kyn and KA levels as a function 
of Trp concentration. Since the metabolite levels are an indirect reflection of enzyme 
activities it would appear that an enzyme(s) involved in the initial step of the formation of 
Kyn may be rate-limiting. Wolf et al [135] used Kyn instead of Trp as the loading 
compound. This was done to bypass the tryptophan 2,3-dioxygenase step and thereby 
eliminate any complications introduced by induction of the apo-enzyme. They loaded 
0.15 g Kyn (the equivalent of 2 g trp) and measured urinary excretion of Kyn, N-acetyl 
Kyn, KA, AA-glucuronide, o-aminohippuric acid, 30HKyn, XA, 30HA. They also 
confirmed that a loading dose of 2 g L-Trp does not exceed the capacity of the trp-NAD 
pathway. These authors found that the dose of Kyn was adequate for stimulation of the 
pathway and that there was a difference in the excretion of metabolites in pre- and post­
menopausal women. Such a load test using Kyn could be used to distinguish between 
abnormal Trp metabolism resulting from induction of tryptophan 2,3-dioxygenase or by 
decreased activity of kynureninase. This approach may be useful for further investigation 
of cataract patients and normals.
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As outlined in Chapter 1, the first step in the metabolism of Trp can be catalysed by either 
one of two enzymes, namely tryptophan 2,3-dioxygenase localised specifically in the 
liver and indoleamine 2,3-dioxygenase in other tissues. The difference observed between 
the controls and a sub-group of cataracts may reflect problems in the regulation of one or 
both of these enzyme systems.
Overall two major subgroups, (i) Kyn/KA/Trp, (ii) 50HA, and possibly (iii) XA of 
cataract patients have been found to display features consistent with a dysfunction in Trp 
metabolism. From the atypical response of Kyn and to a lesser extent KA to serum Trp 
levels in these patients, it is proposed that patients in the first group (ie ( i ) ) may have a 
defective control at the level of either indoleamine 2,3-dioxygenase or tryptophan 
dioxygenase.
C0NSEM1T IFCDIRM
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CONSENT FORM FOR POTENTIAL VOLUNTEERS FOR 
TRYPTOPHAN LOADING STUDY
You are invited to participate in a study of the metabolism of the essential dietary amino acid,
tryptophan. We hope to learn the mechanisms involved in the development of your disease.
You were selected as a possible participant in this study because of the stage you are at in the
progress of your disease.
If you decide to participate, we will:
1) ask you to fast for 8 hr prior to the test. This will involve not having anything to eat 
after the evening meal on the night before the test. You may drink water.
2) on the morning of the test you will be weighed and given an amount of amino acid 
dissolved in water (or in tablet form). This amino acid (tryptophan) is found in many 
foods and is, in fact, an essential part of a healthy diet. However, you will be given an 
amount which is much larger than is normally found in food. This should not adversely 
affect you and you will feel no discomfort
3) at one and two hourly intervals after the dose (for a total of 6 hours) you will have a 
small amount of blood withdrawn from your arm for analysis ( a total of five samples)
4) you will be asked during the test to pass some urine into a small jar. This may not be 
possible, so to help this you will be given a small glass of water to drink each time a 
blood sample is taken. The urine will also be analysed.
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We cannot and do not hold out that you will receive any benefits from this study. This is not 
a standard treatment for your condition, but is purely a research study.
Any information that is obtained in connection with this study and that can be identified with 
you will remain confidential and will be disclosed only with your permission. However, if 
you agree by signing this document, your results, in so far as they reflect in the study, will 
be reported in the scientific literature as data only and you will not be identified in any way.
Your decision whether or not to participate will not prejudice your future relations with this 
Hospital, nor The Wollongong University. If you decide to participate , you are free to 
withdraw your consent and to discontinue at any time and such withdrawal will not 
jeopardize any further treatment or your relationship with the Health Service and your 
medical attendants. If you have any questions later, any of the researchers listed below will 
be happy to answer them.
You will given a copy of the signed consent from to keep.
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CERTIFICATION BY INVESTIGATOR AND 
PATIENT/SUBJECT
I hereby certify that I have disclosed the risks that may be involved, in terms readily 
understood by the patient/subject:
Date Signature of Investigator
CONSENT BY PA TIEN T/SU BJEC T
I hereby certify that I have read and understood all the information provided and agree to 
participate in the research proposal described.
Date Signature of Patient/Subject
Relationship to patient/subject if patient unable to consent :
Signature of witness :
Nature of witness :
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REVOCATION OF CONSENT BY PATIENT/SUBJECT
I hereby wish to W ITHDRAW  my consent to participate in the research proposal described 
above and understand that such withdrawal will NOT jeopardise any treatment or my 
relationship with the Hospital, the Health Service or my medical attendants:
Date : ________________ Signature :
The section for revocation of consent by the patient/subject should be forwarded to :
Mr. A. Elderfield, 
Biochemistry Department,
The Wollongong Hospital, 
Crown Street,
WOLLONGONG NSW 2500
OR Dr. R. Truscott,
Department of Chemistry,
The University of Wollongong, 
P.O. Box 1144, 
WOLLONGONG NSW 2500
AIPIPENIMX IB
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TRYPTOPHAN LOADING DATA SHEET
Name _________________________________  MRN
Postcode of Residence_________  Sex_______  Date of Birth
Occupation _______________________________________________________
Weight __________  Height Body Surface Area __________
OPHTHALMIC EXAMINATION
Scheduled Date for Lens Removal : Surgeon : Dr.
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Name MRN
SLIT LAMP PHOTGRAPHY Date:
Magnification Pupil Dilatation = mm
Nucleus (0.1 x 8 mm beam): nuclear opacity grade =
Cortical (1 x 5 mm beam) : cortical opacity grade =
Vacuoles : present/absent
Post Subcapsular opacities : mm x mm =
(vertical) x (horizontal) = (area)
mm^
MEDICAL HISTORY
(Circle correct response)
Smoking :Yes/No No of cigarettes/day
Alcohol: Yes/No No. of drinks/day
Diet: Meat-meals(protein)/day
<5 <10 10-20 20-40 >40
<1 1-5 5-10 10-20 >20
None 1 2 3 >3
Has the patient womspectacles as a child or suffered from short-sightedness? Yes/No 
Has the patient ever suffered from severe diarrhoea (incapcitated for at least 4 days)? 
Yes/No
Has the patient been taking any analgesics regualrly for more than 3 months? Yes/No 
If so list the analgesic and the dose below.
MEDICATION (include aspirin , paracetamol and any vitamin preparations)
Preparation______________________ Strength___________Frequency____
Preparation______________________ Strength___________Frequency------
Preparation___________________   Strength___________ Frequency____
Preparation _____________________ Strength___________ Frequency____
Preparation__________________  Strength___________ Frequency------
FAMILY HISTORY (eg diabetes, porphyria)
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TRYPTOPHAN LOADING DOSE
Name _  ______________________________________ MRN
Date: / / Time: : hrs Hrs. fasting hrs Dose req'd: ---- g
Tryptophan tablets: Batch No. No.of tablets given = g
Aqueous humor specimen: Yes/No Date collected: Time:
Lens specimen: Yes/No Date extracted: /  /  Time:___:___
Lens Photograph (in vitro): Yes/No Date : _ / _ _ / _
Film Type:____________ Frame No.:_____  Settings: _
Specim en Time (Blood) Time (Urine)
Basal
1 hour
2 hours
3 hours
4 hours
5 hours
6 hours
7 hours
8 hours
9 hours
10 hours
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Name ____________________________ _ __________ . MRN
BIOCHEM ISTRY Analysis Date: / /
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TRYPTOPHAN METABOLITES
Name________________________________________ MRN
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Name MRN
LENS ANALYSIS
Lens Photograph:
Pine Classification:
Lens wet weight:______g
Extraction and purification: Date:__ /
HPLC Analysis: Date: ___
Peak No. Retention
Time
Metabolite Peak Area Concent'n
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AQUEOUS HUMOR ANALYSIS
HPLC Analysis: Date: Volume:______uL
Name__________________ _ __________________ MRN_____________
Peak No. Retention
Time
Metabolite Peak Area Concent'n
ky
TTT\ YX'il’
O
Q
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CATARACT #1 - Male, 63 yrs Grade 3: nuclear
SERUM BIOCHEMISTRY RESULTS
Na
138
K
4
Cl
104
HC03
23
Urea
6.5
Créât
103
Glue
4.7
Prot
67
Alb
39
B i l l
1
ALP
68
GGT
31
AST
30
ALT
14
LD
302
Ca
2.36
P 0 4
1.02
Mg
0.77
UA
0.372
Zn
9.6
Fe T 4
15.6
TSH
1.2
Amyl
41
Choi
3.99
Trig
1.41
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CATARACT #2 - Female, 67 yrs Grade 1: nuclear
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât
141 4.1 106 23 4.8 63
ALT LD Ca P 0 4 Mg UA
11 293 2.45 1.02 0.78 0.189
0 1 2 3 4 5 6
Hrs After Dose
Glue
11
Prot
70
Alb
39
B i l i
10
ALP
114
GGT
25
AST
31
Zn
10.5
Fe T 4
35.9
TSH
0.1
Amyl
49 *
Choi
4.53
Trig
1.72
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CATARACT #3 - Male, 73 yrs Grade 3; nuclear
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Creai
138 5 103 32 5.6 105
ALT LD Ca P 0 4 Mg UA
18 180 2.23 1.15 0.75 0.368
Glue
5.9
Prot
57
Alb
33
B i l i
7
ALP
74
GGT
17
AST
21
Zn Fe T 4 TSH Amyl Choi Trig
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CATARACT #4 - Female, 84 yrs Grade 2 : nuclear, PSCC
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
146
K
4.4
Cl
107
HC03
31
Urea
6.9
Créât
121
Glue
6.1
Prot
75
Alb
41
B i l i
8
ALP
72
GGT
44
AST
37
ALT
22
LD
373
Ca
2.24
P 0 4
1.3
Mg
0.92
UA
0.551
Zn Fe T 4 TSH Amyl
62
Choi
6.52
Trig
2.3
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CATARACT #5 - Male, 57 yrs Grade 4 : nuclear
SERUM BIOCHEMISTRY RESULTS
Na
142
K
4.1
Cl
104
HC03
29
Urea
6.2
Créât
96
Glue
5.3
Prot
62
Alb
37
B i l i
12
ALP
50
GGT
25
AST
47
ALT
26
LD
297
Ca
2.32
P 0 4
0.97
Mg
0.67
UA
0.292
Zn Fe T 4 TSH Amyl
39 *
Choi
5.2
Trig
1.22
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CATARACT #6 - Female, 81 yrs Grade 3 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na
140
K
4.5
Cl
104
HC03
23
Urea
6.8
Créât
89
Glue
5.5
Prot
74
Alb
42
B i l i
16
ALP
65
GGT
39
AST
34
ALT
19
LD
298
Ca
2.46
P 0 4
1.23
Mg
0.87
UA
0.319
Zn Fe T 4 TSH Amyl
73 *
Choi
6
Trig
1.93
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CATARACT #7 - Male, 88 yrs Grade 1 (nuclear)
Time After Dose (bn)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Creai
146 4 108 27 4.6 96
ALT LD Ca P 0 4 Mg UA
17 347 2.36 0.74 0.33 0.319
Glue Prot Alb B i l l ALP GGT AST
6.4 70 39 11 77 26 36
Zn Fe T 4 TSH Amyl
63 *
Choi
4.5
Trig
2.19
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CATARACT #8 - Female, 77 yrs Grade 2 (nuclear)
2 3
Time Áfler Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
144 4.4 102 25 5.7 98 5.8 62 36 13 52 18 28
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Amyl Choi Trig
17 234 2.33 0.96 0.84 0.3 50 6 1.58
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CATARACT #9 - Female, 69 yrs Grade 2 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
141 3.8 104 21 5.6 82 5.3 68 41 12 60 18 25
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Amyl Choi Trig
20 305 2.43 1.12 0.74 0.329 59 * 6.9 0.93
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CATARACT #10 - Female, 69 yrs (no lens)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
144 4.1 106 22 6.2 81 4.2 70 44 9 39 21 26
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Amyl Choi Trig
14 273 2.44 1.41 0.82 0.41 39 * 5.9 1.15
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CATARACT #11 - Female, 74 yrs Grade 2 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât
140 4.2 104 18 6 104
ALT LD Ca P 0 4 Mg UA
15 268 2.53 1.07 0.72 0.245
Glue Prot Alb B i l l ALP GGT AST
5.4 72 41 10 63 33 33
Zn Fe T 4 TSH Amyl
42
Choi
5.52
Trig
0.67
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CATARACT # 12 - Female, 73 yrs Grade 3 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
142 4.5 110 28 5.8 104 5.1 64 35 6 96 28 17
ALT LD Ca P 0 4 M g UA Zn Fe T 4 TSH Amyl Choi Trig
141 2.41 1.35 0.91 8 20.1 2 5.71 0.69
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CATARACT # 13 - Male, 70 yrs Grade 2 (mixed)
SERUM1 BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
142 4.6 108 19 6.3 106 4.5 69 39 11 68 26 29
ALT LD Ca P 0 4  Mg UA Zn Fe T 4 TSH Amyl Choi Trig
20 368 2.31 0.92 0.76 0.345 59 ' 4.87 0.82
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CATARACT #15 - Female, 68 yrs Grade 3 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
142 4.2 104 20 5.5 111 5.8 78 43 10 112 122 36
ALT LD Ca P 0 4  Mg UA Zn Fe T 4 TSH Amyl Choi Trig
18 351 2.46 1.25 0.89 0.417 50 8.9 1.4
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CATARACT #16 - Female, 76 yrs Grade 2 (mixed)
! 2 3
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
i— ■— r
2 3 4
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
143
ALT
17
K
3.8
Cl
105
HC03
24
Urea
4.9
Créât
84
Glue
5.3
Prot
72
Alb
43
B i l l
14
ALP
74
GGT
49
AST
36
LD
279
Ca
2.4
P 0 4
1.09
Mg
0.81
UA
0.335
Zn Fe T 4 TSH Amyl
47 *
Choi
4.5
Trig
0.92
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CATARACT # 17 - Male, 76 yrs Grade 3 (mixed)
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l i ALP GGT AST
143 4.5 104 26 5.6 110 5.6 66 36 17 58 24 27
ALT LD Ca P 0 4 M g UA Zn Fe T 4 TSH Amyl Choi Trig
11 272 2.45 1.22 0.91 0.349 65 * 6.01 1.43
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CATARACT #18 - Male, 53 yrs Grade 2 (mixed)
Time After Dose (brs)
SERUM BIOCHEMISTRY RESULTS
Na
136
K
3.7
Cl
n o
H C 0 3
19
Urea
3.5
Créât
71
Glue
4.8
Prot
80
Alb
38
B i l l
13
ALP
90
GGT
61
AST
49
ALT LD
145
Ca
2.29
P04
1.11
M g
0.81
UA
0.389
Zn
9.7
Fe T 4
11.5
TSH
1.8
Amyl Choi
4.46
Trig
0.69
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CATARACT #19 - Male, 59 yrs Grade 3 : nuclear
SERUM BIOCHEMISTRY RESULTS
Na
141
K
4.4
Cl
106
HC03
23
Urea
5.2
Créât
88
Glue
5.6
Prot
72
Alb
43
B i l l ALP
71
GGT
41
AST
20
ALT LD
123
Ca
2.44
P 0 4
1.37
Mg
0.89
UA
0.38
Zn
12.3
Fe T 4
16.5
TSH
0.8
Amyl Choi
6.54
Trig
1.05
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CATARACT # 20 - Female, 64 yrs Grade 2 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na
141
K
3.6
Cl
108
HC03
22
Urea
5.1
Créât
79
Glue
5.3
Prot
75
Alb
44
B i l l
17
ALP
64
GGT
28
AST
30
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Amyl Choi Trig
183 2.47 1.22 0.95 0.234 14.3 13.4 1 7 1.26
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CATARACT #21 - Male, 50 yrs Grade 2 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
142 5 118 15 30.7 734 5.1 72 39 43 20 15
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Amyl Choi Trig
122 2.21 1.61 1.13 0.52 9.2 14.3 1.8 5.11 1.98
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CATARACT #22 - Male, 79 yrs Grade 1 (mixed)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât Glue Prot Alb B i l i ALP GGT AST
141 3.9 100 41 9.4 144 7.7 66 41 55 34 42
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Am yl Choi Trig
177 2.42 1.45 0.75 0.499 10.4 19.6 0.8 6.11 1.49
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CATARACT #23 - Female, 79 yrs Grade 2 : nuclear
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
138
K
3.8
Cl
107
HC03
21.9
Urea
2.8
Créât
62
Glue
5.9
Prot
78
Alb
42
B i l l
2
ALP
105
GGT
25
AST
18
ALT LD Ca
2.37
P 0 4
0.87
Mg
0.85
UA
0.284
Zn Fe
8.3
T 4 TSH Amyl
48 '
Choi
5.61
Trig
1.1
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CATARACT #24 - Male, 73 yrs Grade 1 (cortical)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât Glue
145 4.3 108 16 6.7 142 5.8
ALT LD Ca P 0 4 Mg UA Zn
23 351 2.6 1.54 0.98 0.442
Prot Alb B i l l ALP GGT AST
83 49 17 57 27 37
Fe T 4 TSH Am yl
47 ’
Choi
6.7
Trig
1.36
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CATARACT #25 - Female, 69 yrs Grade 4
5
SERUM BIOCHEMISTRY RESULTS
Na
142
K
4.4
Cl
110
HC03
16
Urea
5.2
Créât
109
Glue
4.9
Prot
66
Alb
40
B i l i
12
ALP
74
GGT
19
ALT
16
LD
421
Ca
2.5
P 0 4
0.98
Mg
0.87
UA
0.237
Zn Fe T 4 TSH Amyl
87 *
Choi
5.1
1
6
AST
66
Trig
1.2
Appendix C Page 228
CATARACT #26 - Female, 88 yrs Grade 3
SERUM BIOCHEMISTRY RESULTS
Na
144
K
3.9
Cl
106
HC03
19
Urea
7.4
Créât
90
Glue
5.6
Prot
80
Alb
46
B i l l
10
ALP
74
GGT
57
AST
23
ALT
14
LD
293
Ca
2.52
P 0 4
1.05
Mg
1.04
UA
0.351
Zn Fe
23.9
T 4 TSH Amyl
45 '
Choi
7.1
Trig
2.52
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CATARACT #27 - Male, 46 yrs Grade 2
SERUM1 BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
143 4.1 103 21 5 73 5.4 77 45 11 72 30 27
ALT LD Ca P 0 4  Mg UA Zn Fe T 4 TSH Amyl Choi Trig
23 220 2.42 0.99 0.86 0.273 26.9 67 ' 6.8 1.3
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CATARACT #29 - Male, 64 yrs Grade 3
1 2  3 4
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
1 2  3 4
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea
145 3.7 111 28 6.6
ALT LD Ca P 0 4 Mg
18 332 2.35 1.3 0.84
Prot Alb B i l l ALP GGT AST
75 41 83 27 24
Fe T 4 TSH Amyl
48 *
Choi
6
Trig
3.35
Creai Glue
125 5.2
UA Zn
0.41
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CATARACT #30 - Male, 64 yrs (no lens)
SERUM BIOCHEMISTRY RESULTS
Na
143
K
3.9
Cl
106
HC03
27
Urea
9.01
Creat
78
Glue
8.01
Prot
73
Alb
42
B i l l ALP
83
GGT
33
AST
34
ALT
42
LD
454
Ca
2.39
P 0 4
1.09
Mg
0.72
UA
0.356
Zn
13.8
Fe T 4 TSH
0.67
Amyl
61
Choi
4.89
Trig
1.3
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CATARACT #31 - Male, 84 yrs Grade 1
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât Gluc Prot Alb B i l l ALP GGT AST
136 4.5 104 25 7.2 145 6 74 36 105 23 34
ALT LD
424
Ca
2.22
P 0 4
1.16
Mg
0.86
UA
0.306
Zn Fe T 4 TSH Amyl
62 *
Chol
6.03
Trig
1.42
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CATARACT #32 - Male, 66 yrs (no lens)
1 2  3 4
Time After Dose (hn)
2 3 4
Time After Dose (his)
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât
138 4.3 105 25 4.59 88
ALT LD Ca P 0 4 Mg UA
97 511 2.34 0.9 0.79 0.32
Glue
6.3
Prot
80
Alb
40
B i l l ALP
164
GGT
126
AST
113
Zn Fe T 4
13.8
TSH
1.6
Amyl
44
Choi
5.71
Trig
1.29
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CATARACT #33 - Male 68 yrs (no lens)
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
138
K
4.4
Cl
103
HC03
28
Urea
3.7
Créât
87
Glue
5.2
Prot
80
Alb
42
B i l l
14
ALP
70
GGT
55
AST
31
ALT
21
LD
340
Ca
2.77
P 0 4
0.93
Mg
0.78
UA
0.533
Zn Fe T 4
15.2
TSH
1.5
Amyl
60
Choi
5.5
Trig
1.17
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CATARACT #34 - Female, 66 yrs Grade 1
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât
139 4.3 105 28 4.7 101
ALT LD Ca P 0 4 Mg UA
33 506 2.29 1.38 0.8 0.284
Glue Prot Alb B i l i ALP GGT AST
4.8 71 36 11 103 96 34
Zn Fe T 4
13.5
TSH
2.4
Am yl
66 '
C hoi
5.99
Trig
2.67
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CATARACT #35 - Male, 75 yrs Grade 1
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Creat Glue
141 4.3 104 21 5.6 122 5.4
ALT LD Ca P 0 4 Mg UA Zn
18 408 2.6 1.4 0.97 0.474
Urne After Dose (hrs)
Prot Alb B i l l ALP GGT AST
84 45 16 60 23 27
Fe T 4 TSH Am yl Choi Trig
17.7 66 * 7.5 1.14
Appendix C
CATARACT #36 -
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Creat
140 4.1 107 2.9 6.6 86
ALT LD Ca P 0 4 Mg UA
32 538 2.32 1.27 0.83 0.29
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, 71 yrs Grade 1 : nuclear
Glue Prot Alb B i l l ALP GGT AST
5.4 73 43 9 77 19 39
Zn
11.8
Fe T 4 TSH Amyl
78 ’
Choi
6.82
Trig
0.84
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CATARACT #37 - Male, 58 yrs Grade 1
SERUM BIOCHEMISTRY RESULTS
Na
141
K
4
Cl
109
H C03
33
Urea
2.5
Créât
83
Glue
5.1
Prot
76
Alb
41
B i l l
9
ALP
75
GGT
44
AST
28
ALT
18
LD
425
Ca
2.34
P 0 4
1.39
Mg
0.88
UA
0.318
Zn
8.5
Fe T 4 TSH Amyl
62 '
Choi
5.01
Trig
1.07
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CATARACT #38 - Female, 71 yrs Grade 1
SERUM BIOCHEMISTRY RESULTS
Na
141
K
3.7
Cl
99
H C03
26
Urea
7.6
Créât
105
Glue
6
Prot
78
Alb
41
B i l l
10
ALP
81
GGT
30
AST
42
ALT
31
LD
325
Ca
2.41
P 0 4
1.4
Mg
0.81
UA
0.502
Zn Fe
13.3
T 4 TSH Amyl
66 *
C hoi
6.1
Trig
2.97
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CATARACT #39 - Male, 73 yrs Grade 3
T----- ■---- 1 ----- »
1 2  3 4
T¡me After Dose (hrs)
2 3 4
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
136 4 101 23 4.8 95
ALT LD Ca P 0 4 Mg UA
21 324 2.41 1.55 0.84 0.364
Glue
5.2
Prot
71
Alb
41
B i l l
25
ALP
77
GGT
37
AST
24
Zn Fe
24.7
T 4 TSH Am yl
57 *
Choi
4.5
Trig
0.62
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CATARACT #40 - Female, 79 yrs (no lens)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât Glue
145 3.6 108 21 6.1 76 5.8
ALT LD Ca P 0 4 Mg UA Zn
18 299 2.5 1.24 0.83 0.484
Prot Alb B i l l ALP GGT AST
76 42 11 69 26 24
Fe
18.7
T 4 TSH Amyl
56 '
Choi
7.4
Trig
1.92
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CATARACT #41 - Male, 78 yrs (no lens)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
142 4.2 105 28 5.3 109
ALT LD Ca P 0 4 Mg UA
29 412 2.34 1.23 0.9 0.309
Prot Alb B i l i ALP GGT AST
81 45 13 98 31 33
Fe T 4 TSH Am yl
65 '
C ho i
8.67
Trig
1.92
Glue
5.6
Zn
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CATARACT #42 - Female, 85 yrs Grade 3
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
143 3.8 111 19 11.3 140
ALT LD Ca P 0 4 Mg UA
18 383 2.35 1.15 0.9 0.451
0 1 2 3 4 5 6
Time After Dose (hrs)
Glue Prot Alb B i l l ALP GGT AST
6.2 67 38 13 66 15 26
Zn Fe
16.8
T 4 TSH Amyl  
57 *
Choi
5.1
Trig
1.8
HD
CDU Til D-L
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CONTROL #1 - Male, 36 yrs
1 2 3 4 5 6 7 8 9
Time after dose (hrs)
1 2 3 4 5 6 7 8 9
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
142 4.1 104 31 5.8 104
ALT LD Ca P 0 4 Mg UA
35 473 2.43 1.5 0.85 0.332
Glue Prot Alb B i l l ALP GGT AST
6.1 70 42 10 60 21 23
Zn Fe T4 TSH Amyl
67 '
Choi
6.8
Trig
5.42
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CONTROL #2 - Male, 43 yrs
1 2  3 4
Time After Dose (hrs)
2 3
Time After Dose (hrs)
i— 1— i
5 6
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
140 3.7 100 32.9 4.7 85 4.9 80 43 7 62 35 27
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Am yl Choi Trig
26 2.46 1.09 0.75 0.354 13 9.9 3 46 * 5.4 2.98
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CONTROL #3 - Male, 44 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea
142 4.5 101 20 4.4
ALT LD Ca P 0 4 Mg
26 100 2.31 2.54 0.61
Prot Alb B i l l ALP GGT AST
70 44 6 55 19 45
Fe
25.6
T4 TSH Am yl
80
Choi
6.7
Trig
3.07
Créât Glue
108 5.1
UA Zn
0.308
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CONTROL #4 - Male, 38 yrs
1 2  3 4
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât Glue Prot Alb B i l l ALP GGT AST
148 4.3 106 21 8.7 107 4.9 77 51 11 64 21 70
ALT
21
LD
100
Ca
2.61
P 0 4
2.27
Mg
0.59
UA
0.23
Zn Fe
25.8
T 4 TSH Amyl
55 '
Choi
5.9
Trig
2.48
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CONTROL #5 - Male, 42 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
150 4.3 110 18 7.7 132
ALT LD Ca P 0 4 Mg UA
18 100 2.45 2.43 0.59 0.298
Time After Dose (hns)
Time After Dose (hrs)
Glue Prot Alb B i l i ALP GGT AST
5 84 53 11 50 21 69
Zn Fe
27.4
T 4 TSH Am yl
89 *
Choi
5.6
Trig
2.79
u
m
o
l/
L
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CONTROL #6 - Male, 60 yrs
No serum biochemistry data obtained
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CONTROL #7 - Male, 41 yrs
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
144
K
4.4
Cl
102
H C03
25
Urea
4.7
Créât
106
Glue
5.6
Prot
71
Alb
41
B i l l
11
ALP
49
GGT
18
AST
15
ALT
16
LD
220
Ca
2.46
P 0 4
1.09
Mg
0.84
UA
0.366
Zn Fe
21.8
T4 TSH Amyl
46 *
Choi
6.8
Trig
2.38
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CONTROL #8 - Female, 77 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl HC03 Urea Créât
136 4.1 100 25 3 60
ALT LD Ca P 0 4 Mg UA
21 387 2.32 1.12 0.73 0.137
Glue Prot Alb B i l l ALP GGT AST
5.3 58 35 7 93 97 19
Zn Fe T4 TSH Amyl Choi Trig
7.9 44 5.5 0.95
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CONTROL #9 - Female, 63 yrs
SERUM BIOCHEMISTRY RESULTS
Na
141
K
4.2
Cl
99
HC03
26
Urea
5.1
Créât
88
Glue
5.9
Prot
77
Alb
48
B i l l
16
ALP
56
GGT
20
AST
28
ALT
3
LD
247
Ca
2.51
P 0 4
1.24
Mg
0.81
UA
0.285
Zn Fe
20.4
T4 TSH Amyl
73 ’
Choi
8
Trig
1.81
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CONTROL #10 - Female, 60 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât
142 3.9 100 27 5.1 80
ALT LD Ca P 0 4 Mg UA
21 319 2.55 1.14 0.79 0.359
Glue Prot Alb B i l l ALP GGT AST
6.3 76 48 14 87 73 33
Zn Fe T 4 TSH Amyl Choi Trig
12.5 88 6 1.58
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CONTROL #11 - Male, 63 yrs
SERUM BIOCHEMISTRY RESULTS
Na
141
K
4.4
Cl
104
HC03
20
Urea
6.2
Créât
116
Glue
6.3
Prot
76
Alb
48
B i l l
16
ALP
92
GGT
35
AST
39
ALT
14
LD
190
Ca
2.45
P 0 4
1.27
Mg
0.77
UA
0.401
Zn Fe
15.9
T 4 TSH Amyl
43 '
Choi
4.9
Trig
3.01
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CONTROL #12 - Male, 66 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Creat
148 3.8 105 30.9 5.4 96
ALT LD Ca P 0 4 Mg UA
19 325 2.37 0.94 0.74 0.387
Glue Prot Alb B i l l ALP GGT AST
5.9 73 38 7 72 29 14
Zn Fe T4 TSH Amyl Choi Trig
10.7 16.7 13.5 1.9 55 ' 4.69 5.43
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CONTROL #13 - Female, 63 yrs
SERUM BIOCHEMISTRY RESULTS
Na
141
K
4.6
Cl
102
HC03
36
Urea
3.5
Créât
76
Glue
4.9
Prot
69
Alb
36
B i l l
6
ALP
69
GGT
21
AST
16
ALT
17
LD Ca
2.38
P 0 4
1.26
Mg
0.89
UA
0.31
Zn
13.6
Fe
20.1
T4
12.7
TSH
3.4
Amyl
46
Choi
4.94
Trig
0.55
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CONTROL #14 - Female, 63 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât
139 3.9 103 24 5.2 78
ALT LD Ca P 0 4 Mg UA
18 292 2.36 1.17 0.73 0.394
Glue Prot Alb B i l i ALP GGT AST
5.3 72 39 12 69 22 13
Zn Fe T 4 TSH Amyl Choi Trig
15.9 48 ’ 6.2 1.26
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CONTROL #15 - Male, 62 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
148 4.6 103 24 6.7 134
ALT LD Ca P 0 4 Mg UA
16 301 2.68 1.37 0.96 0.556
Glue Prot Alb B i l l ALP GGT AST
5.6 86 49 30 65 64 2
Zn Fe T 4 TSH Amyl Choi Trig
20.7 80 9 2.75
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CONTROL #16 - Male, 66 yrs
3l
50HA
50HT
T -------1------- 1--------1------- 1------- 1------- 1--------1------- 1------- 1--------1------- 1
1 2 3 4 5 6
finie After Dose (hrs)
No serum biochemistry data obtainable
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CONTROL #17 - Male, 63 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
145 4.2 105 25 4.5 98
ALT LD Ca P 0 4 Mg UA
17 330 2.42 1.12 0.87 0.332
0 1 2 3 4 5 6
Time After Dose (hrs)
Glue Prot Alb B i l i ALP GGT AST
6.4 72 42 13 51 27 22
Zn Fe
21.7
T4 TSH Am yl
48
Choi
6
Trig
2.66
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CONTROL #18 - Male, 60 yrs
SERUM BIOCHEMISTRY RESULTS
Na
140
K
4.3
Cl
103
H C 03
29
Urea
6.8
Créât
81
Glue
5.4
Prot
72
Alb
42
B i l l
14
ALP
74
GGT
52
AST
18
ALT
42
LD Ca
2.42
P 0 4
1.25
Mg
0.83
UA
0.31
Zn Fe
21.7
T4 TSH Am yl
60
Choi
6.7
Trig
1.29
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CONTROL #19 - Male, 71 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
141 4.7 103 30 8.7 111
ALT LD Ca P 0 4 Mg UA
64 473 2.39 1.05 0.59 0.367
Glue Prot Alb B i l l ALP GGT
6.1 72 41 21 76 34
Zn Fe T4 TSH Am yl Choi
10.8 16.7 0.7 101 5.37
AST
40
Trig
1.35
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CONTROL #20 - Female, 66yrs
SERUM1 BIOCHEMISTRY RESULTS
Na K Cl H C 03  Urea Créât Glue Prot Alb B i l i ALP GGT AST
141 3.8 103 26 5.4 68 6.8 75 43 10 66 30 26
ALT LD Ca P 0 4  Mg UA Zn Fe T 4 TSH Amyl Choi Trig
34 368 2.31 0.87 0.84 0.298 11.8 14.2 2.6 53 4.7 1.87
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CONTROL #21 - Male, 61 yrs
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
145
K
4.6
Cl
106
H C 03
31
Urea
7
Créât
96
Glue
5.7
Prot
69
Alb
40
B i l i
16
ALP
109
GGT
53
AST
28
ALT
33
LD
391
Ca
2.35
P 0 4
1.04
Mg
0.78
UA
0.457
Zn
11.5
Fe T4
13.9
TSH
1.1
Am yl
78 '
Choi
5.68
Trig
2.31
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CONTROL #22 - Male, 77 yrs
SERUM BIOCHEMISTRY RESULTS
Na
116
K
3.4
Cl
87
H C 03
17
Urea
6.9
Créât
83
Glue
4.6
Prot
55
Alb
37
B i l l
10
ALP
78
GGT
48
AST
27
ALT
30
LD
465
Ca
1.96
P 0 4
1.03
Mg
0.59
UA
0.286
Zn
11
Fe T4
11.5
TSH
2.5
Am yl
30
Choi
4.2
Trig
0.95
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CONTROL #23 - Male, 63 yrs
SERUM BIOCHEMISTRY RESULTS
Na
144
K
4.7
Cl
104
HC03
33
Urea
9.8
Créât
117
Glue
6.1
Prot
71
Alb
44
B i l l
10
ALP
53
GGT
23
AST
45
ALT
42
LD
568
Ca
2.47
P 0 4
1.33
Mg
0.84
UA
0.422
Zn
14.1
Fe T 4
13.1
TSH
2.2
Am yl
86 '
Choi
5.59
Trig
1.12
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CONTROL #24 - Female, 61 yrs
SERUM BIOCHEMISTRY RESULTS
Na
139
K
4.2
Cl
104
H C 03
26
Urea
5.6
Créât
54
Glue
17.1
Prot
67
Alb
38
B i l i
14
ALP
114
GGT
75
AST
32
ALT
46
LD
470
Ca
2.28
P 0 4
0.97
Mg
0.79
UA
0.214
Zn
11.1
Fe T 4
14.7
TSH
2.1
Amyl
34
Choi
4.68
Trig
1.35
u
m
o
l/
L
Appendix D Page 269
CONTROL #25 - Male, 66 yrs
SERUM BIOCHEMISTRY RESULTS
No other biochemistry data obtainable
T4 TSH
16.5 0.8
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CONTROL #26 - Male, 68 yrs
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
130 4.1 92 25 5.7 87
ALT LD Ca P 0 4 M g UA
12 311 2.46 1.11 0.7 0.441
Glue Prot Alb B i l i ALP GGT AST
5.7 69 47 19 78 77 29
Zn Fe
17.5
T4 TSH Amyl
103
Choi
7.01
Trig
1.06
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CONTROL #27 - Female, 67 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
140 3.5 97 30 9.1 103
ALT LD Ca P 0 4 Mg UA
8 313 2.55 1.17 0.81 0.387
Glue Prot Alb B i l l ALP GGT AST
5.3 74 46 19 140 21 25
Zn Fe T4 TSH Am yl Choi Trig
20.3 60 6.6 1.68
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CONTROL #28 - Male, 21 yrs
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât
142 4.3 100 30 4.3 112
ALT LD Ca P 0 4 Mg UA
30 336 2.46 1.15 0.79 0.378
Glue Prot Alb B i l l ALP GGT AST
5.5 79 45 19 54 24 30
Zn Fe T4 TSH Am yl Choi Trig
29.6 42 3.9 0.69
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CONTROL #29 - Female, 27 yrs
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
143 4.1 102 30 5.6 79
ALT LD Ca P 0 4 Mg UA
25 424 2.4 0.98 0.86 0.322
0 1 2 3 4 5 6
Time After Dose (hrs)
Glue Prot Alb B i l l ALP GGT AST
5.5 79 42 14 70 27 29
Zn Fe T4 TSH Amyl Choi Trig
19 64 5.2 0.87
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CONTROL #30 - Male, 30 yrs
201
1.5
1.0 -
0.5*
50HA
50HT
T—i—r i— ■— i— •— i— 1— i
5 61 2  3 4
Hme After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C 03 Urea Créât
141 4.4 102 31 4.9 114
ALT LD Ca P 0 4 Mg UA
74 509 2.31 1.01 0.81 0.396
Glue Prot Alb B i l l ALP GGT AST
5.3 76 45 16 73 23 42
Zn Fe T 4 TSH Am yl
72
Choi
5.72
Trig
1.05
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CONTROL #31 - Male, 37 yrs
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
138
K
4.1
Cl
100
H C 03
28
Urea
2.9
Créât
94
Glue
5.3
Prot
75
Alb
46
B i l l
23
ALP
48
GGT
16
AST
30
ALT
29
LD
420
Ca
2.23
P 0 4
0.95
Mg
0.74
UA
0.299
Zn Fe T4 TSH Amyl
69
Choi
4.73
Trig
0.46
Appendix D Page 276
CONTROL #32 - Female, 24 yrs
0 1 2 3 4 5 6
Time After Dose (firs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl H C03 Urea Créât
141 4 103 27 2.3 73
ALT LD Ca P 0 4 M g UA
24 367 2.34 1.33 0.83 0.221
Glue Prot Alb B i l l ALP GGT AST
4.9 74 42 12 31 15 25
Zn Fe T4 TSH Amyl Choi Trig
10.5 16.1 1.07 58 * 6.31 1.09
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CONTROL #33 - Male, 24 yrs
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
138
K
4.1
Cl
101
H C 03
30
Urea
3.1
Créât
89
Glue
5.1
Prot
70
Alb
39
B i l l
21
ALP
75
GGT
43
AST
41
ALT
38
LD
430
Ca
2.19
' P 0 4
1.21
Mg
0.82
UA
0.401
Zn
12.5
Fe T4 TSH Am yl
60
Choi
4.21
Trig
0.78
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CONTROL #34 - Male, 26 yrs
2 3
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
i— •— i
5 6
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
150
K
4.1
Cl
103
H C 03
28
Urea
3.4
Créât
122
Glue
4.2
Prot
74
Alb
51
B i l l
14
ALP
70
GGT
20
AST
38
ALT
26
LD
471
Ca
2.33
P 0 4
1.53
Mg
1.01
UA
0.351
Zn
13.5
Fe T4 TSH Am yl
68 *
C hoi
6.12
Trig
0.94
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CONTROL #35 - Male, 34 yrs
SERUM BIOCHEMISTRY RESULTS
Na
142
K
4.2
Cl
101
H C 03
30
Urea
5.1
Creat
89
Glue
5.1
Prot
79
Alb
45
B i l l
19
ALP
60
GGT
32
AST
37
ALT LD Ca P 0 4 Mg UA Zn Fe T 4 TSH Amyl Choi Trig
2.3 1.37 0.77 0.371 39 3.4 0.88
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CONTROL #36 - Female, 33 yrs
Time After Dose (hrs)
1.0
1 2 3
Time After Dose (hrs)
2 3 4
Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na
141
K
3.9
Cl
107
H C03
23
Urea
3.7
Creat
73
Glue
5.8
Prot
71
Alb
44
B i l l
13
ALP
49
GGT
16
AST
23
ALT LD Ca
2.13
P 0 4
1.13
Mg
0.79
UA
0.286
Zn Fe T 4 TSH Am yl
102
C hoi
6.31
Trig
0.73
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CONTROL #37 - Male, 32 yrs
Time After Dose (hrs)
5­
4-
á 3‘o ,
 ̂ 2-
KA
0 1 2 3 4 5 6
Time After Dose (hrs) Time After Dose (hrs)
SERUM BIOCHEMISTRY RESULTS
Na K Cl
143 3.9 105
ALT LD Ca
429
H C03 Urea Créât
26 4.6 98
P 0 4 M g UA
1.21 0.77
Glue
5.6
Zn
Prot Alb
75 46
Fe T4
B i l i ALP GGT AST
14 56 76 36
TSH Amyl Choi Trig
49 7.01 1.542.39
IE
Q
Q
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ol
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Figure E l
Total Tryptophan Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
□  Oh 
H l h  
M 2 h 
E3 4 h
□  6 h
(n=37) (n=12) (n=ll) (n=7) (n=2)
Figure E2
Free Tryptophan Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
(n=37) (n=12) (n= ll) (n=7) (n=2)
□  Oh 
E3 l h
H 2 h
□  4 h
□  6 h
um
ol
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Figure E3
K ynurenine Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
□  Oh 
S3 lh
M 2 h 
U 4 h
□  6 h
n=37 n= 11 n=12 n=7 n=2
Figure E4
3-H ydroxyanthraniIic Acid Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
n=37 n=12 n=ll  n=7 n=2
□  Oh 
m  i h  
m  2 h
□  4 h
□  6 h
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Figure E5
X anthurenic Acid Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
n=37 n= 11 n=12 n=7 n=2
B  Oh 
B  l h
m 2  h
E3 4 h
□  6 h
Figure E6
Kynurenic Acid Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
(n=37) (n=12) (n= ll) (n=7) (n=2)
□  Oh 
B  l h  
El 2 h
□  4 h
□  6 h
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Figure E7
A nthranilic Acid Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
□  O h
E9 lh
Ü 2 h
0  4 h
□  6 h
Figure E8
5-H ydroxyanthraniIic Acid Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
(n=37) (n=12) (n= ll) (n=7) (n=2)
□  Oh 
m  i h  
m  2 h
□  4 h
□  6 h
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Figure E9
5-Hydroxytryptophan Response 
to the Tryptophan Load:
All subjects according to Cataract Grade
(n=37) (n=12) (n=ll) (n=7) (n=2)
□  Oh 
B  l h  
■  2 h
□  4 h
□  6 h
IB I  IB IL I©  © M A  IP IH ¥
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